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ABSTRACT 
 
Transporters of the SLC11 family catalyze the selective flow of divalent metal ions across 
cellular membranes of pro- and eukaryotic organisms. Mammals express two SLC11 
proteins, NRAMP1 and DMT1 (or NRAMP2). These transporters play an important role 
in iron uptake and supply, the recycling of iron from senescent erythrocytes and they are 
part of the host defense strategy against bacterial invaders. Whereas the dysfunction of 
DMT1 causes iron-storage diseases, such as hereditary hemochromatosis and 
hypochromic microcytic anemia, mutations in NRAMP2 are associated with an increased 
susceptibility to bacterial infections. With respect to sequence the SLC11 family is highly 
conserved from pro- to eukaryotes with members found in all kingdoms of life. The 
properties of mammalian NRAMP proteins have been studied by electrophysiology and 
in rodent animal models. Besides the profound functional characterization detailed 
structural knowledge was thus far not available. To understand the mechanisms of 
divalent metal-ion binding and transport, high-resolution structural data is inevitable. 
During the course of my PhD studies it was my aim to determine the first high-
resolution structure of a SLC11 family member and to characterize its ion binding and 
transport properties. Due to the numerous sequenced bacterial genomes and the high 
degree of conservation between NRAMP proteins, bacterial homologs were chosen as 
suitable candidates for structural studies. In the course of this work I have cloned more 
than 100 prokaryotic SLC11 homologs and studied their overexpression properties in 
Escherichia coli and assessed their biochemical behavior in a detergent solubilized state. 
After selecting few proteins with superior properties I succeeded to crystallize one 
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homolog from Staphylococcus capitis (ScaDMT), although the crystals only diffracted to low 
(6.5 Å) resolution. To improve the crystallization and diffraction properties of ScaDMT I 
have investigated N-terminal truncations of the protein, which allowed the identification 
of a truncated version of ScaDMT (ScaDMTtru) that diffracted to slightly higher 
resolution (5.5-6.0 Å). However, also these crystals were of insufficient quality for 
structure determination. In another attempt to improve the resolution ScaDMT-specific 
nanobodies were generated in collaboration with Jan Steyaert’s laboratory at the free 
University of Brussels. The nanobodies were used for co-crystallization of complexes 
with the full-length and truncated version of ScaDMT. Crystallization of one nanobody 
in combination with the truncated version of ScaDMT has allowed structure 
determination of the complex at 3.1 Å resolution. Phases were obtained by the single 
anomalous dispersion method, which required collection of anomalous data from crystals 
grown with seleno-methionine-derivatized protein.  
ScaDMT adopts a familiar fold that was previously identified in the amino-acid 
transporter LeuT and other unrelated transport proteins. The transporter crystallized in 
an inward-facing conformation with a substrate-binding site that is accessible from the 
cytoplasm. Putative substrates including Mn2+, Fe2+ and Cd2+ were soaked into the 
crystals, which allowed the identification of a highly conserved binding site located in the 
center of the protein. In parallel cadmium binding to ScaDMT was assayed by isothermal 
titration calorimetry (ITC), which revealed the binding to a single binding site with 
micromolar affinity. To investigate its functional properties, a fluorescence-based assay 
with proteoliposomes containing the reconstituted transporter was established that 
confirmed the transport of the transition-metal ions Mn2+, Cd2+, Co2+ and Ni2+. 
Undisturbed uptake of manganese in the presence of high concentrations of earth-
alkaline metal ions revealed that neither Ca2+ nor Sr2+or Ba2+ are transported by 
ScaDMT. Point mutations of metal ion binding site residues (i.e. Asp49, Asn52, Met226) 
weakened binding of Cd2+, as confirmed by ITC. Investigation of the transport 
properties of corresponding residues in human DMT1, by two-electrode voltage-clamp 
electrophysiology revealed a 19 fold higher Km value for the asparagine mutant (N89A). 
When mutating the binding site aspartate (D86A) or methionine (M265A) no cadmium-
induced currents could be observed.  
The results of this thesis thus have allowed me to provide first structural insight 
into the SLC11 family by determining the first high-resolution structure of a close 
prokaryotic homolog. This structure revealed the location of conserved residues in the 
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center of the protein that coordinate divalent transition-metal ions but not alkaline earth 
metal ions. The results of this work have thus paved the war for future investigations to 
unravel the mechanism of ion transport of this important class of membrane proteins. 
  
 XVI 
 
 
  
 XVII 
 
ZUSAMMENFASSUNG 
 
Proteine der Solute carrier 11 (SLC11) Familie katalysieren den selektiven Fluss 
divalenter Metallionen durch die Membranen pro- und eukaryotischer Organismen. 
Säugetiere besitzen zwei verwandte SLC11 Proteine: NRAMP1 und DMT1 (oder 
NRAMP2). Beide Transporter spielen eine wichtige Rolle sowohl bei der Aufnahme und 
Verteilung von Eisen im Körper als auch bei dessen Wiedergewinnung aus alternden 
Erythrozyten. In Makrophagen ist NRAMP1 ausserdem ein wichtiger Teil des 
Immunsystems im Kampf gegen bakterielle Eindringlinge. Ist DMT1 genetisch verändert 
und als Konsequenz nicht funktionsfähig führt dies zu Eisenspeicherkrankheiten wie der 
erblich bedingten Hämochromatose oder der hypochromischen microzytischen 
Eisenmangelanämie. Mutationen in NRAMP2 sind ferner mit einer erhöhten 
Infektanfälligkeit für bestimmte bakterielle Infektionen verbunden. Die Funktion der 
SLC11 Transporter wurde zuvor mittels elektrophysiologischer Studien und anhand von 
Tiermodellen, untersucht. Obgleich es zahlreiche Studien zur Funktion dieser 
Eisentransport-Proteine gibt, war ihr struktureller Aufbau bisher unbekannt. 
Strukturdaten bei hoher Auflösung sind allerdings unerlässlich um den 
Transportmechanismus von Eisen und anderen Metallionen im Detail zu verstehen.  
Aus diesem Grund habe ich es mir als Ziel gesetzt, im Verlauf meiner 
Doktorarbeit die erste hochaufgelöste Röntgenkristallstruktur eines Mitglieds der SLC11-
Familie aufzuklären, und dessen Ionenbindung und Transporteigenschaften genauer zu 
untersuchen. Aufgrund der hohen Konservierung innerhalb der SLC11 Familie sind 
bakterielle Homologe attraktive Kandidaten für die Röntgenkristallstrukturanalyse. Auf 
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die genetische Information dieser bakteriellen Transporter kann mit Hilfe von 
Dantenbanken, die eine Vielzahl vollständig sequenzierter bakterieller Genome 
enthalten, zurückgegriffen werden. Während meiner Arbeit an diesem Projekt habe ich 
über 100 prokaryotische SCL11-Homologe kloniert, sie in E. coli über-exprimiert und 
ihre biochemischen Eigenschaften, nach Extraktion mit Detergenzien, getestet. Mit Hilfe 
dieser Strategie ist es mir gelungen einige (wenige) Homologe mit herausragenden 
biochemischen Eigenschaften zu identifizieren. Obwohl ich ein Homolog (ScaDMT), 
aus dem Bakterium Staphylococcus capitis, erfolgreich kristallisieren konnte waren die 
Diffraktionseigenschaften dieser Kristalle mit einer maximalen Auflösung von 6.5 Å 
nicht von ausreichender Qualität für die Strukturaufklärung. Um dies zu verbessern habe 
ich systematisch N-terminal verkürzte Konstrukte getestet, wobei es mir gelungen ist 
Kristalle eines verkürzten Proteins (ScaDMTtru) zu erhalten. Leider waren die Kristalle 
des ScaDMTtru -Konstruktes für die Strukturaufklärung ebenfalls ungeeignet, da diese 
sich nur marginal besser verhielten (5.5-6.0 Å Auflösung) als die (Kristalle) des 
ursprünglichen Konstrukts. In einem weiteren Versuch die Qualität der Kristalle zu 
verbessern habe ich, in Kollaboration mit Jan Steyaerts Labor an der Freien Universität 
Brüssel, Lama-Nanobodies, die spezifisch an ScaDMT binden, generiert. Nanobody-
Transporter-Komplexe wurden sowohl mit ScaDMT als auch mit ScaDMTtru für 
Kristallisationsexperiments genutzt was mir erlaubt hat den entscheidenden Durchbruch 
zur Strukturaufklärung zu erzielen. Daten mit einer Auflösung von 3.1 Å konnten von 
einem Komplex, bestehend ScaDMTtru und einem Nanobody, gesammelt werden. Das 
Phasenproblem wurde mittels Anomaler Streuexperimente von Kristallen, die aus mit 
Seleno-Methionin derivatisiertem Protein hergestellt wurden, gelöst.  
Die ScaDMT Struktur zeigt eine bekannte Faltung der Proteinkette, die zuvor in 
anderen Transportproteinen, wie dem Aminosäure Transporter LeuT, gefunden wurde. 
In den Kristallen, liegt ScaDMT in einer nach innen gewandten Konformation vor, in 
der die Substratbindungsstelle von der cytoplasmatischen Seite her zugänglich ist. Zur 
Bestimmung der Substratinteraktion wurden Kristalle mit den divalenten Metallionen 
Mangan, Eisen und Cadmium derivatisiert. Dadurch konnte eine Ionenbindungsstelle im 
Protein identifiziert werden, die aus stark konservierten Aminosäureseitenketten besteht. 
Mittels Titrationskalorimetrie (ITC) konnte ich nachweisen, dass Cadmium mit mikro-
molarer Affinität an ScaDMT bindet. Der selektive Import von Mn2+, Cd2+, Co2+ und 
Ni2+ in Proteoliposomen, die ScaDMT enthalten, konnte mittels Metall-sensitiver 
Fluorophore gemessen werden. Diese Versuche haben auch gezeigt dass hohe 
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Konzentrationen von Kalzium, Strontium oder Barium den Import von Mangan nicht 
beeinflussen, was darauf schliessen lässt, dass diese keine Substrate für ScaDMT sind. 
ITC Messungen von Punktmutanten einzelner Reste in der Substratbindungsstelle 
zeigten eine stark reduzierte Affinität für Cadmium. Um die Konservierung der 
Ionenbindungsstelle im humanen Transporter zu untersuchen habe ich parallel die 
entsprechenden Reste in DMT1 mutiert und mit Hilfe elektrophysiologischer Methoden 
untersucht. Die Messungen zeigten einen starken Einfluss der Mutationen auf die 
Transporteigenschaften, mit einer Mutante bei der die Ionenabhängigkeit zu höheren 
Konzentrationen verschoben ist und zwei weiteren Mutanten die keinerlei Cadmium-
induzierten Transport mehr erlauben. 
Die Ergebnisse meiner Doktorarbeit geben Einblick in die erste hochaufgelöste 
Röntgenkristallstruktur eines nahen bakteriellen Verwandten der Eisentransporter der 
SLC11 Familie. Dank dieser Struktur konnte eine Substratbindungstasche identifiziert 
werden, welche sich im Zentrum des Proteins befindet. Die Aminosäurereste der 
Bindungstasche koordinieren divalente Übergangsmetalle aber keine Erdalkalimetalle. 
Diese Arbeit bildet deshalb eine wichtige Grundlage um den Transportmechanismus 
dieser Membranproteine im Detail verstehen zu können.  
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1. INTRODUCTION 
  
 3
1.1. Principles of ion transport 
 
Cells are enclosed by a physical boundary, the lipid membrane that separates the interior 
from the exterior environment. Lipid Membranes are mainly composed of phospholipids 
and proteins. Phospholipids are amphiphilic molecules comprised of a hydrophilic head 
group, usually containing phosphate attached as ester to a glycerol molecule, and a 
hydrophobic tail of two fatty acid esters linked to the glycerol. In water phospholipids 
spontaneously assemble to a lipid bilayer, where the head groups are exposed to the 
aqueous solution and the polar tails point towards the interior. This barrier is 
impermeable for hydrophilic molecules. To allow communication and exchange between 
the internal and external environment, transport proteins are embedded in the membrane 
and catalyze the movement of various compounds through the lipid bilayer. 
The importance of these molecules, is reflected in the large number of genes encoding 
membrane proteins, which make up ~26 % of all genes in humans (Fagerberg et al., 
2010). Depending on the underlying mechanism by which membrane proteins facilitate 
the transport of solutes they can be divided into two major classes, namely channels and 
transporters.  
Channels allow their substrates, predominantly ions, to flow along their 
electrochemical gradient, which is dependent on the membrane potential and the ion 
concentration gradient. This process is independent of metabolic energy and is thus 
referred to as passive transport or facilitated diffusion. Ion channels are conductors 
usually selective for a specific ion or a class of ions (e.g. anions or cations). At the 
narrowest part of the pore, ion channels have a so-called selectivity filter, which is 
responsible for the discrimination of the ions. Because under typical cellular conditions 
ions need to be kept at non-equilibrium conditions, opening and closing of most ion 
channels is regulated. Ion channel gating can be triggered by different stimuli, such as 
changes in membrane potential (voltage-gating), by the intra- or extracellular binding of 
ligands (ligand-gating), by mechanical forces (in mechanosensitive channels), light (light 
gating) or temperature (temperature-gating).  
In contrast to channels many transporters are able to catalyze the translocation of 
ions against their electrochemical potential. This process is called active transport 
because an energy source is needed in order to allow this thermodynamically unfavorable 
process to take place. Primary active transports, such as ATP-driven pumps, couple 
chemical energy derived from the hydrolysis of ATP to the movement of ions against its 
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gradient. Secondary active transporters use the energy stored in the electrochemical 
gradient of another solute that is co-transported either in the same direction (symport) or 
the opposite direction (antiport). A prerequisite, for the efficient coupling of ion 
transport, is the presence of at least two distinct states in which the binding site for the 
molecules is accessible to only one side of the membrane at a time. This principle 
underlies the alternating access model, first proposed by P. Mitchell in 1957 (Mitchell, 
1957) and later refined by O. Jardetzky in 1966 (Jardetzky, 1966). It is the most widely 
accepted scheme to describe the series of conformational changes necessary for ion 
transport.  
Our understanding of how membrane transport proteins work has enormously 
advanced over the last decades. We now know better how they are integrated in the 
membrane during translation (Park and Rapoport, 2012; White and von Heijne, 2004), 
how they are regulated (Hicke and Dunn, 2003), how proteins might have evolved that 
share the same fold but perform completely unrelated tasks (Bernsel et al., 2008; 
Fagerberg et al., 2010; von Heijne, 2006) and in many cases we have gained knowledge 
on the functions of membrane proteins in health and disease (Ng et al., 2012; Sanders 
and Nagy, 2000). Structural biology has significantly contributed to the present 
understanding of membrane proteins. Despite the recent advances, there are still many 
open questions concerning membrane transport processes that are to date not 
understood.  
1.2. The solute carrier 11 family 
 
With over 384 members the solute carrier families constitute the second largest family of 
membrane proteins, following the G protein-coupled receptors with over 800 genes. The 
SLC tables classify these human membrane transport proteins based on their function. In 
general these transporters are membrane proteins with an α-helical transmembrane core. 
Different SLC families do not share significant sequence homology. Within the families 
the members need to share a sequence homology of at least 20-25%. Members of the 
currently 52 SLC families transport a variety of solutes ranging from organic and 
inorganic ions to complex organic molecules such as sugars and fatty acids. The SLC 
transporters also include the Multidrug and toxin extrusion (MATE) family (SLC47). 
From a mechanistic perspective, SLC proteins can be either secondary active or 
facilitative transporters (uniporters).  
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In humans the solute carrier 11 family consists of two members, the proton-coupled 
divalent metal ion transporters 1 and 2 also known as natural resistance-associated 
macrophage protein NRAMP1 and NRAMP2 (DMT1). In the late 70s of the last century 
J. Plant and A.A. Glynn identified a gene locus on mouse chromosome 1 that conveys 
resistance to several intracellular pathogens, including Salmonella typhimurium, Leeishmania 
donovani, Mycobacterium bovis and Mycobacterium lephraemurium (Plant and Glynn, 1974, 1976, 
1979). In 1993 Vidal et al. proposed, based on the tissue distribution of mouse NRAMP 
1 mRNA transcripts and computer-assisted analysis, that the gene is localized to 
macrophages and encodes for a membrane transport protein (Vidal et al., 1993). In 1994 
two groups simultaneously published the successful cloning of the human cDNA of 
NRAMP (later NRAMP1) located on chromosome 2 (Cellier et al., 1994; Kishi, 1994). 
Remarkably, in the publication of Kishi the first 67 residues are not present and the gene 
starts only 6 residues before the DPGN motif. Soon after that, the second family 
member NRAMP2 was identified in several mammals (Cellier et al., 1995; Dosik et al., 
1994; Gruenheid et al., 1995). Human NRAMP2 is located on chromosome 12 and was 
successfully cloned by Vidal et al. in 1995. 
1.3. NRAMP1 and NRAMP2 
 
The first functional characterized mammalian homolog was ratNRAMP2 in 1997 
(Gunshin et al., 1997). The authors of this study have overexpressed ratNRAMP2 in 
Xenopus laevis oocytes and measured the transport of Fe2+ but also other transition metal 
ions such as Mn2+, Co2+, Cd2+, Cu2+, Ni2+, Pb2+ and to a very low extent Zn2+, by two-
electrode voltage-clamp electrophysiology. By this they revealed the broad substrate 
specificity of this transport family and in further experiments they could show that the 
transport of Fe2+ is driven by a proton electrochemical gradient. Via in situ hybridization 
of ratNRAMP2 mRNA with a labeled cRNA probe in cryosections of different tissues, 
the authors were able to identify the distribution of rat NRAMP2 mRNA in the 
duodenum and to a lesser extent in kidney, liver, brain, heart, lung and testis (Gunshin et 
al., 1997). 
Human NRAMP1 and NRAMP2 share a sequence identity of ~63% and a 
similarity of ~73%. Depending on the isoform they are between 550 and 598 amino 
acids long (uniprot NRAMP1 P49279, NRAMP2 P49282).  
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Figure 1 Sequence alignment of NRAMP1 and NRAMP2. 
The two sequences were aligned with CLUSTALW. Identical residues are shown in yellow, 
similar amino acids are marked in green. Secondary structure elements and binding site residues 
originate from an alignment with ScaDMT. Important residues are highlighted: The three 
residues involved in ion binding are marked in violet, the two highly conserved histidine residues 
are marked by a blue dot, residues associated with diseases are in red, the two N-linked 
glycosylation sites are marked with a black star. 
 
NRAMP1      -------------MTGDKGPQRLSGSSYGSISSPTSPTSPGPQQAPPRETYLSEKIPIPD 47 
hDMT1       MVLGPEQKMSDDSVSGDHGESASLGNINPAYSNPSLSQSPGDSE-EYFATYFNEKISIPE 59 
 
 
                                            
NRAMP1      TKPGTFSLRKLWAFTGPGFLMSIAFLDPGNIESDLQAGAVAGFKLLWVLLWATVLGLLCQ 107 
hDMT1       EEYSCFSFRKLWAFTGPGFLMSIAYLDPGNIESDLQSGAVAGFKLLWILLLATLVGLLLQ 119 
 
 
 
NRAMP1      RLAARLGVVTGKDLGEVCHLYYPKVPRTVLWLTIELAIVGSDMQEVIGTAIAFNLLSAGR 167 
hDMT1       RLAARLGVVTGLHLAEVCHRQYPKVPRVILWLMVELAIIGSDMQEVIGSAIAINLLSVGR 179 
 
 
                                              
NRAMP1      IPLWGGVLITIVDTFFFLFLDNYGLRKLEAFFGLLITIMALTFGYEYVVARPEQGALLRG 227 
hDMT1       IPLWGGVLITIADTFVFLFLDKYGLRKLEAFFGFLITIMALTFGYEYVTVKPSQSQVLKG 239 
 
 
                                           
NRAMP1      LFLPSCPGCGHPELLQAVGIVGAIIMPHNIYLHSALVKSREIDRARRADIREANMYFLIE 287 
hDMT1       MFVPSCSGCRTPQIEQAVGIVGAVIMPHNMYLHSALVKSRQVNRNNKQEVREANKYFFIE 299 
 
 
                                                               
NRAMP1      ATIALSVSFIINLFVMAVFGQAFYQKTNQAAFNICANSSLHDYAKIFPMNNATVAVDIYQ 347 
hDMT1       SCIALFVSFIINVFVVSVFAEAFFGKTNEQVVEVCTNTSS-PHAGLFPKDNSTLAVDIYK 358 
 
 
                                                                               
NRAMP1      GGVILGCLFGPAALYIWAIGLLAAGQSSTMTGTYAGQFVMEGFLRLRWSRFARVLLTRSC 407 
hDMT1       GGVVLGCYFGPAALYIWAVGILAAGQSSTMTGTYSGQFVMEGFLNLKWSRFARVVLTRSI 418 
 
 
 
NRAMP1      AILPTVLVAVFRDLRDLSGLNDLLNVLQSLLLPFAVLPILTFTSMPTLMQEFANGLLNKV 467 
hDMT1       AIIPTLLVAVFQDVEHLTGMNDFLNVLQSLQLPFALIPILTFTSLRPVMSDFANGLGWRI 478 
 
 
 
NRAMP1      VTSSIMVLVCAINLYFVVSYLPSLPHPAYFGLAALLAAAYLGLSTYLVWTCCLAHGATFL 527 
hDMT1       AGGILVLIICSINMYFVVVYVRDLGHVALYVVAAVVSVAYLGFVFYLGWQCLIALGMSFL 538 
 
 
 
NRAMP1      AHSSHHHFLYGLLEEDQKGETSG 550 
hDMT1       DCGHTVSISKGLLTEEATRGYVK 561 
 1a 1b 2 
3 
4 5 
6a 6b 
7 
8 
10 9 
11 
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In Figure 1 a sequence alignment of human NRAMP1 (isoform 1) and NRAMP2 
(DMT1, isoform 3) is shown, where key residues highlighted. 
Four splice-variants of NRAMP2 are known. They differ in their N and C 
terminal regions as well as in their 3` untranslated regions (UTRs). Isoform 1 (1B-
IRE(+)) contains an iron responsive element (IRE) in the 3`UTR. Isoform 2 (1B-IRE(-)) 
has no IRE at its 3`UTR and additionally IRE(-) isoforms have a specific 3`coding region 
that is 25 amino acids in length and differs from the 18 amino acid C-terminal residues in 
IRE(+) isoforms. The variants 1A-IRE(+) and 1A-IRE(-) (isoform 3 and 4 respectively) 
start both from exon 1A, and have therefore N termini that are 29 amino acid longer 
than the 1B variants (Mackenzie et al., 2007). The iron responsive element is believed to 
modulate the mRNA stability in response to the iron status in the cell. The N-terminal 
variants (exon 1A or 1B) are thought to operate as cell specific signals for the subcellular 
localization in different compartments (Shawki et al., 2012). Mackenzie et al. found that 
all four human NRAMP2 variants transport iron with similar efficiency. Expression 
levels in Xenopus laevis oocytes, however, are significantly higher for isoform 3 (1AIRE(+), 
Mackenzie et al. 2007). 
For human NRAMP1 no splice variants are known. Although there are two 
isoforms annotated in the UniProt Knowledgebase, the expression of only one has been 
confirmed. Based on our studies, it is questionable whether isoform 2 is a functional 
NRAMP transporter variant, since the missing amino acids 14 – 131 (compared to 
isoform 1) contain the highly conserved DPGN motif, which is part of the metal ion 
binding site identified in the bacterial homolog ScaDMT (Ehrnstorfer et al., 2014).  
Both hNRAMP members are predicted to contain 12 transmembrane spanning 
helices, with both termini located in the cytoplasm. This predicted topology is valid for 
most of the eukaryotic family members. Some yeast homologs are predicted to have one 
additional transmembrane segment at their N terminus. Human NRAMP1 and 
NRAMP2 both contain two conserved N-linked glycosylation sites (N-X-S/T motif, 
Vidal et al. 1993). Originally they were predicted to be localized in a loop connecting TM 
5 and 6. From the X-ray structure of a prokaryotic transporter described in this thesis it 
is now clear that the relevant asparagines (N365, N379) are located in the loop 
connecting TM7 and TM8 (Figure 2). hNRAMP1 and 2 are heavily glycosylated, on 
SDS-PAGE the glycosylation accounts for ~40% of the molecular weight of these 
proteins (Gruenheid et al., 1999). Disruption of the two glycosylation sites in hNRAMP1 
did not change the correct endosomal targeting when overexpressed as EGFP-fusion 
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protein in RAW 264.7 cells (a mouse leukemic monocyte macrophage cell line). The 
authors thus concluded that the loss of glycosylation does not interfere with folding and 
sorting (in the glycosylation deficient mutant) of hNRAMP1 (White et al., 2004). 
1.4. Physiological roles of mammalian NRAMP2/DMT1  
 
NRAMP2 has two pivotal roles in our body: One is the uptake of dietary iron from the 
gut. This is why NRAMP2 is well expressed in enterocytes of the duodenum (Gunshin et 
al., 1997; Tandy et al., 2000). Inorganic iron that is ingested is mainly present in its ferric 
form as trivalent cation, since the divalent ferrous iron easily oxidizes. The ferrireductase 
Duodenal cytochrome B (DcytB) is expressed in the brush border of the duodenum, at 
the same locations as NRAMP. It has thus been suggested to reduce ferric iron to its 
ferrous form, which can subsequently be transported by NRAMP2 (McKie, 2008; McKie 
et al., 2001). The slightly acidic pH at the proximal duodenum (pH 6.0) may help to 
stabilize ferrous iron (Fallingborg, 1999). Remarkably, however, a study with DcytB 
knockout mice, did not show any pronounced effect on iron acquisition (Gunshin et al., 
2005).  
A small part of the ferrous iron that is imported by NRAMP2 is bound to ferritin and 
stored within the cells (Anderson et al., 2009; Andrews, 2008). The remainder is exported 
by ferroportin, an iron transporter located at the basolateral side of the enterocyte 
(Donovan et al., 2005). There the ferrous iron is oxidized by the ferroxidase hephaestin 
and bound to the soluble protein transferrin which transports iron in the body (Vulpe et 
al., 1999). Figure 2A illustrates the uptake and the export of iron in the enterocyte.  
Transferrin is a ~80 kDa large glycoprotein that can tightly bind two ferric iron 
atoms at the neutral pH of the blood with an extraordinary small dissociation constant of 
10-23 M (10 yocto mol) (De Domenico et al., 2008). Transferrin is expressed and secreted 
in hepatocytes (Zakin, 1992). Under physiological conditions 20-30% of the transferrin 
population circulating in the blood is present as apo-transferrin (with no iron bound). 
This reduces free plasma iron to a minimum, thus preventing that toxic iron radicals 
accumulate. In addition to its role in dietary iron absorption in enterocytes, NRAMP2 is 
essential for cells to take up iron from the blood (Gruenheid et al., 1999). In this tightly 
regulated process iron-bound transferrin binds to the transferrin receptor 1 TFR1, which 
is highly expressed in reticulocytes (erythroid precursors) and on all dividing cells (Ponka 
and Lok, 1999). 
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Figure 2 Dietary iron uptake in enterocytes and transferrin mediated iron uptake in cells. 
(A) The ferrireductase DcytB (blue) reduces ferric iron to ferrous iron, which is then imported 
along a proton gradient by the membrane protein DMT1 (green). Cytoplasmic iron is either 
bound to Ferritin or exported via the iron exporter Ferroportin (red). (B) Iron-bound transferrin 
is docking to the Transferrin receptor TFR1 (light green) at the plasma membrane. An 
endocytotic vesicles is formed. Upon acidification of the lumen, through an ATPase (brown), 
ferric iron is released from transferrin. A ferrireductase (not shown) reduces the iron, which then 
gets transported to the cytoplasm by DMT1. 
 
The TFR1-transferrin-2Fe(III) complex is then internalized by receptor mediated 
endocytosis via clathrin-coated pits, which in turn fuse with endosomes (Jefferies et al., 
1984; Soda and Tavassoli, 1984). Endosomes are acidified by an ATP-dependent proton 
pump resulting in a luminal pH of ~5.5, which causes the release of iron from the 
transferrin complex triggered by a conformational change of the protein, (Dautry-Varsat 
et al., 1983; Sipe and Murphy, 1991). A metalloreductase known as STEAP3 (6-
transmembrane epithelial antigen of the prostate 3, Ohgami et al. 2006; Sendamarai et al. 
2008), reduces ferric iron to ferrous iron, which is subsequently transported by NRAMP2 
into the cytoplasm, where it is either bound by ferritin or exported by ferroportin 
(Munro and Linder, 1978). The transferrin receptor and apotransferrin remain bound to 
each other under acidic conditions. Only when reaching the cell surface via endosome 
fusion the complex disassembles once it faces the higher pH of the outside (Dautry-
Varsat et al., 1983). The process is illustrated in Figure 2 (B).  
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1.5. Physiological roles of mammalian NRAMP1 
 
In contrast to NRAMP2, the expression of NRAMP1 is primarily confined to 
phagocytes (which include neutrophils, eosinophils, basophils, monocytes and 
macrophages), the spleen and the liver (Govoni et al., 1997). NRAMP2 plays a critical 
role in the recycling of iron from senescent red blood cells (Soe-Lin et al., 2009). Human 
erythrocytes circulate on average 115 days in the blood (Mock et al., 2011) and they 
contain more than 50% of the total iron of the human body. Daily 200 billion of 
senescent erythrocytes are ingested by macrophages and degraded in their lysosomes (de 
Back et al., 2014). In order to regain the iron, the enzyme heme oxygenase 1 degrades 
heme and releases iron, biliverdin and carbon monoxide (Abraham and Kappas, 2008; 
Schacter, 1988). Subsequently the ferric iron is oxidized by the ferroxidase Seap3 (Zhang 
et al., 2012a). NRAMP1 (Soe-Lin et al., 2008) and NRAMP2 (Jabado et al., 2002; Soe-Lin 
et al., 2010) are transporting the ferrous iron from the phagocytotic vesicles to the 
cytosol where it is either bound to ferritin or exported via ferroportin (FPN, SLC40A1; 
Figure 3(A)). Due to the efficient recycling of iron in the human body we only need to 
take up 1-2 mg of dietary iron per day, albeit we daily need ~20-30 mg of iron for the 
production of new erythrocytes (Ganz and Nemeth, 2012). 
 
Figure 3 Iron recycling from erythrocytes and iron transport across phagosomes.  
(A) The macrophage takes up senescent erythrocytes (red ellipsoid) via endocytosis. An ATPase 
(brown) acidifies the vesicle to allow the transport of iron to the cytoplasm mediated by 
NRAMP1 and DMT1 (green). Cytoplasmic iron will be exported via ferroportin (red) or gets 
bound to ferritin. (B) In case a bacterium is taken up from a macrophage by phagocytosis the 
principle is the same as shown in (A). The bacterium (violet) is trapped in the vesicle, which gets 
depleted from divalent metal ions through proton coupled metal symport via NRAMP1 and 
DMT1 (green). 
H+Fe2+ 
NRAMP 
H+ 
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Even before NRAMP1 was identified as a key player for iron recycling from senescent 
erythrocytes ingested by macrophages, the gene locus of NRAMP1 was associated with a 
resistance to certain bacterial infections in laboratory mice (Plant and Glynn, 1979). Mice 
found to be susceptible to certain bacterial infections had a point mutation within an 
aspartate at position 169 instead of the native glycine residue (Malo et al., 1994). In 
studies with knockout Nramp1-/Nramp1-mice the same phenotype, namely higher susceptibility 
for several Mycobacteria, or S. typhimurium and L.donovani, was observed indicating the 
deleterious effect of the G169D point mutation in mouse NRAMP1 (Vidal et al., 1995b). 
Based on experiments where increased dietary iron in wt/wtmice fostered the replication of 
Mycobacterium avium (Gomes et al., 2001). It was concluded that NRAMP1 depletes the 
bacterium from divalent metal ions, after ingestion by macrophages. At the same time 
another group suggested that NRAMP1 imports iron into phagosomes (Kuhn et al., 
1999, 2001). However there have been several studies showing that NRAMP1 (Forbes 
and Gros, 2003; Jabado, 2000) acts similarly as its closely related family member 
NRAMP2 as proton coupled symporter (Canonne-Hergaux et al., 2001; Gunshin et al., 
1997; Mackenzie et al., 2006, 2007). Given the fact that NRAMP1 and NRAMP2 both 
share two highly conserved motifs (DPGN, MPHNX3H), which contain an aspartate, 
asparagine and methionine that have been identified to coordinate divalent metal ions in 
ScaDMT (the homolog from Staphylococcus capitis, investigated in this study) it more likely 
that NRAMP1 and NRAMP2 share the same direction of divalent metal transport. The 
process is illustrated in Figure 3 (B). 
1.6. Iron homeostasis - a tightly controlled regulatory 
network 
 
NRAMP1 and 2 are up to now the only iron importers in mammals that have been 
identified. The corresponding exporter is ferroportin. Both transporters import iron as 
free ions. Additionally iron can be taken up as complex with heme and although the 
import of heme is less well understood, there has been recent progress in the 
identification and initial characterization of a mammalian heme transporter termed 
HRG1 (for heme responsive gene 1) (Rajagopal et al., 2008; White et al., 2013). Because 
of the high reactivity of ferrous iron, which would lead to the generation of reactive 
oxygen species (ROS), detrimental to living cells, iron is tightly regulated in our body.  
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Several proteins involved in iron metabolism, are controlled at the mRNA level: Besides 
the gene encoding for DMT1 also the transferrin receptor TFR1 gene contains at its 
3`UTR a so-called iron responsive element IRE (Casey et al., 1989). In the absence of 
iron, iron-regulatory proteins (IRP1 or IRP2) bind to the stable stem loops formed by 
the 3`IRE elements, consequently protecting the mRNA from cleavage by endonucleases 
(Caughman et al., 1988; Rouault et al., 1988). Ferritin mRNA contains IRE elements as 
well, but they are encoded at its 5` UTR (Aziz and Munro, 1987). Under iron-depletion, 
IRPs inhibit translation of the ferritin encoding mRNA by binding to the hairpin 
structure formed at its 5`end (Hentze et al., 1987). Ferritin and transferrin are the major 
iron storage proteins in our body. In contrast to transferrin, which binds two ferric iron 
molecules per transferrin dimer, ferritin is a 24 subunit multimer, which can hold up to 
4500 iron atoms per complex (Harrison and Arosio, 1996). Ferritin has ferroxidase 
activity that allows it to oxidize ferrous iron to ferric iron, which it stores as inorganic 
complex in the core of the protein. Besides the multiple regulatory elements on the 
mRNA level, there are additional regulatory mechanisms at the protein level that 
influence iron uptake and storage. An example for post-translational regulation is the 
hepcidin/ferroportin system.  
Hepcidin is a 25 amino acid long peptide-hormone mainly expressed by 
hepatocytes that is up-regulated during iron overload (Pigeon et al., 2001). At high iron 
levels, hepcidin binds to the ferroportin transporter inducing its internalization and 
degradation, thereby reducing cellular iron release in macrophages and enterocytes 
(Nemeth et al., 2004). The process is illustrated in Figure 4. Since, additionally to the 
regulation of iron homeostasis hepcidin also acts as antimicrobial substance, that is able 
to disrupt bacterial membranes (Maisetta et al., 2013; Park et al., 2001), it was given the 
name hepatic bactericidal protein. Besides the regulation by IREs and hepcidin, high 
levels of dietary iron are known to reduce the levels of DMT1 and DcytB present at the 
apical membrane of enterocytes by a mechanism that is not well understood (Yeh et al., 
2000). It is hypothesized that DMT1 and DcytB might be internalized or that the 
expression levels of the two proteins might be down regulated (Yeh et al., 2009). Besides 
the discussed processes that contribute to the complex network regulating iron levels in 
our body, there may be other regulatory mechanisms that are still less well understood, 
e.g. the effect of hypoxia on hepcidin levels through hypoxia-inducible factor (HIF) 
proteins (Liu et al., 2012). 
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Figure 4 Iron regulation  
(A) Ferroportin regulation by hepcidin. Binding of hepcidin to ferroportin causes the 
internalization of the transporter by endocytosis and its subsequent degradation in lysosomes. (B) 
Regulation of hepcidin expression in response to changing iron levels. Binding of HJV to BMPR 
induces a signaling cascade mediated via SMAD proteins, which bind to the hepcidin gene and 
regulates its transcription.  
1.7. Diseases associated with iron imbalance 
 
Because iron levels are controlled in a concerted multi-layered process, malfunction of 
either of the involved proteins can have a deleterious effect on iron metabolism.  
Iron-overload disorders. Point mutations in four different genes have been 
associated with the most common iron-overload disorder in humans, hereditary 
hemochromatosis. The most prevailing type of hereditary hemochromatosis is caused by 
a recessive mutation in the HFE gene (Feder et al., 1996). The HFE protein is distantly 
related to the major histocompatibility complex and binds to the TRF1 receptor in 
endosomes, thereby competing with transferrin for binding to the receptor (Giannetti 
and Björkman, 2004; Ramalingam et al., 2000). Patients with mutations in their HFE 
gene have low hepcidin levels and suffer from iron accumulation in the liver, pancreas 
and heart, which can lead to hepatic cirrhosis, diabetes and heart failure. Type II 
hereditary hemochromatosis is caused by a mutation in the membrane-bound 
hemojuvelin (HJV) protein, which affects hepcidin expression via binding to BMPR 
(Bone morphogenic protein receptor) and SMAD signaling (Figure 4B). The disease is 
also called juvenile hemochromatosis due to its fast progression that might lead to 
premature death (Babitt et al., 2006). Type III hereditary hemochromatosis is the result 
of a mutation in the TFR2 receptor causing a similar phenotype as in type I 
A
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hemochromatosis (Chen and Enns, 2012; Roetto et al., 2002). Type IV hemochromatosis 
originates from mutations in the FPN gene, causing iron accumulation either in 
macrophages (Fernandes et al., 2009), or in hepatocytes because the liver is known to 
have the highest relative iron uptake rate compared to other tissues in our body (Craven 
et al., 1987). 
Iron-deficiency disorders. Anemia is a widespread pathological condition in the 
entire human population. The World Health Organization WHO projects a global 
anemia rate of ~25%, based on their “worldwide anemia prevalence survey”, conducted 
from 1993-2005 (World Health Organization, 2008). Lowest rates were found in Europe 
(~10% of the population are anemic) and in other First World countries. More than 45% 
of the population in South East Asia and Africa has anemic hemoglobin concentrations. 
Main causes are nutritional iron-deficiency and infections with the ubiquitously present 
bacterium Helicobacter pylori (De Domenico et al., 2008; Hentze et al., 2010; Hershko 
and Skikne, 2009). Despite the fact that in developing countries iron deficiency is 
predominantly caused by environmental factors, there are also hereditary causes that 
have been identified in patients with anemic conditions (Canonne-Hergaux et al., 2000; 
Finberg et al., 2008). Mutations in DMT1 are known to cause hypochromic microcytic 
anemia. Although patients are severely anemic and show reduced iron uptake, they 
additionally suffer from hepatic iron overload. This can be explained by the impaired 
iron recycling from erythrocytes in this disease, with iron stores that accumulate in the 
liver (Iolascon and De Falco, 2009). DMT1 mutations identified in patients include, the 
conservative point mutation E399D causing exon 12 skipping (Mims et al., 2005), R416C 
causing a complete loss-of-function of DMT1 (Iolascon et al., 2006), G212V in 
combination with an in-frame deletion of Val114 (Beaumont et al., 2006). Recently a 
patient carrying a novel N491S mutation and the known G212V mutation has been 
identified (Bardou-Jacquet et al., 2011).  
Hypochromic microcytic anemia is treated with erythropoietin or its glycosylated 
successor darbopoietin combined with oral or intravenous iron supplementation, which 
helps to maintain hemoglobin levels and relieves the strongest symptoms (Iolascon and 
De Falco, 2009; Steinbicker and Muckenthaler, 2013). Besides this combination therapy 
there is no other adequate treatment known for these patients. Patients with hereditary 
hemochromatosis are treated with ferritin, iron-chelating infusions and regular 
phlebotomy to slow down disease-progression (Camaschella and Poggiali, 2011). There is 
currently no treatment available that helps to slow hepatic iron overload, which as long-
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term condition can cause liver cirrhosis. In 2007 a study reported that hepatic iron 
overload was reduced in iron-loaded mice that were treated with the calcium channel 
blocker nifedipine (Ludwiczek et al., 2007). Based on 59Fe2+ uptake measurements in 
COS-7 and HEK293 cells overexpressing DMT1, the authors concluded that nifedipine 
increases DMT1-mediated iron transport, which might be a new therapeutic approach 
for the treatment of iron overload disorders. However these results were challenged by 
Mackenzie et al, who reported in 2010 that nifedipine did not increase iron transport in 
Xenopus oocytes or in transiently transfected HEK293 cells overexpressing different 
isoforms of hDMT1 (Mackenzie et al., 2010). 
To date mechanisms for the regulation of hepcidin by pharmacological 
compounds, can be considered the most promising direction to treat the most prevalent 
iron-overload disorders. A review published in 2007 draws an analogy between hepcidin 
in hemochromatosis and the role of insulin in diabetes (Pietrangelo, 2007). The 
development of a reliable serum-hepcidin blood test may thus significantly ease the 
diagnosis of iron-related disorders (Delaby et al., 2014). Increased iron levels have also 
been found in neurodegenerative diseases such as Parkinson’s (Andersen, 2004; Berg et 
al., 2001) and Alzheimer’s disease (Smith et al., 1997). Elevated DMT1 expression levels 
in animal models of Parkinson’s (Salazar et al., 2008) and Alzheimer’s disease (Zheng et 
al., 2009) have fostered the hypothesis that DMT1 might play an important role in the 
progression of neurodegenerative diseases (Hirsch, 2009; Lee and Andersen, 2010). 
Further knowledge on iron transport and its regulation is thus needed to better 
understand the complex system of iron homeostasis in health and disease. As one of the 
predominant proteins in cellular iron transport processes, a detailed structural and 
mechanistic understanding of DMT1 will in that respect be of large importance.  
1.8. Plant Nramps 
 
Plants are highly dependent on the availability of transition metal ions. Shortage in iron 
or manganese reduces their capacity for photosynthesis and thus limits their growth. 
Proteins of the photosystem I and II contain iron (as [2Fe-2S], [4Fe-4S] iron sulfur 
clusters) and manganese (as Mn4CaO5), which are both essential cofactors for electron 
transport (Amunts and Nelson, 2009; Liu et al., 2011). For that reason chloroplasts, the 
organelles where photosynthesis takes place, are in need for the large quantities of iron 
and manganese (Yruela, 2013). There is a large diversity of metal transporters that 
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catalyze transition metal ion transport in plants. The model system Arabidopsis thaliana 
contains in total 8 different metal ATPases, 15 different ZIPs (zinc-regulated-iron-
regulated-like proteins and 6 different NRAMP homologs (Maser, 2001; Mills et al., 
2003; Williams et al., 2000). This variety of low- and high affinity metal transporters 
ensures metal ion supply under different environmental conditions (Hall and Williams, 
2003). NRAMP homologs of A. thaliana (AtNRAMP 1-6) are confined to distinct 
organelles, which allows the separate regulation of each subtype, which caused 
speculations about altered substrate specificity of different AtNRAMP proteins (Curie et 
al., 2000; Thomine et al., 2000). The best characterized plant NRAMP transporters 
include the AtNRAMPs (Lanquar et al., 2010; Williams et al., 2000) and the NRAMPs 1-
6 identified in Oryza sativa (Belouchi et al., 1995; Takahashi et al., 2011).  
Besides the analysis of loss-of-function mutants in the corresponding plant, yeast 
complementation assays have been used to characterize the metal transport properties of 
plant NRAMPs (Cailliatte et al., 2009, 2010; Oomen et al., 2009; Thomine et al., 2000). 
AtNRAMP1 has been identified as iron transporter that is up-regulated in the root under 
iron-deficiency (Curie et al., 2000). AtNRAMP3 and 4, in contrast, are located in the 
vacuolar membrane and are involved in iron and cadmium transport (Cailliatte et al., 
2010; Lanquar et al., 2010). OsNRAMP5 was found to transport manganese and 
cadmium (Sasaki et al., 2012). Comparison of the amino acid sequences of AtNRAMP1-
6 and OsNRAMP1-3 (Williams et al., 2000) reveal that they all contain the conserved 
motifs DPGN and MPHNX3H, two sequence motifs that contain residues that are part 
of a binding site in the NRAMP homolog ScaDMT from the bacterium Staphylococcus 
capitis (Ehrnstorfer et al., 2014) that coordinates different transition metal ions. It is thus 
unclear whether different NRAMP homologs in plants have different selectivity 
properties. Due to the numerous NRAMP homologues present it plants it can be 
expected that additional subtypes will be discovered in future studies. Recently a new 
subtype of NRAMP transporters, termed NRAMP aluminum transporter 1 (NRAT1), 
was identified in O. sativa. The authors overexpressed NRAT1 in yeast and detected their 
aluminum content by ICP-MS (Li et al., 2014). NRAT1 is 57% identical to OsNRAMP1, 
35% identical to ScaDMT and 30% identical to hDMT1. Despite the fact that two of the 
three residues responsible for metal ion binding in ScaDMT are conserved in NRAT1, 
the glycine of the DPGN motif is replaced by a serine. Remarkably, in this transporter 
the MPHNX3H motif is changed to TPYNX3H, which places a threonine instead of the 
strictly conserved methionine that was found as part of the coordination site of transition 
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metal ions. In this conserved sequence stretch the close-by histidine residue is replaced 
by a tyrosine. It will thus be interesting to investigate whether NRAT1 has an altered 
substrate specificity compared to other family members. 
1.9. Prokaryotic DMTs 
 
Soon after the first characterization of mammalian NRAMP proteins (Gunshin et al., 
1997), prokaryotic homologs were identified by sequence analysis of prokaryotic 
genomes (Agranoff et al., 1999; Kehres et al., 2000; Makui et al., 2000). On average, 
bacterial NRAMPs share a sequence identity of 30-35% with hNRAMP2, which is 
unusually high compared to other transport proteins. Among the first prokaryotic 
transporters to be identified, were the NRAMP homologs from Salmonella typhimurium 
and Escherichia coli. With radioactive uptake measurements of 54Mn2+ into bacteria 
expressing the respective homolog, Kehres et al. could show that both proteins transport 
Mn2+, independent of the presence of calcium or magnesium (Kehres et al., 2000). 
Addition of “cold” Ni2+, Cu2+, Zn2+, Co2+, Fe2+ or Cd2+ inhibited uptake of 54Mn2+ thus 
suggesting that these ions may also be transported substrates. Maximum uptake of 
54Mn2+ was increased at lower pH, without shift in the apparent Km of the ion thus 
suggesting that transport may be coupled to protons. Although NRAMPs have been 
shown to have a broad substrate specificity, the relevant ion in a physiological context is 
manganese since iron is taken up by bacteria mainly as complex with siderophores or 
porphyrins (Guerinot, 1994; Makui et al., 2000). Mn2+ is an essential cofactor for 
enzymes such as superoxide dismutases, pyruvate carboxylases and ribonucleotide 
reductase (Kehres and Maguire, 2003). An important aspect of bacterial manganese and 
iron aquisition has to be viewed in the context of host-pathogen interaction (Chu et al., 
2010; Forbes and Gros, 2001; Nairz et al., 2010, 2014; Plant and Glynn, 1974). E.P. 
Skaar described in his review “The battle for iron between pathogens and their vertebrate 
hosts” (Skaar, 2010), strategies of the bacteria and their eukaryotic host to sequester 
metal ions. G. Schatz wrote a delightful short-story on the metal manganese where he 
does not miss to mention the war between bacterial and human NRAMP transporters 
being a matter of life and death (Schatz, 2003). 
The transmembrane topology of the E. coli NRAMP homolog Mnth (for H+ 
stimulated Mn2+ transporter) has been investigated by fusing reporter proteins into the 
loops predicted by hydropathy analysis. A secreted form of the antibiotic β-lactamase 
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was used as indicator for periplasmic localization and chloramphenicol acetyltransferase 
served as reporter protein for cytoplasmic localization (Courville et al., 2004). The 
experimental data confirmed the prediction of 11 transmembrane segments with a 
cytoplasmic N terminus and a periplasmic C terminus. It was not until 2009 that the 
topology of murine NRAMP2 was investigated by similar methods (Czachorowski et al., 
2009). In this case the 10 amino acid long hemagglutinin A (HA) peptide was fused into 
the predicted loops of mNRAMP2. The extra- or intracellular localization of the HA-tag 
was detected by immunofluorescence (with a rhodamine coupled secondary antibody). 
The study with mNRAMP2 indicated that mammalian NRAMP transporters have an 
additional twelfth transmembrane segment resulting in a cytoplasmatic N and C 
terminus. The structural relationship of SCL11/NRAMP transporter with a large class of 
transport proteins was recently proposed based on sequence analysis (Cellier, 2012a, 
2012b). This proposal could be confirmed in my work by the structure determination of 
the first family member.  
1.10. Aim of this thesis 
 
While functional data on the SLC11 transporters has clarified their role as H+ coupled 
transporter of transition metal ions, the detailed structural organization of the family was 
unknown. Because high-resolution structural data is inevitable in order to understand the 
mechanisms of divalent metal-ion binding and transport it was my aim to determine the 
first high-resolution structure of a SLC11 family member. In order to understand the ion 
selectivity properties of SLC11 proteins, I have established a transport assay that allowed 
the characterization of metal ion selectivity in a prokaryotic family member. 
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2. RESULTS 
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2.1. Selection of prokaryotic homologs of the SLC11 
family suitable for structural studies  
 
Members of the SLC11 family are found in all kingdoms of live and are highly conserved 
from bacteria to mammals. Bacterial and archaeal homologs share 25-35% sequence 
identity and 40-65% homology with the human SLC11 transporters, and were thus 
straightforwardly identified after the discovery of the human SLC11 gene (Makui et al., 
2000; Zaharik et al., 2004). All SLC11 transporters share a common topology of 10 
highly conserved (predicted) transmembrane segments (Courville et al., 2008). All 
eukaryotic SLC11 transporters contain two additional transmembrane helices (Courville 
et al., 2004; Czachorowski et al., 2009; Xue et al., 2009) on their C terminus, whereas in 
bacteria two topologies are present. While a small number of prokaryotic SLC11 
homologs supposedly contain 12 transmembrane segments, like eukaryotic transporters, 
in the majority of transporters the last α-helix is absent and proteins thus contain 11 
transmembrane segments with a predicted extracellular C terminus. Termini and loop 
regions are the least conserved parts of SLC11 transporters and they are usually shorter 
in bacteria. Due to their widespread occurrence, their high sequence conservation and 
compactness I have selected a large set of bacterial homologs to identify SLC11 
transporters amenable for structural studies. 
2.1.1. In silico homolog selection 
 
The protein sequence of human DMT1 (including and excluding the last two predicted 
transmembrane segments) was used as query for BLAST (basic local alignment search 
tool) searches on all available annotated bacterial and archaeal genomes. Pairwise 
sequence alignments were scored based on the Blosum62 block substitution matrix 
(NCBI BLASTp; Altschul et al. 1990, ,States & Gish 1994) according to their degree of 
sequence conservation.  
The number of sequenced genomes has been increasing almost exponentially 
over the last years. By the end of 2013 more than 10 000 bacterial genomes were 
available in the GOLD genome database (Pagani et al., 2012). Above 3000 of these were 
fully sequenced, annotated and available for sequence based homology searches (Pagani 
et al., 2012) at that time. To further select among the large number of homologs 
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identified in BLAST searches, additional criteria were applied: Homologs from 
extremophilic organisms were prioritized in the first round due to the stability of their 
proteins under extreme conditions (e.g. temperature, ionic strength, pH, pressure, de 
Champdoré et al. 2007), despite their on average lower sequence conservation compared 
to eubacterial strains. Additionally, proteins with short and compact termini and loops 
were given preference, since flexible parts might be disadvantageous for crystallization. 
Genomes of microorganisms classified in biosafety level 2 were only included if the 
genomic DNA was available. Interestingly, the genome of Ralstonia metallidurans, a 
bacterium known to grow in heavy metal polluted sediments, that proved to be a 
promising source of different ion transport proteins, was one of the few organisms that 
appears not to contain any homolog of the SLC11 family. In addition to the described 
selection criteria, proteins from bacteria containing two different branches of the 
phylogenetic tree were chosen to ensure a genetically diverse pool. By this selection bias 
to a small subset was avoided to reduce the risk of excluding a subfamily of proteins that 
may show superior biochemical properties, despite the fact that they may not optimally 
match the chosen selection criteria. The 35 homologs selected in round 1 based on a 
BLAST search with human DMT1 as query are depicted in Table 1.  
After characterization of the first set of homologs, a second round of target 
selection was performed, which was based on the results of the first selection. The 
expression screening was carried out in a similar way for both selections. The sequences 
of the two best-behaved homologs identified in round one (29LLA, 99CCU) were used 
as input query in order to increase the chance of selecting homologs with superior 
biochemical properties suitable for structural studies. This BLASTp search lead to the 
identification of 51 additional SLC11 transporters selected for expression screening 
(Table 2). For all but four homologs, 11 transmembrane helices were predicted by 
OCTOPUS (Anon 2011, Viklund et al. 2008) a tool, designed to predict alpha-helical 
transmembrane segments and signal sequences (Table 1, Table 2). As a second 
transmembrane helix prediction tool TOPCONS (Bernsel et al., 2008, 2009), developed 
by the Bioinformatics Center of the University of Stockholm, was used. In two cases less 
than 11 transmembrane segments were predicted, (with 7 and 9 segments respectively for 
the homologs 50MTU and 94CLI). Transport of a DMT homolog from Oncorhynchus 
mykiss with 10 putative transmembrane segments has been reported but it is not clear if 
fewer segments would still fold into a functional transporter. It can thus be assumed that 
the sequences available for 50MTU and 94CLI were incomplete (Cooper et al., 2007).  
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Together with the master student Jürg Laederach more homologs were selected based on 
the most stable proteins in the first and second screening round (i.e. with the transporter 
29LLA, 88BEG, 98ELE, 99CCU, 135SCA, and hDMT1 as query; Laederach, 2011). This 
search resulted in the identification of three novel homologues that were characterized 
together with the master student Fabian Arnold (Arnold, 2013). When including the 
results of the third screening 105 prokaryotic DMT genes were successfully cloned and 
investigated with respect to expression levels, extractability and biochemical stability. The 
work on these homologs is described in the respective master theses and will therefore 
not be discussed in this work.  
Figure 5 shows the phylogenetic tree calculated from a multiple sequence 
alignment generated by ClustalW2 (Goujon et al., 2010; McWilliam et al., 2013) from the 
86 selected homologs together with human DMT1. 
 
Table 1 Homologs selected for screening, round 1.  
BLASTp search was carried out with hDMT1 as query sequence. 32 of the 35 bacterial strains 
were either obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) 
or ATCC. 33 homologs are predicted to contain 11 transmembrane helices.  
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Table 2 Homologs selected for screening, round 2.  
51 Homologs were selected based on a BLASTp search with 29LLA and 99CCU as query 
sequences. 58LUL and 101FJO were both predicted to contain 12 transmembrane helices. 
50MTU and 94CLI were predicted to contain 7 and 9 transmembrane helices respectively.  
 
The sequences cluster in two main branches: 25% of the selected bacterial homologs 
cluster in relative proximity to human DMT1 and 75% of the selected bacterial SLC11 
genes cluster in a second group distinct from human DMT1. The two stable proteins 
29LLA and 99CCU, used as query for a second round of BLASTp searching, are located 
in either of the two main families. ScaDMT, the bacterial homolog that could 
successfully be crystallized, is closer in sequence to 29LLA than to human DMT1. Three 
of the four homologs predicted to contain 12 transmembrane spanning segments cluster 
in the same branch of the phylogenetic tree.  
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Figure 5 Phylogenetic tree of hDMT1 and 86 homologs selected in two rounds of 
BLASTp searches.  
Human DMT1 is highlighted in blue. The two stable homologs 29LLA and 99CCU identified in 
round one are marked in violet. The homolog (135SCA) selected for structural and functional 
studies is depicted in green. The four homologs predicted to have 12 TMs (OCTOPUS) are 
marked with triangles (29LLA, 58LUL, 60CPI, 100SWA). 
2.1.2. Cloning of prokaryotic DMT homologs 
 
Bacterial strains were purchased from DMSZ either as freeze-dried cell pellets or as 
growing cultures, depending on their availability. The genomic DNA was isolated by 
phenol-chloroform extraction. For all risk-2 strains, genomic DNA was ordered from 
DSMZ. 65 genes of interest could be successfully amplified from genomic DNA by the 
use of different DNA polymerases and a variation of PCR conditions. 19 genes could 
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not be amplified by the applied methods and were thus not pursued. The primers 
included specific 5’ and 3’ SapI sites suitable for the FX (fragment exchange) cloning 
procedure and were designed in an automated fashion by a python script available at 
www.fxcloning.org (Geertsma and Dutzler, 2011). 
 
 
Figure 6 Schematic view of FX-cloning.  
The gene of interest (green) is amplified with primers containing flanking SapI sites (arrows 
indicate the orientation of the SapI sites). The digested PCR product is then ligated to the 
digested entry plasmid pINITIAL, thereby replacing the ccdB cassette (pink). For expression, the 
gene is subcloned through SapI digest of pINITIAL (+ gene of interest) and the desired 
expression vector, followed by ligation. Once the gene replaced the ccdB cassette in the 
expression vector SapI sites are lost, adding an N terminal serine and a C terminal alanine to the 
gene of interest (modified from Geertsma and Dutzler, 2011). 
 
The shuttle vector pINITIAL and the three expression vectors used in this study 
(pBXNH3, pBXC3H, pBXC3GH) are part of the FX vector collection designed by Eric  
Geertsma (Geertsma and Dutzler, 2011). The FX-cloning method exploits advantages of 
the type II restriction enzyme SapI (Saccharopolyspora species) for the generation of 
constructs. SapI cuts 5’ distal from the recognition sequence and therefore enables the 
generation of different overhangs for directed insertion into vectors. The SapI site will be 
removed upon digestion, depending on the orientation of the recognition sequence. The 
SapI sites in the shuttle vector pINITIAL are maintained on the plasmid after digestion, 
to allow a simple strategy for sub-cloning into the desired expression vectors (Figure 6). 
The vectors used for expression screening carry two SapI sites oriented in a way that the 
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recognition sequence is lost upon digestion. The selection for vectors with correct inserts 
by the FX-cloning method is highly efficient due to the presence of a so-called ‘kill-
cassette’ in original vectors. This cassette is located between the two SapI sites and 
encodes the Control-of-cell-death-gene B (CcdB) gene. The cytotoxic CcdB protein 
targets the subunit GyrA of the DNA gyrase (a subunit of the bacterial topoisomerase 
II), which then causes double strand breaks in the DNA. Vectors containing the CcdB 
gene are maintained in cells encoding for GyrA462 (Arg462 to Cys substitution) a mutant 
of the GyrA subunit that is resistant to CcdB (Bahassi et al., 1999; Bernard and 
Couturier, 1992). For cloning, the digested insert is ligated into the digested vector and 
the plasmids are subsequently transformed to CcdB sensitive cells. Only cells carrying a 
plasmid where the insert has replaced the CcdB cassette will survive. The different 
overhangs generated by SapI prevent re-ligation of the empty vector and they ensure a 
directed insertion of the insert. 
The expression vectors pBXNH3, pBXC3H and pBXC3GH are schematically 
depicted in Figure 7. pBXNH3 encodes for an N-terminal His10-tag cleavable by a 3C 
human rhino virus protease (3C protease). The vector pBXC3H has the same 3C 
cleavable His10-tag but in this case the tag is located on the C terminus of the gene. 
pBXC3GH encodes for a C-terminal 3C cleavable GFP- His10-fusion-tag (GFP, green 
fluorescent protein). The C-terminal GFP-fusion construct was chosen as a folding 
indicator and for detection purposes in high-throughput applications due to its 
fluorescence properties (Drew et al., 2005, 2006; Geertsma et al., 2008a; Kawate and 
Gouaux, 2006). Furthermore fusion-tags have been reported to enhance expression 
(Esposito and Chatterjee, 2006; Wagner et al., 2007; Waldo et al., 1999; Xie and Hong, 
2009). The GFP-fusion protein can only correctly fold in the cytoplasm (Drew et al., 
2002). For several homologs 11 transmembrane segments were predicted, resulting in a 
periplasmic C terminus and therefore leading to unfolded non-fluorescent GFP. 
However, since the results were obtained from hydropathy analysis and thus the location 
of the C terminus was not always conclusive, I decided to investigate C-terminal GFP-
fusion constructs for all selected homologs. 
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Figure 7 Constructs used for the expression screening of prokaryotic SLC11 homologs.  
The three different constructs incorporate either an N-terminal (pBXNH3) or a C-terminal 
(pBXC3H) His10-tag (red), which in all cases includes a cleavage site for 3C protease (orange). 
pBXC3GH has in addition GFP (green) fused to C terminus of the SLC11 homolog (blue). The 
two additional amino acids serine (S) and alanine (A) are introduced by the FX-cloning method 
(grey). 
 
For crystallographic studies it is preferable to have the fusion tag N-terminally as it leaves 
only two additional amino acids from the 3C cleavage-site after proteolysis, compared to 
five additional amino acids remaining after cleavage on the C terminus. As a third 
construct the C-terminal His10 –tag was tested. This construct does not contain GFP and 
therefore is applicable independent on the localization of the C terminus of the protein. 
The His10-tag included in all constructs can be used for detection in western blot analysis 
and serves as an affinity-tag for immobilized metal affinity chromatography (IMAC) 
purification by binding to Ni-NTA beads. 
 
2.1.3. Expression and extraction screening of selected SLC11 
homologs 
 
Protein crystallography has strict requirements with respect to the biochemical stability 
of the target protein. Preferably milligram amounts of well-folded protein need to be 
produced and purified to homogeneity before crystallization experiments are set-up. 
Additionally, membrane proteins have to be stable in a detergent solubilized state, ideally 
at protein concentrations of several milligrams per milliliter. Therefore the successful 
overexpression of a target protein is a critical hurdle scientists need to overcome along 
the path to a new high-resolution structure.  
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One approach to identify the most promising constructs for further investigations, 
involves the screening of many homologs. The use of GFP as fusion protein had a major 
impact on the ease of detection in all experimental steps during screening, starting from 
overexpression, extraction, detergent exchange and the use of fluorescence size exclusion 
chromatography (FSEC) to reveal the monodispersity of the target protein (Geertsma et 
al., 2008a; Kawate and Gouaux, 2006).  
When fused to the C terminus of the membrane protein, GFP can also be used 
as folding indicator (Geertsma et al., 2008a). The GFP moiety will only fold properly and 
become fluorescent if the N-terminally fused protein is correctly folded as well. Thus the 
measurement of the GFP-fluorescence in intact cells allows for the initial assessment of 
functional target protein overexpression. Later, the fluorescence of GFP can be exploited 
to quantitate the amount of target protein extracted from the lysate and the population 
of protein that is retained in the supernatant after removal of insoluble proteins by 
ultracentrifugation. In-gel fluorescence measurements can detect stable membrane 
protein – GFP-fusions since GFP does not unfold under standard SDS-PAGE 
conditions (Drew et al., 2006, 2008). The fusion protein with the folded, and therefore 
globular GFP moiety migrates faster in the SDS-PAGE gel compared to the unfolded 
non-fluorescent fraction. The comparison of the in-gel GFP fluorescence image with the 
corresponding anti-His western blot from the same gel can be utilized to distinguish 
between folded and unfolded protein fractions (Geertsma et al., 2008a). Furthermore 
Kawate and Gouaux showed in 2006 that the GFP fluorescence can be exploited to 
record the size exclusion chromatography profile of the fusion protein when crude lysate 
is injected to a HPLC system equipped with a fluorescence detector (Kawate and 
Gouaux, 2006). 
Proteins expressed without GFP were analyzed for their expression and 
extraction properties by western blot with an antibody recognizing the His10 -tag. In 
these cases the stability in detergent solution and the monodispersity were assessed after 
scale-up of the expression in 2.5 liter cultures followed by affinity purification and 
injection to size exclusion chromatography. 
For expression purposes the pBAD promotor was chosen since it allows tight 
control of transcriptional activity in dependence on the inducer concentration. This is 
particularly important for membrane proteins, as in these cases a strong overexpression 
often causes the misfolding of the protein. By titration of the inducer its ideal 
concentration, at which the functional overexpression is maximized, can be determined. 
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For protein expression the strain Escherichia coli MC1061, which has a disrupted ara gene 
and is therefore unable to metabolize arabinose, was used as host.  
 
  
Table 3 Overview of the 86 homologs selected for cloning and expression tests. 
Homologs that could not be amplified are marked in grey. Minus (-) indicates that the sample 
was either not expressed (exp.) or extracted (ext.). Expression, extraction and stability properties 
on FSEC/SEC were ranked between medium (+) to very good (+++). Plus signs marked in 
orange indicated cases where, although detectable in in-gel fluorescence experiments or on 
western blots, degradation of the protein was observed. 88BEG and 98ELE were not 
monodisperse on SEC and degraded over a period of 1-2 days after SEC. 
 
The expression screening was carried out in 24-well plates in 4 ml cultures. For each 
homolog three different constructs (NH3, C3H, C3GH) were combined with up to three 
different arabinose concentrations. Cells were lysed by bead beating and the supernatant 
was recovered after low spin centrifugation. In all cases membrane proteins were 
extracted by the addition of DDM (n-dodecyl- -D-maltopyranosid). Samples for 
western blot analysis were taken before and after ultracentrifugation to compare the total 
expression levels with the amount of extracted proteins that remains in the supernatant 
 
exp. ext. FSEC SEC exp. ext. SEC exp. ext. SEC exp. ext. FSEC SEC exp. ext. SEC exp. ext. SEC
2SPH 93AUR - - + - + -
3GAU 94CLI + - + + - - -
5FPS + + - - - - - - 97CLI - - - - - + -
6SAU - - - - - - 98ELE - - + + +
12ATU ++ + - - - 99CCU - - ++ ++ + - -
16SIN - - 100SWA
17RPA - - - - 101FJO ++ + - ++ + -
19STH - - - - 103LIN - - - - - -
23NPU + - 106SSP + + - + + - + -
25SMU - - 107SCA - - + + - - -
29LLA ++ ++ + + + - + - 112DAC - - + + - - -
32BSU 113LPL + + - + - - -
34DGE 118OCA + - + - + -
35DRA 119RET + - + - ++ ++ -
36SFU 125DMA
39CSA + - + - + - 126DVU - - - - - -
46CTE 128SWO - - - - - -
49PME - - + + - 129ECO - - - - - -
50MTU 130MTU - - - - - -
52PAR 135SCA - - + + +++ + - -
53PCA - - + - - - 137LWE - - ++ + - -
56NPH - - + - - - 138CGL
58LUL + + + - + - + - 141CSE - - - - - -
60CPI + - + - + - 142GAD - - + + - - -
61SLI + + - - - - 146NHA - - + + - - -
65TRO 147BIN - - - - - -
66CAG + + + - + - 148LME - - + + + +
68GBR - - + - - - 149GOX - - + - + -
69DTU 153WPA + - - - + -
72XCE + + - + - + - 155BPU + + - + + - + -
76KFL - - - - - 156BXE - - + - - -
77DLO 157MLU - - - - - -
78BCA + + - - - - 162HTU - - + - - -
79BCO + + - - - - - 164ACH + + - - - + +
83BAN + - - - - - 165BLO + + - + + + -
84BPS 167RER - - + - + -
86BIN 168ESI - - + + - + -
87BPL 169AAC - - ++ + - - -
88BEG - - + + + 172SSA - - + + - -
89PJO 178BTH - - - - - -
90BCO - - + + + - - 179BFR - - - - - -
91BDO + + + - - - - 180POR - - - - - -
92VPA - - + + - - - 184HVO - - - - - -
pBNH3pBXC3GH pBC3H pBNH3 pBXC3GH pBC3H
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(after ultracentrifugation). In case of GFP-tagged proteins, SDS-PAGE samples were 
analyzed by measurement of in-gel fluorescence followed by western blot analysis. The 
results of this screen are summarized in Table 3.  
For round one the number of genes that could not be amplified from genomic 
DNA is comparably high. A likely cause is that in most cases gDNA was isolated from 
dried cell pellets of probably low cell density, which might explain the poor success rate 
of PCR. Additionally some of the bacterial strains needed very harsh conditions to break 
their cell wall (e.g. several hours of incubation at max. 80 °C). In these cases lysis was not 
complete and the integrity of the gDNA might have suffered from the incubation. In 
round two all bacterial genomes were obtained as pre-purified gDNA from DSMZ. In 
this case only two out of 51 genes were not successfully amplified (Table 3).  
In summary, 49 different genes could be expressed in at least one of three 
investigated expression constructs. Six homologs (66CAG, 78BCA, 91BDO, 148LME, 
164ACH, 165BLO) were expressed and extracted but showed significant degradation as 
observed by in-gel fluorescence and western blot analysis. Out of the 33 genes that were 
extractable in detergent solution, only six genes were sufficiently stable for large-scale 
expression, protein purification and crystallization screening. Three of these genes 
(88BEG, 90BCO, 98ELE) were significantly degrading during and after purification, 
which was also reflected in the heavy precipitate visible in the crystallization setups (data 
not shown).  
The results of the three most promising candidates (29LLA, 99CCU, 135SCA) 
are depicted in Figure 8. 29LLA was expressed as GFP-fusion construct and subjected to 
FSEC (Figure 8a, c). 29LLA-GFP eluted at 7.6 ml, which corresponds to an apparent 
molecular weight of ~80-90 kDa on this column. Calculated from the amino acid 
sequence, the molecular weight of 29LLA-GFP is 82.9 kDA (29LLA 55.9 kDa, GFP 27 
kDA). The positive control LacS-GFP, which is 3.3 kDa smaller, elutes at slightly higher 
elution volume. Due to the detergent surrounding the solubilized membrane protein, the 
apparent molecular weight estimated from the elution volume on SEC is generally larger 
than its theoretical mass derived from the amino acid composition. The absolute 
fluorescence measured for the peak of 29LLA-GFP is by 1/3 smaller (3.4 FU) compared 
to LacS-GFP (5.1 FU) indicating lower expression levels or extraction efficiency. There is 
another peak towards lower molecular weight, indicating that 29LLA-GFP is not fully 
monodisperse.  
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Figure 8 Candidate selection by western blot and FSEC analysis. 
29LLA, 99CCU and 135SCA were identified as candidates with superior expression and 
extraction properties. (a) The GFP fluorescence of the extracted protein was detected for 29LLA 
in an SDS-PAGE gel (left), which was subsequently used for western blot analysis (right). (b) 
Samples of 99CCU and 135SCA after lysis (L) and after extraction (S) were analyzed by western 
blot analysis. All three proteins are visible as single bands after extraction. (c) FSEC analysis of 
29LLA-GFP. The positive control LacS-GFP (green) and the fluorescence negative control LacS 
(red) are represented in an overlay with the elution profile of 29LLA-GFP (blue). Elution 
volumes of the main peaks are indicated in volume (ml) and fluorescence units (FU).  
 
No significant fluorescence signal is detected for LacS expressed without GFP. Homolog 
99CCU and 135SCA are both expressed and appear as single band on SDS-PAGE 
before and after extraction. Judging from western blot analysis it appears that most but 
not all of 99CCU is extracted (Figure 8b). Since both proteins were expressed without 
GFP their stability and aggregation behavior was investigated after purification from a 
large-scale expression culture (see next chapter). 
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A summary of the screening results is shown in Figure 9. The majority of genes (73%) 
could be overexpressed and detected by western blot analysis. At least 50% of the C3H 
and C3GH constructs but only three out of 20 proteins expressed as NH3 fusion could 
be extracted in DDM. The majority of the GFP fusion constructs (C3GH) were not 
stable when tested on FSEC. The behavior during scale-up and purification of the three 
best-behaved candidates (29LLA, 99CCU, 135SCA) will be described in the following 
chapter. 
 
 
Figure 9 Screening funnel of tested prokaryotic DMT homologs. 
The figure summarizes the screening results obtained for the 105 investigated homologs 
Numbers in the funnel refer to individual homologs described in this study, values in brackets 
refer to the total number of tested homologs. In the table all homologs are listed as individual 
constructs (from left to right: round I+II, round III, total including all three rounds). NH3-
constructs were only prepared for round 1 and 2. 
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2.2. Biochemical characterization of selected prokaryotic 
SLC11 homologs 
 
For crystallization the target protein needs to be pure, stable and monodisperse in a 
detergent solubilized state. In order to achieve this, affinity purification on metal chelate 
resin via the His10-tag attached to the protein was followed by size exclusion 
chromatography. IMAC was used as main purification step. This technique is based on 
the metal chelating properties of imidazole groups which form complexes with divalent 
metal ions such as Ni2+, Co2+, Fe2+ and Zn2+ (Block et al., 2009; Porath et al., 1975). 
Recombinant proteins fused to a polyhistidine-tag selectively bind to a metal loaded 
nitrilo-tri-acetic acid resin whereas untagged protein will not bind and is thus efficiently 
removed. Excess imidazole is added to elute the bound protein by competing for the 
metal ion. The second critical purification step is SEC, which separates proteins based on 
their shape and their molecular weight (Mori and Barth, 1999; Porath and Flodin, 1959). 
In that way high molecular weight aggregates can be efficiently separated from the target 
protein. SEC is a frequently used tool to monitor stability, oligomeric state and 
monodispersity of a protein, as these biochemical parameters determine the selection of 
suitable targets for crystallization studies. A stable and monodisperse protein typically 
elutes as single symmetrical peak at an elution volume corresponding to its size. Unstable 
or impure protein will result in a chromatogram containing multiple peaks with 
significant amount of the target protein in the void fraction. In case of a well-behaved 
protein a purity of 95 % should be reached with this protocol. After SEC, all fractions 
were analyzed by SDS-PAGE. 
This two-step purification protocol was used for further characterization of 
promising candidates selected during the expression and extraction screening. Well-
expressed bacterial homologs that could be extracted in DDM, and were detected as 
single band on a western blot were selected for this thorough investigation. For protein 
expression, E.coli cells carrying the respective expression vector were cultivated in TB 
medium in shaker flasks and grown o/n after induction with arabinose. The same 
temperature profile as for the test-expressions was used. The next day, the cells were 
lysed and membrane vesicles were prepared. At harvest, the optical density (OD600) of 
the culture was typically 1.5-2.0, which is low compared to the overexpression of other 
membrane proteins under similar conditions. This resulted in 3-4.5 g vesicles from 2.4 l 
of culture (1.6 g vesicles/l culture), which were usually enough for initial protein 
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purification. Variation of the expression conditions (temperature, OD600 at induction, 
duration of expression) did not change the yield significantly. The large-scale cultures 
used for crystallization screening were grown in a fermenter to yield a higher cell mass 
per liter of culture. The OD600 at harvest was reproducible and did marginally vary 
depending on the DMT homolog, The OD600 was ~10-11 for 29LLA, ~11-12 for 
99CCU and ~12-14 for 135SCA. One 9 l fermenter typically yielded between 45 and 100 
g membrane vesicles, which was sufficient for 1-3 large-scale protein purifications to set-
up ten 96-well crystallization plates (with 100 nl drops). For membrane protein 
extraction the vesicles were incubated with the mild non-ionic detergent DDM. Insoluble 
material was removed by high-spin centrifugation and the supernatant was incubated 
with Ni-NTA resin to bind the His-tagged target protein to the matrix. To remove 
unspecific bound proteins, the resin was washed with buffer containing intermediate 
amounts of imidazole. After elution of the bound protein with high amounts of 
imidazole the sample was incubated with 3C protease to cleave off the fusion-tag. The 
cleavage was combined with a dialysis step to lower the imidazole concentration. The 
protease is His-tagged and can therefore be removed together with the cleaved tag by 
rebinding to fresh Ni-NTA resin. The flow-through, containing the cleaved target 
protein was concentrated and subjected to SEC on a Superdex S200 column equilibrated 
in running buffer containing DDM 5x above its critical micelle concentration (CMC). 
The S200 column is capable of separating proteins with a mass range of 10-500 kDa. The 
void volume of the column is 8.4-8.6 ml. Due to the detergent micelle surrounding the 
membrane protein; the apparent size can be significantly higher than its calculated 
molecular weight. The prokaryotic DMT homologs elute at about 13 ml on an S200 
column, which corresponds to an apparent molecular weight of 120-140 kDa. Since 
these proteins are on average 45-55 kDa in size, the detergent contributes to >50 % of 
the (apparent) molecular weight. 
 
The sequence alignment of the three stable homologs and human DMT1 underlines 
general properties of these transporters (Figure 10). From the alignment it is apparent 
that the amino acid composition of the transmembrane regions is fairly conserved. 
29LLA and 135SCA (ScaDMT) share a sequence identity to hDMT1 of 28% and 36% 
respectively, and a similarity of ~40%. Whereas 99CCU shares a high sequence similarity 
to 29LLA (43%) and ScaDMT (52%), its homology to hDMT1 is lower (28%) compared 
to the two other prokaryotic homologues. 
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Figure 10 Sequence alignment.  
The three stable bacterial DMT homologs and human DMT1 (isoform 3) are aligned with 
ClustalW2 (Larkin et al., 2007). Secondary structure elements are shown below. Labels indicate: 
(violet circle) residues of the transition metal binding site, (blue circle) residues involved in pH 
dependence and H+ transport of hDMT1. 
 
ScaDMT          ----MKLKDDN------YEQQQSLDEINNTI--------------------------HFD 24 
29LLA           ----MNDKEHQRHRLIYHTNGKSLEEINGTVEVPKNVG---------------------- 34 
hDMT_Aire       MVLGPEQKMSDDSVSGDHGESASLGNINPAYSNPSLSQSPGDSEEYFATYFNEKISIPEE 60 
99CCU           --------------------MSAL---ADRL----------------------------- 8 
 
                                            
ScaDMT          HKSS-ASQKFLAFLGPGLLVAVGYMDPGNWITSMQGGAQYGYTLLFVILISSLAAMLLQS 83 
29LLA           -----FFKMLLTYSGPGALVAVGYMDPGNWSTSITGGQNFQYLLISVILMSSLIAMLLQY 89 
hDMT_Aire       EYSCFSFRKLWAFTGPGFLMSIAYLDPGNIESDLQSGAVAGFKLLWILLLATLVGLLLQR 120 
99CCU           --------KN---IGPGALVAAGFVGPGTVTTCTVSGASYGTTMLWALLFATVSTIIFQE 57 
 
 
 
ScaDMT          MTVRLGIATGKDLAQMTRHFLS-KPVAIIFWIIAELAIIATDIAEVIGSAIALDLIFG-- 140 
29LLA           MSAKLGIVSQMDLAQAIRARTS-KTLGIVLWILTELAIMATDIAEVIGAAIALYLLFN-- 146 
hDMT_Aire       LAARLGVVTGLHLAEVCHRQYP-KVPRVILWLMVELAIIGSDMQEVIGSAIAINLLSVGR 179 
99CCU           MAARIGIATQEGLGENIRDNIKNPALKWIAIIIVIVAIFIGNIAYETGNITGGILGIQSI 117 
 
 
 
ScaDMT          IPLIVGALITVFDVFLLLFIMRFG-FRKIEAIVGTLIFTVLAIFVFEVFISSPQLTDILN 199 
29LLA           IPLILAVFITVLDVFLLLLLTRIG-FRKIEALVICLILVILAIFAYQVALSNPDWKGIIE 205 
hDMT_Aire       IPLWGGVLITIADTFVFLFLDKYG-LRKLEAFFGFLITIMALTFGYEYVTVKPSQSQVLK 238 
99CCU           YPDASMIAIAIVVGAVAFGLMWAGSYDLVEKVLTAIVVFMGVVFLVTALASPVDWGAVLA 177 
 
 
                                                      
ScaDMT          GFVPHK------EIVTNQGILYIALGIIGATIMPHNLYLHSSIVQSRKYDRHDNEEKAQA 253 
29LLA           GFIPNNRTFASSPTVAGMSPLTGALGIIGATVMPHNLYLHSSISQSRKINHQDKSDVARA 265 
hDMT_Aire       GMFVPS------CSGCRTPQIEQAVGIVGAVIMPHNMYLHSALVKSRQVNRNNKQEVREA 292 
99CCU           GLFSPQ------LPTNDNKGLLTAIGLIGTTIVPYNLFLHASGAAERWSDPKQIADAR-- 229 
 
 
 
ScaDMT          IKYATIDSNLQLSIAFVVNCLLLTLGAALFF-----------GTKTNDLGGFYDLYHALK 302 
29LLA           VRFSTWDSNIQLTVAFVVNSLLLIMGVAVFK-----------TGVIDDPS-FFGLYDALS 313 
hDMT_Aire       NKYFFIESCIALFVSFIINVFVVSVFAEAFFGKTNEQVVEVCTNTSSPHAGLFPKDNSTL 352 
99CCU           -----FDSILSIGLGGVISMAILICAAANLQ-----------------PLGIQVKNGADM 267 
 
 
 
ScaDMT          TEPVLG------ATLGGVMSTLFAVALLASGQNSTITGTLAGQIVMEGFLRLSIPNWLRR 356 
29LLA           NPSVLSNGLLADVAKTGALSTLFAVALLASGQNSTITGTLTGQVIMEGFIHMRMPMWARR 373 
hDMT_Aire       AVDIYKGGVVLGCYFGPAALYIWAVGILAAGQSSTMTGTYSGQFVMEGFLNLKWSRFARV 412 
99CCU           ALALQP-------LLGNWATWMIALGLLAAGVSSAITAPLSAAYAVNGVLGWKKGLKDIR 320 
 
 
 
ScaDMT          LITRSLAVIPVIICLIIFKGN-----SEKIEQLLVFSQVFLSIALPFSLIPLQLATSNKK 411 
29LLA           LVTRLLSVVPVLICVSMTRGQTLKAQHEAINNLMNNSQVFLAFALPFSIIPLLMLTNSKE 433 
hDMT_Aire       VLTRSIAIIPTLLVAVFQDVEH-------LTGMNDFLNVLQSLQLPFALIPILTFTSLRP 465 
99CCU           FKTIWGIVLVAGVVMAVALGKS-------PTQLILVAQAANAILLPIMAFFVMYCANSKK 373 
 
 
 
ScaDMT          LMGPFINKTWVNIISWTLIVILSGLNVYLIIQTFQEL----------------------- 448 
29LLA           EMGDFKNNLIIKFLGWISVIALTYLNLIGLPNQIDSF------LPNNLSLSHFIAGLLIV 487 
hDMT_Aire       VMSDFANGLGWRIAGGILVLIICSINMYFVVVYVRDLGHVALYVVAAVVSVAYLGFVFYL 525 
99CCU           -LGPVRNHLFANVAGVVIILITLFICYRNFSSFVTSLQSLLGA----------------- 415 
 
 
 
ScaDMT          ------------------------------------ 448 
29LLA           GVIILLIWSIFELHRGNKKLYLK------------- 510 
hDMT_Aire       GWQCLIALGMSFLDCGHTVSISKGLLTEEATRGYVK 561 
99CCU           ------------------------------------ 415 
 1a 1b 2 
3 
4 5 
6a 6b 
7 
8 
10 9 
11 
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The N terminus of all three bacterial homologs is, on average 2/3 shorter than the N 
terminus of hDMT1 (23 amino acids compared to 62 amino acids). Additionally their 
extracytoplasmic loops L5, L7, L9 (between TM5-6, TM7-8 and TM9-10) are more 
compact. Whereas 99CCU is the most compact protein with only 415 amino acid 
residues with the shortest loop regions, none of the metal binding site motifs is fully 
preserved. Instead of the highly conserved DPGN motif in helix 1 the residues in 
99CCU are GPGT with a glycine replacing the aspartate and a threonine the asparagine 
residue. Additionally there is a valine instead of the methionine located in the unwound 
region of helix 6. Furthermore in 99CCU only one of the two highly conserved histidine 
residues is present (a tyrosine replaces the histidine that is usually located two residues 
after the binding site methionine). It is unclear how the altered binding site in 99CCU 
affects transport, but due to the importance of the residues for metal ion recognition, a 
different substrate-specificity can be expected. An experiment that investigates the 
transport properties of 99CCU, and a mutant of ScaDMT with equivalent replacements 
(i.e. D49G, N52T, M226V and H228Y) would reveal the altered transport properties. 
The prokaryotic homolog 29LLA is with 510 amino acids the longest of the three 
prokaryotic transporters. This can be explained by the long C terminus, which is 
predicted to encode for an additional transmembrane helix. However, the residues 
encoding the putative 12th transmembrane helix do not share strong homology with 
hDMT1.  
In the following chapters the three selected homologs (29LLA, 99CCU and 
ScaDMT) are discussed with respect to their biochemical properties observed during 
large-scale expression and purification in maltoside detergents. 
 
2.2.1. Purification of 29LLA 
 
The first homolog selected for large-scale purification was 29LLA from the bacterium 
Lactococcus lactis. 29LLA was expressed as GFP fusion protein, which is in agreement with 
its predicted 12 transmembrane spanning segments. When expressed as fermentation 
culture the cell density was reproducibly around an OD600 of 10-11, at harvest. From 1 l 
fermenter culture I typically obtained ~5 g membrane vesicles. For 1 mg of purified 
protein (after SEC), 3 l of fermentation culture (corresponding to 15 g membrane 
vesicles) were required, which is improved compared to 20 l of shaker flask culture that 
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would be necessary for the same amount of protein (despite using the same medium, 
inoculum, temperature profile). Due to the comparably low binding efficiency of 29LLA 
to IMAC resin, 1.2 ml of 50 % Ni-NTA slurry were necessary per 1 g of vesicles. 
Consequently the protein was more diluted after elution and needed extensive 
concentration before size exclusion chromatography. Compared to 99CCU and 135SCA, 
29LLA was the least stable homolog during the two concentrating steps (before SEC and 
before crystallization), as usually 20-30% of 29LLA was lost during each concentration 
step. In Figure 11 the size exclusion profile of 29LLA together with its corresponding 
SDS-PAGE and in-gel fluorescence images is shown. The protein was still fused to GFP 
and loaded onto the SEC column directly after the IMAC. The calculated size of this 
construct is 82.9 kDa.  
 
Figure 11 Size exclusion chromatography of 29LLA. 
29LLA was expressed as C-terminal His10-GFP-fusion protein and purified in DDM. (a) Size 
exclusion profile detected by UV absorption at 280 nm. Elution volume and peak height of the 
void peak (8.45 ml, 9.8 mAU) and main peak (12.2 ml, 57.6 mAU) are labeled. The protein elutes 
as a single peak that is, although slightly tailing, well separated from the void peak. (b) SDS-
PAGE gel of the void fraction and the three main peak fractions 1-3. The target protein is the 
main band at 65 kDa and there is no protein detectable in the void peak. (c) In-gel fluorescence 
measurement of the gel shown in (b) confirms that there is little fluorescence signal in the void 
peak thus underlining that the fraction of aggregated protein is not significant. Whereas the main 
band corresponds to the target protein fused to GFP, smaller bands around 28 kDa found in 
fractions 1-3, most probably come from degradation products that still include the GFP moiety. 
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On SDS-PAGE the protein is found close to the 65 kDa MW marker. The higher 
molecular weight band, which as it is not fluorescent, might probably be an impurity. 
The 4 bands at ~28 kDa are fluorescent, and thus probably correspond to proteolytic 
cleavage of the C-terminal GFP. The small void peak does not contain a significant 
amount of the target protein. The main band in fractions 1-3 contains a small fraction 
with apparent smaller molecular weight, which could be due to the loss of few amino 
acids on the N terminus. Figure 12 shows the chromatogram of the same protein after 
incubation with 3C protease. The sample was subjected to SEC without prior removal of 
the GFP. There is uncut protein detectable in the main peak at 12.9 ml as visible in the 
SDS-PAGE and the corresponding in-gel fluorescence image of the gel.  
 
Figure 12 Size exclusion chromatography of 29LLA after cleavage of the fusion protein.  
(a) Size exclusion profile of 29LLA and GFP detected by measurement of the UV absorption at 
280 nm. Elution volume and peak height of the void peak (8.6 ml, 13.08 mAU) and main peak 
(12.9 ml, 48.9 mAU) are labelled in the figure. The target protein elutes as a single peak well 
separated from the void. (b) SDS-PAGE gel of the void fraction and the four main peak 
fractions 1-4. The cleaved target protein corresponds to the main band at ~40 kDa. There is no 
protein detectable in the void peak. (c) In-gel fluorescence measurement of the gel shown in (b). 
There is very little fluorescence in the void peak. The size corresponds to the target protein fused 
to GFP. In fractions 1-3 residual 29LLA still fused to GFP is detectable. In fraction 3 and 4 the 
GFP of the second peak at 16.9 ml with 28.4 mAU is already visible. 
 
A second IMAC step was introduced after cleavage, to remove the fusion-tag and the 
His-tagged 3C protease prior to SEC. In this purification, the protein eluted at the same 
volume as in the medium-scale purification experiment, although with a shoulder at 
higher molecular weight. On SDS-PAGE the fractions show a double band containing a 
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minor fraction with apparent smaller molecular weight (Figure 13). Despite this 
heterogeneity, 29LLA was concentrated to 7.5 mg/ml and subjected to crystallization 
screening. These setups did not show any crystals, instead the protein heavily precipitated 
in most of the wells. 
 
Figure 13 Large-scale purification of 29LLA and initial crystallization trials.  
(a) SEC chromatogram of the large-scale purification of 29LLA. (b) SDS-PAGE analysis of the 
peak fractions.  
 
Taken together, 29LLA could be purified in the mild maltoside detergent DDM. A 
double band detected on SDS-PAGE could come from proteolytic cleavage. In order to 
determine if proteolytic digest occurs during purification each gel band could be analyzed 
by mass spectrometry. Investigating freshly purified protein in a limited proteolysis 
experiment, followed by SDS-PAGE and mass spectrometry, might additionally help to 
identify a stable core of 29LLA. Systematic N- and C-terminal truncations of 29LLA 
have been investigated during this study (data not shown) but did neither result in 
compelling stability improvements nor in improved crystallization properties of the 
protein. 
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2.2.2. Purification of 99CCU 
 
The prokaryotic SLC11 homolog of Cryptobacterium curtum (99CCU) was identified in the 
expression screening as promising candidate, fused to a C-terminal His10-tag. For 99CCU 
eleven transmembrane segments are predicted. The protein has very compact loops even 
compared to other bacterial homologs. The expression yields are comparable to 29LLA. 
With 20 g membrane vesicles approximately 6 mg of protein was eluted from an IMAC 
column. Compared to 29LLA the losses after size exclusion chromatography were lower. 
Typically 15-20% of protein was lost at the final concentration step, resulting in 1.8 mg 
pure 99CCU, that were used for crystallization experiments. In Figure 14a the 
chromatogram of the protein purified in the detergent DDM is shown. The protein 
elutes at 13.1 ml, similar as observed for 29LLA and is well separated from the small 
void peak. In this chromatogram there is also a small shoulder found at higher elution 
volume. In Figure 14b the corresponding fractions were loaded on a SDS-PAGE gel and 
stained with Coomassie blue dye. As for 29LLA there is no target protein detected in the 
void fraction.  
 
Figure 14 Size exclusion chromatography of 99CCU purified with DDM. 
(a) The protein elutes at 13.1 ml as symmetrical peak with a small shoulder towards the lower 
molecular weight. The void peak, corresponding to higher molecular weight aggregates, is very 
small. (b) SDS-PAGE gel of the void and the four peak fractions. The protein runs as double 
band indicating heterogeneity. This double band behavior was not observed in subsequent 
purifications. (c) Reinjection of the protein three days after the first SEC. 
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The Protein migrates with an apparent molecular weight of 45 kDa. The faint band at 25 
kDa might originate from degradation products. The peak fractions were stored at 4 °C 
and subjected to a second size exclusion run three days later. The chromatogram is 
shown in Figure 14c. Also in the second run the small shoulder at higher elution volume 
is found, but there is no void peak and no shift in the elution volume of the main protein 
peak, thus indicating that the protein is stable in the detergent DDM. 
For crystallization screening, the expression was scaled-up, the protein was 
purified by the same procedure and concentrated to 5.0 and 7.5 mg/ml. Crystallization 
was broadly screened (>2000 conditions in different full and sparse matrix screens), with 
the help of the crystallization facility of the Dept. of Biochemistry, in 100 nl volume by 
vapour diffusion in sitting drops. Despite its purity and apparent stability, 99CCU did 
not crystallize when purified in the detergent DDM. In a next attempt the crystallization 
behavior of the protein in shorter chain detergents of the same class was investigated. 
The protein was purified in the detergent DM, which is two methyl groups shorter as 
DDM resulting in a smaller micelle size: An empty detergent micelle of DDM in aqueous 
buffer is ~64 kDa compared to 37 kDa of an empty DM micelle (Kunji et al., 2008). In 
Figure 15 the SEC profile and its corresponding SDS-PAGE analysis is shown. 99CCU 
is monodisperse and elutes at 13.7 ml with a small shoulder at higher elution volume. 
The protein is pure as confirmed by SDS-PAGE. 
Whereas the protein appears to be stable in the detergents DM and DDM, there 
are first signs of reduced stability in the shorter chain maltopyranoside NM. In Figure 15 
the SEC profile and the corresponding SDS-PAGE analysis is depicted. For purification 
in NM, protein extraction and IMAC were performed in DM and the detergent was 
exchanged to NM on the S200 column. This procedure is gentle but may result in an 
incomplete detergent exchange. Still in several cases detergent exchange by this protocol 
has been shown to significantly improve crystallization behavior of the protein. For 
crystallization of 99CCU in DM and NM (n-nonyl-β-D-maltopyranosid) solution, the 
protein was concentrated to 5, 7.5 and 10 mg/ml and used for broad crystallization 
screening, but in no case any crystals were observed. In summary 99CCU, showed 
promising biochemical properties and was successfully purified in different maltosides. 
However, despite its promising behavior and a broad screening of conditions, the protein 
did not crystallize in any of the three detergents. Crystallization is a complex process that 
is sensitive to biochemical, chemical and physical properties of the sample such as purity, 
 43 
stability, proteolysis that might occur, its isoelectric point (pI), and conformational 
heterogeneity.  
 
Figure 15 Purification of 99CCU in the detergent DM and NM.  
(a) Size exclusion profile in DM. The protein elutes as one symmetric peak with a small peak at 
lower and a slight shoulder at higher elution volume. The void peak is small. (b) SDS PAGE gel 
showing a single band corresponding to 99CCU in the elution peak and no protein in the void 
fraction. (c) Size exclusion chromatogram of 99CCU purified in NM. The protein is well 
separated from the void. A detector problem caused the double peak. The elution volume is 
shifted to 14 ml, which can be explained by the smaller micelle of NM. (d) The SDS PAGE gel 
shows a single band, indicating that the protein is pure. 
 
Successful crystallization also depends on the properties of the surrounding solution 
including precipitant type and concentration, salt type and concentration, pH and buffer, 
detergent, lipids, temperature, crystallization volume, and the crystallization technique 
(eg. vapor diffusion, the use of bicelles or lipidic cubic phase). Judging from size 
exclusion and SDS-PAGE analysis the protein was sufficiently stable and pure after 
purification. Despite these promising starting condition, the process of crystallization 
remains still an empirical process and requires extensive screening. While a large set of 
different conditions were tested (>3800), they cover only a small fraction of the possible 
experimental space. Conformational heterogeneity or a disadvantageous net surface 
charge of the protein at certain pH values may prevent crystallization. For 99CCU other 
detergents apart from maltosides were not thoroughly investigated. In addition to that it 
may have been worth to investigate other crystallization techniques such as crystallization 
in bicelles (Ujwal and Bowie, 2011) or in lipidic cubic phases (Landau and Rosenbusch, 
1996). It can also not be excluded that lipids might have had a significant impact on the 
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crystallization properties of the protein. In such a case it might be worthwhile to add 
lipids during purification, before crystallization (e.g. by the HILIDE method (Gourdon 
et al., 2011)) or as additive together with the mother liquor during crystallization. Since 
ScaDMT, the homolog presented in the next chapter, was better behaved and 
crystallized, I decided not to explore all possibilities for crystallization of 99CCU and 
instead focused my efforts on improving the ScaDMT crystals. 
2.2.3. Purification and crystallization of ScaDMT 
 
The third bacterial homolog identified as promising candidate for further biochemical 
characterization, ScaDMT (135SCA), was cloned form the bacterium Staphylococcus capitis. 
Although phylogenetic distances between 29LLA and 135SCA are small, 11 
transmembrane segments were predicted for ScaDMT, in contrast to the 12 TMs 
predicted for 29LLA. The protein was expressed as C-terminal His10-tag construct and 
scale-up to fermenter cultures yielded on average 10 g membrane vesicles per 1l medium 
(OD600 at harvest 12-14). After purification, following similar procedures as described for 
99CCU, ScaDMT was stable in the longer chain detergent DDM and the shorter 
detergent DM. In Figure 16 SEC profiles of the protein purified in DDM (left) and in 
DM (right) are shown.  
 
Figure 16 Size exclusion chromatogram of ScaDMT.  
(left) Purification of ScaDMT in DDM. The protein elutes as single peak. The purity was 
confirmed by SDS-PAGE, which shows one major band with traces of impurity at 60 kDa. 
(right) ScaDMT purified in DM. The protein elutes as sharp main peak with a small second peak 
towards higher molecular weight. Peak fractions were pooled and loaded on SDS-PAGE (peak). 
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The protein elutes as single narrow and symmetric peak and is pure as judged from SDS-
PAGE analysis. Both samples were concentrated to 7.5 mg/ml and subjected to 
crystallization screening. Expression levels of ScaDMT were significantly higher as those 
of 29LLA and 99CCU. From 10 g vesicles on average 10 mg protein eluted from the 
IMAC column and after size exclusion ~2.0 mg pure ScaDMT was available for further 
experiments (1.7 mg pure protein/l culture). In contrast to DM the protein was not 
stable when purified in the detergent NM) which is one methyl group shorter than DM, 
and instead showed time-dependent aggregation (data not shown). 
In contrast to 29LLA and 99CCU, I have succeeded with crystallization of 
ScaDMT. When purified in DDM, ScaDMT did not crystallize despite the broad range 
of investigated conditions (>2400). Contrary to DDM, crystals of ScaDMT purified in 
DM were observed in a single well of a screen containing more than 2400 conditions. 
The precipitant solution leading to successful crystallization contained 200 mM CaCl2, 90 
mM NaCl, 90 mM MES, pH 6.0, 26-30% PEG400 (Note: MgCl2 instead of CaCl2 as well 
as PEG300 instead of PEG400 were tolerated). Micro-crystals appeared three weeks 
after the drops were set up and grew over a period of 6 weeks to needles with a maximal 
dimension of about 10 μm (Figure 17). For the investigation of their diffraction 
properties the crystals were cryo-protected by stepwise increase of the PEG 
concentration to 35% and frozen in liquid propane.  
 
 
 
Figure 17 Crystals of ScaDMT.  
(a) Initial crystal hit. (b) Crystals after fine screening. (a, b) The drops were both imaged 7 weeks 
after the experimental set-up. Images taken under a polarization filter. (c) Diffraction pattern 
collected at PXI. Resolution limit 6.5 Å. 
 

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Diffraction experiments were carried out at the X06SA (PXI) beamline at the Swiss Light 
Source. Initial crystals diffracted up to 7.5 Å. After refinement of crystallization 
conditions larger crystals were obtained but the diffraction did not improve significantly. 
The best crystal diffracted to ~6.5 Å and allowed data collection (Table 4), which was 
processed with XDS. The data is 92.7% complete and extends up to 6.5 Å. The crystals 
are of space group P3221 with cell dimensions of a=b=150.9 Å, c=157.3 Å, α=β=90°, 
γ=120°. The Matthews parameter was calculated to estimate the number of protein 
molecules per asymmetric unit (Kantardjieff and Rupp, 2003). For these crystals two 
molecules per asymmetric unit would results in a solvent-content of 75%, which is not 
unusual for membrane protein crystals. These crystals were later used to determine the 
structure of full-length ScaDMT by molecular replacement  (see chapter 2.7). 
 
 
Table 4 Data collection statistics of ScaDMT 
The number of reflection, the completeness of the data set, its calculated R-factor and the 
I/sigma are displayed for different resolution shells. 
2.2.4. Summary 
 
I have started my work towards the structure determination of a DMT transporter by 
selecting stable proteins from a large set of prokaryotic homologs. For that purpose I 
have cloned 86 homologs from genomic DNA of different bacteria. From this set three 
proteins were sufficiently stable for scale-up purification and screen for crystallization.  
Figure 18 summarizes the progress of this project, from expression screening to 
crystallization, in percent of all successfully cloned homologs. Exact numbers are listed in 
Figure 9. Among the investigated proteins the homolog 29LLA from the bacterium 
Lactococcus lactis was the least stable transporter, which yielded heavy precipitate in 
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crystallization experiments. The homolog 99CCU from the bacterium Cryptobacterium 
curtum was better behaved as it was stable in DDM, DM and NM but it did not crystallize 
either. ScaDMT from the bacterium Staphylococcus capitis was stable when purified in the 
detergent DDM and DM. While no crystals were obtained in DDM, ScaDMT was 
successfully crystallized in the detergent DM. The diffraction of these crystals was limited 
to 6.5 Å and could not be improved further. 
 
 
 
Figure 18 Summery of the screening of 
prokaryotic DMT homologs. 
In total 67/105 genes could be amplified 
and screened for expression. 72 % (49/76) 
of these proteins could be expressed in at 
least one of the three vectors used. Around 
25 % were not extractable. Only one tenth 
of the extractable proteins were stable and 
monodisperse (3/5). On average one out of 
50 investigated homologs yielded protein 
crystals (1/2). Numbers in parentheses 
indicate the number of proteins described in 
this study/total number of homologs 
investigated in this project. 
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2.3. Biochemical characterization of ScaDMT 
2.3.1. Biochemical characterization of truncated ScaDMT 
constructs 
 
Flexible parts of a folded protein such as disordered termini or loops might interfere 
with the formation of an ordered crystal lattice and as a consequence prevent 
crystallization or lead to poor diffraction properties of the crystals (Rupp, 2010). The 
removal of flexible parts has been successfully applied in several cases to improve the 
packing properties of proteins in crystals and thus increase the resolution of the 
diffraction data (De Kerpel et al., 2006). 
In an attempt to improve the crystal packing of ScaDMT, its N and C terminus were 
systematically shortened and new constructs were tested for their stability in detergent 
solution. While homologues of the SLC11 family are highly conserved, particularly in 
their predicted trans-membrane regions, their N terminus is poorly conserved and 
predicted to be flexible. By analyzing the sequence with respect to its probability not to 
fold into defined structures with the program DRIPPRED (MacCallum, 2004), the first 
30 residues of the N-terminal region of ScaDMT were predicted to be unstructured 
(Figure 19).  
 
Figure 19 Disorder prediction of ScaDMTs termini.  
The upper panel shows the first 50 residues of ScaDMT, the lower panel the 48 residues of the 
C-terminal region. The amino acids that were predicted to be disordered (DRIPPRED, 
MacCallum, 2004) are highlighted in grey. The start of the respective truncations is indicated in 
blue. The last amino acid of the respective C-terminal truncation is highlighted in red. Secondary 
structure elements are shown below. 
 
 
 
ScaDMT 
 
 
N-term   1 MKLKDDNYEQQQSLDEINNTIHFDHKSSASQKFLAFLGPGLLVAVGYMDP 
 
 
 
 
 
 
C-term   IPLQLATSNKKLMGPFINKTWVNIISWTLIVILSGLNVYLIIQTFQEL 448 
 
 
 
 
10 11 
 1a 1b 
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Several constructs were thus prepared with part of these residues removed. As 
predictions contain a certain degree of uncertainty, also two constructs removing half of 
the first predicted transmembrane segment were included. As any removal of a part of a 
transmembrane segment was expected to result in unstable protein, these constructs 
should serve as upper boundaries of how many residues of the N terminus can be 
removed without interfering with protein folding and stability. Although on the C 
terminus no disorder was predicted, the removal of amino acids was also investigated in 
this case.  
2.3.2. Expression test and western blot analysis of truncated 
ScaDMT constructs 
 
Fourteen truncated constructs of ScaDMT were prepared with the FX-cloning method. 
For expression, the genes were cloned into the same vector as used for the expression of 
full length ScaDMT. Test-expressions and western blot analysis were performed as 
described earlier. ScaDMTΔ17-448 gave the strongest signal on the western blot, 
indicating good expression and extraction properties. ScaDMTΔ25 and ScaDMTΔ29, 
two constructs starting close to the first predicted transmembrane helix were as well 
detected in the total lysate as well as in the extracted fraction. In contrast no expression 
could be detected for the shorter construct ScaDMTΔ32. Similarly ScaDMTΔ37 was 
poorly expressed and not extractable in detergent solution. Unexpectedly ScaDMTΔ42, a 
shorter construct in which part of the first transmembrane helix was removed was well 
expressed and extractable in DM. Constructs with shortened C terminus such as 
ScaDMT1-Δ437 and ScaDMT1-Δ441 were expressed but only poorly extractable in mild 
detergent, which indicates that they are not probably folded. Among the C-terminal 
truncations, only the longest construct ScaDMT1-Δ445 with three residues on the C-
terminus removed was the construct that was fully extractable in DM (Figure 20). In 
summary the removal of residues of the putatively disordered N terminus of ScaDMT 
was well tolerated and provided stable shortened protein constructs that are potentially 
suitable for crystallization experiments. Remarkably, in the shortest stable construct 
ScaDMTΔ42 a part of the predicted first transmembrane helix was removed. 
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Figure 20 Western blot analysis of ScaDMT truncations.  
Expression and extraction analysis of N- and C-terminal truncation constructs. The constructs 
are labeled on top. t. indicates the total sample loaded after cell lysis, sn. the supernatant after 
extraction with detergent and ultracentrifugation. The size of the molecular weight marker (75 
kDa) is indicated by the black line. 
2.3.3. Purification of selected ScaDMT truncation constructs 
 
As result of the expression screening, the shortened constructs ScaDMTΔ16 and 
ScaDMTΔ42 were selected as most promising candidates for scale-up and purification in 
DM due to their strong expression properties. In addition ScaDMTΔ24 and 
ScaDMTΔ28 were selected because of the proximity of the N-terminus to the first 
predicted trans membrane segment. Among the C-terminal truncations ScaDMT1-Δ445 
was selected as only construct with suitable expression and extraction properties. All 
constructs were expressed in shaker flask cultures (each 4 x 0.6 l TB) according to the 
protocol described previously. The OD600 at harvest was between 1.0 and 1.8, which is 
on average lower than for the full length ScaDMT protein (when expressed in shaker 
flask cultures the OD600 in this case was 1.6-2.0). Nevertheless, despite the small amount 
of membrane vesicles (1.5-2.8 g), the amount of protein was sufficient for purification 
and size exclusion chromatography. Fermenter cultures of the two most promising 
truncated ScaDMT constructs (ScaDMTΔ28 and ScaDMTΔ42) were grown in the same 
way as described for full-length ScaDMT. The OD600 at harvest was reduced for both 
proteins, although for ScaDMTΔ28 (OD600 3.5) the effect was more pronounced than 
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for ScaDMTΔ42 (OD600 10 compared to 12-14 for ScaDMT full-length). The proteins 
were efficiently extracted with the detergent DM and purified by the standard two-step 
protocol described earlier. The amount of protein eluted from the Ni-NTA column was 
very similar to what I observed for full-length ScaDMT. Only ScaDMTΔ42 eluted less 
than 0.8 mg protein per g of membrane vesicles. After proteolysis and concentration all 
proteins were subjected to size exclusion chromatography. When applied to SEC, 
ScaDMTΔ16 purified in DM eluted as peak at ~13.3 ml, which is shifted by 0.7 ml 
compared to WT (which in DM elutes at ~12.6 ml) but with a shoulder towards higher 
molecular weight and a second peak at the void volume (left). The void peak did contain 
aggregated target protein and no void peak was observed when injecting the main peak 
fractions three days later, thus indicating that the largest part of the protein was stable for 
several days at 4 °C (Figure 21 right). Some higher molecular weight impurities (observed 
in Fraction 11 and 13 around 75 kDa) could contribute to the shoulder seen in the 
chromatogram (Figure 21 left, small panel). 
 
 
Figure 21 Size exclusion profile of ScaDMTΔ16.  
(left) ScaDMTΔ16-448 was purified in DM and injected on a Superdex S200 column. The 
fractions 3, 11, 13 and 16 highlighted in blue were analyzed by SDS-PAGE (inset). Molecular 
weights are indicated in kDa. The fractions 15 and 16 were pooled and subjected to a second 
SEC three days after the initial purification (highlighted in green). (right) SEC run of the peak 
fractions three days after purification. There is no void peak detectable. The shoulder towards 
higher molecular weight is seen in both SEC runs. 
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While comparably pure (see fraction 16 on SDS-PAGE) with the bulk of the protein 
eluting as sharp peak at corresponding elution volumes, ScaDMTΔ16 is not fully 
monodisperse as indicated by the shoulder observed in both SEC chromatograms. 
ScaDMTΔ16 yielded 0.3 mg of SEC purified protein per liter of culture. 
The SEC profile of the seven amino acids shorter construct ScaDMTΔ24 is 
shown in Figure 22. Also in this case a void peak is detected that contains small amounts 
of aggregated target protein. However, the main peak eluting at 13.5 ml is sharp and 
symmetrical. In this chromatogram the shoulder observed in construct ScaDMTΔ16 is 
less pronounced in ScaDMTΔ24. Again the elution profile of the second SEC run upon 
reinjection of the protein after an incubation time of three days is promising, as there is 
no void peak and only a small shoulder observed. The behavior of ScaDMT24 thus 
suggests that the protein construct is stable in the detergent DM after storage at 4 °C for 
several days. The purification of ScaDMTΔ24 resulted in 0.45 mg sufficiently pure 
protein per liter of culture. 
 
 
Figure 22 Size exclusion profile of ScaDMTΔ24.  
(left) SEC profile of ScaDMTΔ24 purified in DM. Fractions 3, 14 and 15 (blue bars) were loaded 
on a SDS-PAGE gel shown in the upper left of this figure. Molecular weights (kDa) are 
indicated. Fractions 14 and 15 (green) were subjected to a second round of SEC three days after 
the initial purification. (right) Size exclusion profile of the peak fractions, three days after 
purification. There is no void peak detectable. The shoulder towards higher molecular weight has 
almost vanished. 
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ScaDMTΔ28, which is only four amino acids shorter than ScaDMTΔ24, shows a 
comparable behavior on SEC (elution volume of main peak at ~13.5 ml). The protein is 
stable for several days at 4 °C although the small shoulder on the second SEC 
chromatogram is somewhat broader compared to the longer construct (Figure 23). The 
yield for ScaDMTΔ28 was, with 0.6 mg/l culture, the highest amongst the tested 
ScaDMT truncation constructs but this still only corresponds to one third of the yield 
usually observed for full-length ScaDMT (~2 mg/l culture). 
 
 
Figure 23 Size exclusion profile of ScaDMT28.  
(left) SEC profile of ScaDMTΔ28 purified in DM. Fractions 3, 13 and 15 (blue bars) were loaded 
on a SDS-PAGE gel shown in the upper left of this figure. Molecular weights are indicated in 
kDa. Fractions 14 and 15 (green) were subjected to a second SEC run three days after the initial 
purification. (right) Profile of the second SEC run. There is no void peak detectable but the 
shoulder towards higher molecular weight has become broader. 
 
Unexpectedly, but consistent with previous experiments, the shortest construct 
ScaDMTΔ42, which removes parts of the first predicted transmembrane helix is stable in 
detergent solution (Figure 24). Consistent with being the shortest of the tested 
constructs, the main peak elutes at 13.7 ml. Even if the protein peak is somewhat 
asymmetric, the SDS-PAGE of the corresponding fractions shows a single species at the 
expected size. When subjected to a second round of SEC after incubation at 4 °C for 
three days the protein elutes as a single sharp peak with a small shoulder at lower elution 
volume. Although the protein was well behaved, the yield of purified protein (0.4 mg/l 
culture) was reduced by 80% compared to full-length ScaDMT. 
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Figure 24 Size exclusion profile of ScaDMTΔ42.  
(left) SEC profile of ScaDMTΔ42 purified in DM. Fractions 3, 12, 14 and 16 (blue bars) were 
loaded on a SDS-PAGE gel shown on the upper left. Molecular weights in kDa are indicated. 
Fraction 14 (green) was subjected to a second SEC three days after the initial purification. (right) 
SEC profile of the second size exclusion run. There is no void peak detectable. In the second 
chromatogram, the peak is more symmetric that in the first SEC profile. 
 
ScaDMT1-Δ445 was the only C-terminally truncated construct tested for purification in 
DM. The protein was not stable during purification (Figure 25). The void peak obtained 
during SEC contains the target protein indicating the formation of high molecular 
aggregates.  
 
 
Figure 25 Size exclusion profile of 
ScaDMT1-Δ445.  
ScaDMT1-Δ445 was purified in DM. 
Fractions 2 and 3 (blue bars) were loaded on 
a SDS-PAGE gel. Molecular weights are 
indicated in kDa. 
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The results from scale-up and purification demonstrate that constructs of ScaDMT that 
were shortened at the N terminus are stable and well behaved. This includes a construct 
where the first 41 amino acids were removed, which is proposed to lack part of the first 
transmembrane helix. In contrast C-terminal truncations had a strong effect on the 
stability of the protein. ScaDMT1-445, the only construct that could be extracted in 
mild non-ionic detergents heavily aggregated during purification in DM. 
2.3.4. Crystallization of ScaDMT 42-448 
 
Due to their promising biochemical behavior, the protein constructs ScaDMTΔ28 and 
ScaDMTΔ42 were purified in DM, concentrated (5.0, 7.5 and 10 mg/ml) and used for 
broad crystallization screening. No crystals were obtained for ScaDMTΔ28 and crystals 
of ScaDMTΔ42 only grew in the same condition already identified for WT ScaDMT. For 
the truncated protein the crystals grew faster and were less fragile compared to WT 
(Figure 26 left). However, despite their larger size, the diffraction limit improved only 
slightly compared to full-length ScaDMT. The best crystal of the construct ScaDMTΔ42, 
hereafter referred to as ScaDMTtru, was tested at the X06SA beamline of the SLS and 
diffracted to 5.7-6.0 Å resolution. An example diffraction pattern is depicted in Figure 26 
on the right panel.  
 
 
Figure 26 Crystals of ScaDMT42-448.  
(left) ScaDMTΔ42 was purified in the detergent DM and used for crystallization screening. 
Crystals appeared after 1 week of incubation at 4 °C. (right) Diffraction pattern of crystal frozen 
in liquid propane and exposed at the X06SA beamline of the SLS. 

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From the best crystal 137° of data were collected (at 1.0° increments, λ=1.0 Å) at the 
X06SA beamline of the SLS. The reflections were integrated and scaled with XDS 
(Kabsch, 1993). The crystals of the truncated protein are of the same space group as full-
length ScaDMT: P321 (a=b=151.9 Å, c= 157.6 Å, α=β=90°, γ=120°). Judging from the 
data statistics (Table 5), the resolution of the dataset is limited to 5.7-6.0 Å, with an 
I/sigma of 1.97 in the highest resolution shell (6.02-5.68 Å). The data is complete to 
~6.0 Å. Although in the highest resolution shell the R-factor is high, it is in an 
appropriate range for the complete data set (“total”, 6%). Although there was a slight 
improvement in the maximal resolution compared to WT, the crystals of ScaDMTtru did 
not diffract sufficiently well to embark on the next step for structure solution. 
 
 
Table 5 Statistics of the best data set of ScaDMTtru after integration and scaling. 
The number of reflections, the completeness of the data set, R-factor and I/σI are plotted for 
different resolution shells.  
2.3.5. Summary 
 
In an attempt to improve the diffraction propertied of ScaDMT crystals, I have 
investigated shorter versions of the protein. N-terminal truncations of residues, predicted 
to be disordered, in ScaDMT, have allowed me to identify constructs that were stable 
and well behaved in detergent solution. ScaDMTΔ42, a minimal construct that lacks 41 
residues on the N terminus, could be purified and crystallized. Crystals of ScaDMTΔ42 
were obtained from the same condition as the full-length protein. Although these crystals 
grew much faster compared to ScaDMT, they are of the same crystal form and their 
resolution could not be sufficiently improved for structure determination by this 
approach. The construct ScaDMTΔ42 is following referred to as ScaDMTtru. 
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2.4. Nanobodies as crystallization chaperones 
 
Crystallization chaperones are auxiliary proteins that can be used for the co-
crystallization with the membrane protein of interest and that potentially improve the 
diffraction properties of crystals. They can either be covalently inserted into a loop of the 
target protein, as done in case of the human beta 2-adrenergic receptor where T4-
lysozyme was fused to the receptor protein (Rosenbaum et al., 2007), or used as non-
covalent binders recognizing a structured epitope of the target protein. The second 
strategy is more widely exploited with a variety of different protein scaffolds: Binding 
epitopes of antibodies are usually used as Fab fragments or as scFv’s (single chain variable 
fragments), variable domains fused into one single protein chain. Alternative scaffolds 
are designed ankyrin repeat proteins (darpins), fibronectin derived monobodies and 
camelid derived nanobodies (Koide, 2009; Lieberman et al., 2011; Tereshko et al., 2008). 
Certain binding proteins such as darpins, monobodies and scFv’s are usually 
selected from a naïve, synthetic library via ribosome-, phage- or yeast-surface display 
(Gera et al., 2013; Lipovsek and Plückthun, 2004; Winter et al., 1994). Antibodies and 
nanobodies in contrast are commonly generated by the immunization of animals (mice in 
the case of antibodies, and camelids in the case of nanobodies). This latter approach 
exploits the high variability of the animal immune system which contains around 1011 
different binders (Janeway, 2001; Schroeder, 2006). Furthermore, upon repetitive 
stimulation, selected immunoglobulins undergo a process termed affinity maturation 
(Eisen and Siskind, 1964), which is used in nature to increase the potency of an antibody 
and which can be exploited for the generation of highly specific and affine binders 
against a target protein.  
In 1993 it was discovered, that the camelid immune system contains, additionally 
to their conventional antibodies, special immuoglobulines that consist of heavy chains 
only (Hamers-Casterman et al., 1993). The binding domains of such VHH antibodies, also 
called single-domain VH antibody fragments or nanobodies, are usually less than 15 kDa 
in size and they have become popular tools for various biological and biochemical 
problems. In Figure 27 a schematic comparison of conventional antibodies and heavy 
chain-only antibodies is depicted. As representation of a conventional hetero-tetrameric 
antibody, an IgG (150 kDa), consisting of four protein chains connected to each other by 
disulfide bonds, is shown. For different biochemical purposes antibodies can be partially 
digested and Fab fragments (~50 kDa) that do no longer contain the Fc part can be used 
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as monomeric binding proteins. In contrast to IgG antibodies, camelid heavy chain-only 
antibodies do not have light chains (~90 kDa). The parts, which recognize the epitope, 
are two VH domains. ScFv’s (~25 kDa) are engineered antibody fragments that contain 
two variable domains, one derived form the heavy chain and the other from the light 
chain of a conventional antibody. Both chains are tethered to each other via a flexible 
peptide linker. Each variable region of an antibody or antibody fragment, includes three 
complementarity determining regions (CDR), loops in the protein domain that are highly 
variable in their sequence and flexible, so they can be used to optimize the binding 
interactions.  
 
 
Figure 27 Schematic representation of different antibody types. 
(A) A Conventional IgG antibody with its constant and variable parts is shown. (B) A camelid 
heavy chain antibody is comprised of a doublet of two constant and one variable heavy (VH) 
domain. (C) Fab fragments can be generated by proteolytic digest of IgG antibodies. (D) ScFv’s 
are fragments where two variable domains are connected via a flexible linker. (E) The VH 
fragment, or nanobody, is the epitope binding entity of heavy-chain only antibodies that is used 
in various applications. 
 
One of the proposed advantages of nanobodies is their unusually long CDR3 region, 
consisting of a typically 16-18 amino acid long variable loop, which is generally longer 
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than in conventional antibodies (in mouse antibodies this loop is ~9 amino acids, in 
human ~12 amino acids). This loop is ideally suited for the binding into cavities (De 
Genst et al., 2006; Saerens and Muyldermans, 2012). The use of nanobodies as 
crystallization chaperones has already been successfully applied for the structure 
determination of different membrane proteins (Löw et al., 2013; Pardon et al., 2014; 
Rasmussen et al., 2011).  
2.4.1. Generation of ScaDMT specific nanobodies 
 
The nanobodies used in this study were generated in collaboration with the lab of Prof. 
Jan Steyaert at the Free University of Brussels, Belgium that is specialized in the 
generation of highly specific nanobodies against different target proteins by the 
immunization of Llamas (Lama glama) and the subsequent selection of suitable binders by 
display techniques (Pardon et al., 2014).  
To generate nanobodies recognizing structured epitopes of ScaDMT, Llamas 
were immunized with the protein on a weekly basis for six consecutive weeks. For this 
purpose ScaDMT was freshly purified each time shortly before the immunization and 
sent on ice to our colleagues in Brussels. After an incubation period, following the last 
injection of target protein, blood was taken to collect the B-lymphocytes for the 
subsequent amplification of nanobody-encoding mRNA. For that purposed the entire 
population of encoded antibodies and nanobodies was amplified by RT-PCR and the 
nanobody fraction was subsequently cloned into a phage-display library after separation 
by agarose-gel electrophoresis. As for each immunization several different targets were 
injected, the selection of binders by phage display was performed in the laboratory of 
Prof. Jan Steyaert to ensure the protection of intellectual property (Pardon et al., 2014). 
In case of ScaDMT, two rounds of phage display were performed with biotinylated 
versions of the target proteins ScaDMT and ScaDMTtru. For expression, both constructs 
were cloned into an expression vector as fusion proteins with a C-terminal AVI-tag 
followed by a 3C protease site. The AVI-tagged proteins were purified in DM and 
subjected to SEC. The peak fractions were pooled and the biotinylation proceeded by 
incubating the protein with the biotin ligase BirA, the substrate biotin and cofactors such 
as ATP and magnesium. His-tagged BirA was removed by binding to Ni-NTA resin and 
the target proteins were subjected to a second SEC run to remove the remaining buffer 
components and to confirm the monodispersity of the protein (Figure 28). 
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Figure 28 Size exclusion profile of avi-tagged and biotinylated ScaDMT and ScaDMTtru.  
ScaDMT and ScaDMTtru were expressed with an AVI-tag fused to their C-terminus. After 
biotinylation with BirA the proteins were subjected to a second SEC run. The chromatogram on 
the left hand side corresponds to the elution profile of ScaDMT, the chromatogram on the right 
to ScaDMTtru. Both protein peaks were pooled and loaded on a SDS-PAGE gel. ScaDMT and 
ScaDMTtru are both monodisperse and pure.  
 
The biotinylated proteins were shipped on ice to our collaborators in Brussels where they 
performed phage-display and single-clone ELISA to detect the signal of individual 
nanobodies. 16 different nanobodies, binding either of the two constructs, were in that 
way identified in the lab of Jan Steyaert, from whom we obtained plasmids encoding the 
corresponding anti-ScaDMT nanobodies. Figure 29 displays a sequence comparison of 
the 16 different nanobody sequences aligned with ClustalW2 (Goujon et al., 2010; Larkin 
et al., 2007). The phylogenetic tree visualizes the three main clusters into which 13 of the 
nanobodies can be categorized. Three nanobodies (nb) are more distant to the other 
nanobody sequences but they can still be assigned to be closer related to one group. 
Nb08 is closest to group I, nb98 closest to group II and nb94 can be associated with 
group III. Based on the sequence alignment, the overall variability of the three CRD 
regions is evident. Group I nanobodies have the largest sequence differences in CDR1 
and are rather uniform in CDR3, which fits the criteria suggested in Pardon et al., 2014 
to define a nanobody family (>80% sequence identity in CDR3, identical length). In 
contrast to group I, group II and III nanobodies have differences in CDR3. On average 
the CDR3 of the 16 nanobodies is 15 amino acids long. Nanobodies nb94 (18 residues), 
nb98 (20 residues) and nb06 (21 residues) possess the longest CDR3 loops. The CDR3 
of nb18 is with 7 residues comparably short.  
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Figure 29 Sequence alignment and phylogenetic tree of the 16 selected nanobodies.  
A phylogenetic tree of the 16 nanobodies selected against ScaDMT/ScaDMTtru is shown on the 
top; a residue-by-residue comparison of the nanobodies is depicted at the bottom. The three 
groups that cluster together are highlighted by rectangles: Group I (blue), group II (green) and 
group III (yellow). Identical amino acids are marked in yellow, residues identical in most of the 
nanobody sequences are marked in green. CDR regions 1-3 are marked by a rectangles (blue) and 
labeled. Residues shared by more than half of the nanobodies are depicted in violet. Identical 
residues found in CDR3 within group I are highlighted in green.  
 nb90
 nb26
 nb00
 nb04
 nb14
 nb08
 nb12
 nb18
 nb24
 nb16
 nb22
 nb98
 nb02
 nb06
 nb20
 nb94
I 
II 
III 
nb90    QVQLQESGGGLVQTGDSLRLSCVAS GVTF-SSHA MGWFRQAPGKERELVAG INWSGGRT YYADSV 64  
nb00    QVQLQESGGGLVQAGTSLRLSCAAS GRTF-SSYA MAWFRQAPGKERELVAG INWSGGRT YDADSV 64  
nb26    QVQLQESGGGLVQAGTSLRLSCAAS GRTF-SSHA MGWFRQAPGKERELVAG INWSGGRT YHADSV 64  
nb04    QVQLQESGGGLVQAGTSLRLSCEAS GRDF-GSYA MAWFRQALGKERLLVAG VNWSG-RT YYADSV 63  
nb14    QVQLQESGGGTVQAGTSLRLSCAAS GRDF-GSYA MAWFRQAPGKERELVAG VNWSG-RT YYADSV 63  
nb12    QVQLQESGGGLVQAGGSLRLSCGAS GDIS-SINA ISWYRQAPGKEREFVAV ITDGG-SI NYAGSV 63  
nb18    QVQLQESGGGLVQPGGSLRLSCAAS GSIFKSMRG MGWYREAPGKERELVAL ITLGG-TT NYYDSV 64  
nb16    QVQLQESGGGLVQAGGSLRLSCAAS RSIF-SIDT ANWYRQPPGMQRELVAT ITRDG-NA NYADSV 63  
nb22    QVQLQESGGGVVQAGGSLRLSCAAS GIMF-SINT MGWFHQPPGKQRELVAA ITSGG-RS NYADSV 63  
nb24    QVQLQESGGGLVQPGGSLRLSCAAS ASIF-SIND MGWYRQAPGKQRELVAA ITRGG-TT KYADSV 63  
nb08    QVQLQESGGGLVQPGGSLRVSCAAS GFTF-STYA MTWVRQAPGKGLEWVST VDNNGDRR TYADSV 64  
nb02    QVQLQESGGGLVQAGGSLRLSCAAS GGTF-STYD LGWFRQAPGKEREFVAA ITWSGGFT LYADSV 64  
nb06    QVQLQESGGGLVQAGGSLRLSCEGY GRTF-STYA MGWFRQAPGKEREFVAS ISWSGDST AYADSV 64  
nb20    QVQLQESGGGLVRAGGSLRLSCAAS GLTT-SNYN MAWFRQAPGKERESVAS IGWTG-VT YYGDSV 63  
nb94    QVQLQESGGGLVQAGGSLRLSCAAS GRTF-TTYT MAWFRQAPGKEREFVAA IRWSDDTT YYTNSV 64  
nb98    QVQLQESGGGLVQAGASLKLSCVVS GHIL-STHV MGWFRQAPGREREFVAA LSWSGVTT KYADSV 64  
 
CDR1 
CDR3 
CDR2 
 
nb90    KGRFTISRDNAKNTVFLQMNSLKPEDTSVYYC VAGQVV------VEDPKRYHY WGPGTQVTVSS 122   
nb00    KGRFTVSRDNAKNTVFLQMNSLKPEDTSVYYC VAGQVV------VEDPKRYQF WGQGTQVTVSS 123   
nb26    KGRFTISRDNAKNTVFLQMNSLKPEDTSVYYC VAGQVV------VEDPKRYHY WGPGTQVTVSS 122  
nb04    KGRFTISRDNAKNMVFLQMNSLKPEDTSTYYC VAGQVV------VEDPKRYHY WGQGTQVTVSS 121   
nb14    KGRFTISRDNAKNTVFLQMNSLKPEDTSVYYC AAGQVV------LEDPKRFHY WGQGTQVTVSS 121 
nb12    KGRFTISRENNKRTVYLQMNDLRPEDTAVYFC NADASD-----GETTDYD-DY WGQGTQVTVSS 121 
nb18    KGRFTMSRDNGKNVLYLHMTSLKPEDTAVYYC RSNLYD-----S--------- WGQGTQVTVSS 114 
nb16    KGRFTISRDRARNTVYLQMNSLKPEDTGVYYC NAAIR------TTVRTSAQEY WGQGTQVTVSS 121 
nb22    KGRFTISRDNAKNTVYLQMNSLKPEDTGVYYC NGHINP-----FSLKDGQVDT WGQGTQVTVSS 122 
nb24    KGRFTISRDNAKNTLYLQMNSLKPEDTAVYYC NRGWLF-----NSRYYP--DY WGQGTQVTVSS 120 
nb08    KGRFTISRDNAKNTLYLQMNSLKAEDTAVYYC AKYETT-----VVVTTLR--Y WGQGTQVTVSS 121 
nb02    RGRFTISKDNTKVTGYLQANSLKPEDTAVYYC AAR----PPG-LSNIRYGYVY WGQGTQVTVSS 123 
nb06    EGRFTISRDNAKKTVSLQMNSLKPEDTAIYYC AASDDIWQIGRLSRTQDDYDY WGQGTQVTVSS 128  
nb20    KGRFTISKDNAKNTLYLQMNSLKPEDTAIYYC AASSRR-------LPSMNFDY YGKGTQVTVSS 120 
nb94    KGRFTISRDNAKNTVYLQMNSLKPEDTAVYYC AADRDLLYG---IRGVAQYQY WGQGTQVTVSS 125 
nb98    KGRFTISRDNAKNMVHLEMNNLKPEDTAVYYC AMKQSGRPVVVLTASASGYDH WGQGTQVTVSS 128 

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2.4.2. Characterization of ScaDMT specific nanobodies 
 
To investigate the suitability of the selected nanobodies for co-crystallization 
experiments they were characterized with respect to capability to form stable complexes 
with ScaDMT constructs, in conditions that are close to the ones used during 
crystallization. The complex was prepared by incubation of the membrane protein with 
1.5 molar excess of the nanobody for 20 min at 4 °C. The stability of the complex was 
tested on SEC. Co-migration of both proteins was assayed either on an analytical SEC 
column on a HPLC system or with a preparative Superdex S200 column. In both cases 
the proteins were detected by their absorbance at 280 nm. In these experiments the peak 
containing ScaDMT shows a clear shift in the elution volume towards higher molecular 
weight when injected together with nanobody 04 (nb04) and nanobody 16 (nb16), which 
suggests that both protein form stable complexes that do not dissociate during SEC 
(Figure 30 right panel and SDS-PAGE analysis (data not shown)).  
 
 
Figure 30 Size exclusion chromatography analysis of ScaDMT nanobody complexes. 
Comparison of the elution volumes of ScaDMT and ScaDMT-nanobody complexes on a S200 
column. (a) ScaDMT, purified in the detergent DM elutes at 13.6 ml. (b, d) Nb04 and nb16 bind 
to ScaDMT as indicated by the shift in elution volume. Interestingly both nanobodies appear to 
promote dimerization of the ScaDMT nanobody complex in solution. (c) Nanobody 12 does not 
bind to ScaDMT strong enough to co-migrate during the SEC run. The green line indicates the 
reference elution volume of ScaDMT alone. 
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In contrast no co-elution with ScaDMT was found for nanobody 12 (nb12) in SEC 
(Figure 30 lower left panel) and the corresponding SDS-PAGE analysis (data not 
shown), thus indicating that this nanobody did not form stable complexes with the 
membrane protein.  
For analysis on HPLC, purified ScaDMT was used as reference for the un-
complexed transporter and nb16 was used as reference for the nanobody. Two 
indicatures were used to judge whether a stable nanobody transporter complex was 
formed: A shift in the retention volume was observed due to the increased size of the 
complex. In addition the absorption of the complex was increased as all nanobodies 
selected against ScaDMT/ScaDMTtru have a comparably high extinction coefficient (1.3-
1.5), therefore the complex peak absorbs stronger at 280 nm compared to the transporter 
alone (Table 6).  
 
 
Table 6 HPLC analysis of nanobody ScaDMT complexes.  
Nanobodies were injected together with ScaDMT onto an analytical size-exclusion column 
(PC3.2/300, GE Healthcare) connected to a HPLC system. The elution volume and the 
absorption maximum at 280 nm of potential complexes were compared to the ScaDMT elution 
profile. Peak 1 corresponds to ScaDMT or the ScaDMT-nb complex, peak 2 to the elution of the 
free nanobody. A shift towards shorter elution time and an increase of the absorption maximum 
of peak 1 indicates the co-migration of the nanobody with ScaDMT. 
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Both indicators were positive for nb00, nb06, nb08, nb14, nb22, nb24, nb90, nb94 and 
nb98, thus indicating that a stable complex is formed. In the case of nb02, nb18 and 
nb20 no significant shift in both the elution volume and the AU280 was detected and 
these nanobodies were thus considered as weak binders. Nb26 could not be investigated 
since the protein was not well behaved during expression and purification.  
In summary, from the 16 different nanobodies selected against ScaDMT 11 
nanobodies (69%) form a stable complex that co-migrates during size exclusion 
chromatography, 4 nanobodies (25%) that gave a signal on ELISA, which indicates 
binding, do not co-migrate on SEC, thus suggesting that the affinity of the complex is 
low. One nanobody (6%) was not well behaved and thus excluded from further analysis.  
2.4.3. Co-crystallization of ScaDMT-nanobody complexes 
 
Before they were used for co-crystallization, the expression of nanobodies had to be 
scaled-up. As the expression levels varied significantly in the originally used pMESy4 
vector, the genes encoding for different nanobodies were sub-cloned into pBXNPHM3, 
an arabinose inducible expression vector. In this vector all nanobodies were expressed as 
fusion proteins containing a His10-MBP-3C tag following the PelB signal sequence at 
their N terminus, which targets the protein to the periplasm that is required for the 
formation of disulfide bonds. The fusion to maltose binding protein (MBP) was found to 
increase the expression level of the nanobodies in E. coli. After incubation with 3C 
protease this tag only adds two additional amino acids (Glycine-Proline) from the 
cleavage site to the proteins N terminus. Large-scale expression was carried out either in 
shaker flasks or in fermenter cultures. After purification using IMAC and SEC, the 
nanobodies were concentrated and mixed with SEC purified and concentrated ScaDMT 
(nb in 1.5 times molar excess). After incubation on ice, the complex was subjected to 
SEC, which allowed the removal of free nanobody. Peak fractions of the ScaDMT-nb 
complex were concentrated (12 mg/ml) and used for crystallization screening (Figure 
31).  
A high affine, SEC positive binder is a preferred tool for co-crystallization but it 
cannot be excluded that a weak binder might also be suitable. The high protein 
concentrations present in a vapor diffusion experiment can in principle shift the 
equilibrium towards the nanobody-transporter complex even in cases where the 
nanobody would not bind strong enough to co-migrate on SEC. To rule out to miss a 
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weak binder that may still improve crystallization, nanobodies nb12, nb18 and nb00 were 
included in crystallization screening. In this case the purified nanobodies were mixed 
with ScaDMT in slight stoichiometric excess (i.e. 1.2:1) and used for crystallization 
experiments without SEC of the complex . 
 
 
Figure 31 Size exclusion analysis of ScaDMT-nanobody complexes.  
Purified ScaDMT was injected together with molar excess of the respective nanobody on a SEC 
column equilibrated in buffer containing DM. (a-f) SEC runs of samples used for crystallization 
screening. The green line marks the reference elution volume of ScaDMT alone. 
 
All nanobody complexes were subjected to broad crystallization screening covering 
about 1000 different conditions (i.e. 10 screens in 96-well format). As the nanobodies 
influence the stability, solubility and crystal packing of the transporter the crystallization 
conditions were expected to change. Indeed crystals were observed in several new 
conditions for different nanobody complexes. Crystallization experiments with nb06 and 
nb08 yielded small crystals growing in the presence of alkaline earth metal ions. 
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ScaDMT-nb06 yielded needle-shaped crystals in a condition similar to the original high 
calcium chloride condition of WT (Figure 32 A). ScaDMT-nb08 crystallized in two 
conditions, one in the presence of calcium chloride and a second one in magnesium 
chloride (Figure 32 b, c). When tested at the X-06SA beamline at the SLS these crystals 
showed poor diffraction properties (Table 7). Nanobody 22 and nb24 crystallized each in 
one condition but crystals were fragile and their diffraction could thus not be 
investigated. 
 
 
Figure 32 Crystallization conditions and images of selected ScaDMT nb complexes.  
(A) ScaDMT-nb06 crystallized in a high calcium condition at pH 8.4. (B, C) ScaDMT-nb08 
crystals were very fragile and soft. They grew either in high magnesium concentrations at pH 4.5 
or in high calcium concentrations.  
 
The complex of ScaDMT-nb16 crystallized in several different conditions in low and 
high molecular PEGs (PEG 400-8000). Several conditions contained calcium but there 
were also crystals growing in conditions containing either lithium sulfate, ammonium 
sulfate or zinc acetate as salt additive. Crystals grew in a broad pH range (pH 4.5- pH 
9.4). Despite the large number of conditions, crystals of the complex did generally not 
diffract to higher resolution than crystals of ScaDMT alone (Table 7). Among the 
investigated crystals, a crystal form growing in an ammonium sulfate condition at pH 4.6 
was identified that diffracted to 6 Å and which had an unusually long c-axis as 
manifested in the close spacing between adjacent reflections on a diffraction image 
(Figure 33).  
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Figure 33 Diffraction image of ScaDMT-nb16 complex in a crystal form with a large unit 
cell dimension. 
Crystals of ScaDMT-nb16 were grown in 200 mM ammonium sulfate, 100mM sodium acetate 
pH 4.6 and 12% w/v PEG 4000. Their diffraction was anisotropic and extended in the best 
direction to 6.3 Å resolution. The crystal has a very long c-axis, as already visible from the 
diffraction pattern. 
 
Interestingly, nb16 was found to stabilize ScaDMT, which allowed the exchange from 
DM to the shorter detergent NM in the last purification step (Figure 34). A pronounced 
double peak, with the first peak corresponding to a dimer of the ScaDMT-nb16 complex 
was observed in gel filtration. The molecular weight of these peaks as monomers and 
dimers was verified by MALS experiments (Figure 35). 
 
 
Figure 34 Size exclusion profile of ScaDMT in complex with nb16 in the detergent NM. 
The nanobody-ScaDMT complex elutes as a double peak corresponding to a monomeric and 
dimeric form of the complex.  
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ScaDMT elutes with an apparent molecular weight of ~122 kDa of which more than 
56% are contributed form the detergent DM surrounding the protein. The ScaDMT–nb 
complex elutes in two peaks: The monomer-complex elutes with an apparent molecular 
weight of ~133 kDa of which >52% of the weight is contributed by the detergent DM. 
The dimer-complex elutes at ~271 kDa with a remarkably reduced weight contribution 
from the detergent of ~37%. This can be explained by the protein-protein interaction, 
excluding detergent molecules from the area of the dimer-interface. 
 
 
Figure 35 Multi angle light scattering. 
Gel filtration and light scattering results of ScaDMT, nb16 and the ScaDMT–nb16 complex in 
the detergent DM. The respective molecular weight of the protein-detergent complex obtained 
from light scattering is shown in the chromatogram in green, the molecular weight of the protein 
complex alone in red. The corresponding values with and without the detergent component are 
depicted in the table. 
 
Crystals of the complex grown in NM showed anisotropic diffraction up to 4.5 Å in the 
best direction (Table 7). Crystals grew also after exchanging into the shorter chain 
detergent octyl-maltoside (OM), but in this case fewer crystals and more precipitate 
indicated that the protein might be less stable in OM. In this case also the diffraction 
properties were deteriorated with crystals showing anisotropic diffraction up to 6.5 Å 
(Table 7).  
In summary, four nanobody complexes of ScaDMT (nb04, nb06, nb08 and 
nb16) were successfully crystallized. In four cases no co-migration on SEC was observed 
(i.e for nb00, nb12, nb18 and nb20) thus indicating weak affinity. No apparent 
correlation between sequence-based group assignment of nanobodies (I, II or III) and 
their biochemical behavior was observed (Figure 36). Nanobody 16 had the most drastic 
impact on the crystallization behavior of ScaDMT. In this case highly anisotropic 
diffraction up to a maximum resolution of 4.5 Å was observed.  
 
Protein 
(complex) MW +DM MW –DM
ScaDMT 121.80 kDa  52.68 kDa
nb16 13.17 kDa 12.30 kDa
ScaDMT–nb16 
(monomer) 133.40 kDa 63.43 kDa
ScaDMT–nb16 
(dimer) 279.60 kDa 170.50 kDa
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Table 7 Summary of ScaDMT-nanobody complex crystals.  
ScaDMT was co-crystallized with different nanobodies in vapor-diffusion experiments. In all 
experiments ScaDMT was initially purified in the detergent DM and mixed with purified 
nanobody. The complex was subsequently subjected to another SEC chromatography. In 
specified cases the detergent was changed to NM or OM during that step. The crystallization 
conditions and the diffraction properties are specified for each crystal form. 
 
 
Figure 36 Phylogenetic tree of the nanobodies 
selected against ScaDMT/ScaDMTtru. 
The three families classified by sequence analysis 
are marked in rectangles (group I in blue, group II 
in green and group III in yellow). Nanobodies 
marked with a red dot did not co-migrate with 
ScaDMT on SEC. Nanobodies marked with a 
violet star did co-crystallize. Nb16, which was 
successfully used for structure determination, is 
highlighted by a green star. 
  
  		

 15  311#""$ " # 21=5111 61$(# 6,6 '#:
 211 29=511 211$#!# 6,7 "#! !#
8,6!#
21!#
17  3112 36=511 61!" 9,5 '#:
 211#""$$#!#!# 36=511 61 7,6 '#9
27  211
35+21135 21=5111 61 7,6 '#:
 3112 36=511 211 7,5 '#8
 3112 21=5111 61( :,5 '#:
 211 29=511 211$#!# 6,7 '#8,6
 311$"$# 23=5111 211$#!# 5,7 '#7,4
$#'"
 311## 21=9111 211	) 7,6 '#8
$#'"
 311## 21=4111 211$## 5,6 '#:
 3113+1,22=&-%

36=511 61 8,5 '#8,6
 3113+211( 36=511 61 8,5 "#! !#
5,6!#
8!#
 3113+31$! 36=511 61 8,5 "#! !#
5,9!#8,6
!#
 3113+311 36=511 61 8,5 "#! !#
6!#
8!#
 3113+511
#(!
36=511 61 8,5 '#7,6
 3113+311$
#!#
36=511 61 8,5 "#! !#
5,6!#
8!#
 211
35+21135 21=5111 61$## 5,6 "#! !#
7,6!#
9!#
 311#""$ " # 21=5111 61 7,6 '#9
 . 6=5111 61( :,5 '#8
 nb90
 nb26
 nb00
 nb04
 nb14
 nb08
 nb12
 nb18
 nb24
 nb16
 nb22
 nb98
 nb02
 nb06
 nb20
 nb94
 70 
2.4.4. Crystallization of the ScaDMTtru-nb16 complex 
 
Besides the full-length protein, nb16 was also found to bind to the truncated version 
ScaDMTtru as confirmed by SEC (Figure 37). Crystals of the ScaDMTtru-nb16 complex 
grew in similar conditions as the WT ScaDMT-nb16 complex but also after replacing 
calcium by potassium or magnesium ions. The condition in high potassium chloride was 
the first crystal that was found to diffract close to 4 Å (Table 8). Crystals growing in 
magnesium chloride showed anisotropic diffraction to 4.5-5.5 Å. Crystals growing in 
high calcium with PEG 4000 as precipitant diffracted anisotropically to 4.5-7.5 Å as well. 
The replacement of PEG 4000 by PEG 400 improved the diffraction significantly and 
isotropic data to 4 Å could be collected.  
 
 
Figure 37 Size exclusion profile of ScaDMTtru in complex with nb16. 
ScaDMTtru purified in DM was incubated with nb16 and loaded onto a S200 column. The 
complex elutes at 13.2 ml as one major peak with a small shoulder towards higher molecular 
weight.  
 
As for ScaDMT also the ScaDMTtru -nb16 complex showed increased stability in shorter 
chain detergents and therefore tolerated detergent exchange into NM on SEC (Figure 
38). In NM, ScaDMTtru-nb16 crystals grew at high calcium concentrations in PEG 400 in 
a broad pH range. They were of hexagonal shape and grew in drops of 150 nl volume, 
after equilibration to a maximal size of 250-300 μm. These crystals diffracted 
reproducibly beyond 4 Å, a striking improvement reached by the use of a shorter chain 
detergent.  
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Figure 38 Size exclusion profile of ScaDMTtru in complex with nb16 in NM. 
ScaDMTtru was purified in DM, incubated with nb16 and loaded onto a S200 column 
equilibrated in buffer containing NM. The main peak elutes at 13.8 ml. The asymmetry of the 
peak was frequently observed when loading large amounts of protein, which may exceed the 
capacity of the column.  
 
 
Table 8 Summary of crystallized ScaDMTtru-nanobody complexes  
ScaDMTtru–nb16 complex crystallized by vapor diffusion in sitting drops. ScaDMTtru was 
purified in the detergent DM incubated with purified nanobody and purified on SEC. Detergent 
was exchanged into NM on SEC if indicated. Crystallization conditions and the diffraction 
properties are specified. 
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As scale-up of the crystallization experiments to 250 nl in 96-well plates and 1 μl in 24-
well plates yielded crystals of decreased size and quality, all further crystallization 
experiments were carried out at 150 nl. A second crystal form appearing in the same 
condition of large volume crystallization setups grew in clusters of small needles that 
were not suitable for data collection. The increase in the crystallization volume thus 
favored growth of an unsuitable crystal form and was thus no pursued.  
 
 
Figure 39 Diffraction of ScaDMtru-nb16.  
(left) Diffraction image of a ScaDMTtru-nb16 crystal, which diffracted X-rays to 3.1 Å. (right) 
Image of the crystal used for the diffraction experiment, which was grown in 200 mM CaCl2, 50 
mM Hepes pH 7.4, 25% PEG400, cryo-protected and flash frozen in liquid propane. 
 
The best crystal observed after an extensive screen, allowed data collection to 3.1 Å 
(Figure 39). The protein crystallized in the space group P3121 with unit cell parameters of 
a=b=114.4 Å, c= 257.9 Å, == 90°, = 120° (Table 9). The number of molecules 
per asymmetric unit was estimated by calculation of the Matthews coefficient and the 
corresponding solvent content (Kantardjieff and Rupp, 2003; Matthews, 1968). With two 
ScaDMTtru-nb16 complexes per asymmetric unit the solvent content would be 69 %, 
which is in the expected range for a membrane protein.  
 
 

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ScaDMTtru–nb16  Data collection 
Wavelength (Å) 1.0 
Space group P3121 
Cell dimensions  
    a, b, c (Å) 114.4, 114.4, 257.9 
    α, β, γ (°)  90.0, 90.0, 120.0 
Resolution (Å) 50–3.1 (3.3–3.1) 
Rmerge 6.0 (120.) 
I / σI 21.0 (2.1) 
Completeness (%) 99.6 (98.2) 
Redundancy 9.5 (15.2) 
 
 
 
 
 
Table 9 Data collection statistics for 
ScaDMTtru–nb16 
Statistics for the best native dataset 
collected from a ScaDMTtru–nb16 crystal 
grown in NM. 
 
2.4.5. Summary 
 
Crystallization chaperones have been successfully used to improve the crystallization 
properties of difficult targets, such as membrane proteins. They stabilize the protein in a 
specific conformation, reduce the flexibility of loop regions, and in the case of 
membrane proteins increase the hydrophilic surface available for crystal contacts. In 
collaboration with the group of Prof. Jan Steyaert, nanobodies targeting ScaDMT, were 
raised in Llamas by immunization of the animal with purified, detergent solubilized 
protein. For selection purposes, the entire repertoire of nanobodies was cloned into a 
phage-display library, which was subsequently used to enrich ScaDMT specific binders 
via phage display technology. In that way, 16 different nanobodies that recognize 
ScaDMT in ELISA assays were obtained. Complex formation of identified binders with 
ScaDMT was subsequently analyzed by SEC. Eleven out of 16 nanobodies were found 
to form tight complexes and were thus used for co-crystallization experiments with the 
transport protein. For four complexes crystals were obtained, although most of these 
crystal forms diffracted to low resolution. One nanobody, nb16, has stabilized the 
membrane protein in detergent solution. The complex with ScaDMT crystallized in 
several different conditions, but the diffraction was usually anisotropic and limited to 4.5 
Å in the best direction. The exchange of the complex into the shorter chain maltoside 
detergents NM or OM did not improve the diffraction properties. In contrast, crystals 
grown from nb16 in complex with, ScaDMTtru, a truncated version of the transporter, 
diffracted up to 4 Å in the detergent DM. By exchanging the detergent to NM, the 
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diffraction was successfully improved to 3.1 Å, which is of suitable resolution for 
structure determination in case phases can be obtained.  
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2.5. Seleno-methionine derivatization of ScaDMTtru and 
structure-determination of the ScaDMTtru-nb16 
complex by SAD phasing 
 
An electron density map is calculated by the fourier transformation of the structure 
factors, which contain for each reflection amplitude and a phase angle. The diffraction 
data collected from a crystal reveals the amplitude of each reflection whereas the phase 
information is lost. In order to retrieve the phase information, different methods are 
available: In Molecular Replacement the structure of a closely related protein, can be 
used as a search model, which is then positioned in the crystal structure to reconstruct 
the packing in the crystal form who’s structure needs to be determined. This 
reconstructed crystal structure can be used to calculate a set of initial phases that are 
combined with the measured structure factor amplitudes to calculate an electron density 
map. However, in cases where no similar structure is available, phases need to be 
determined experimentally either by isomorphous replacement or anomalous diffraction 
techniques. Direct methods (ab initio) are successfully applied in small-molecule 
crystallography but are usually not feasible for macromolecular crystallography. 
Experimental phasing methods rely on the presence of a small subset of heavy 
atoms that have recognizable features in the diffraction pattern. In both cases the 
substructure of the heavy atom components is determined first. Isomorphous 
replacement methods require the preparation of a heavy atom derivative that is usually 
prepared by soaking of native crystals and collection of a heavy atom derivative data set. 
The difference in the diffraction due to bound heavy atoms can then be calculated by 
subtracting the amplitudes of the heavy atom derivative data set from the native data set, 
and by determination of the substructure with Patterson methods. This method relies on 
the assumption that the heavy atom and the native data sets are isomorphous, which 
means that the protein components in both, the native and the heavy atom derivative 
data set needs to be the same. In membrane protein crystals, heavy-atom binding 
frequently decreases the resolution and changes the crystal packing, resulting in non-
isomorphism, which prevents structure determination by isomorphous replacement. 
Furthermore it can be difficult to identify a suitable heavy atom derivative that 
incorporates a sufficient number of heavy atoms within the asymmetric unit, to obtain 
phases with low error.  
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Single anomalous diffraction experiments do not rely on isomorphism between different 
crystals, since all data used for phase calculation, are collected from the same crystal. 
Data is collected close to the absorption edge of certain elements, at which the 
absorption of a small fraction of the incident beam is maximized and photons are re-
emitted with a phase shift (of 90°). This effect is generally stronger for heavier atoms, 
e.g. the anomalous scattering of selenium is stronger than of sulfur. Anomalous 
scattering causes a breakdown of Friedel’s law, which describes the symmetry in the 
structure factor amplitudes between reflections with indices hkl and –h-k-l. In case of 
anomalous scattering the differences in the intensity between the Friedel pairs can be 
quantified. As these differences are generally small, a high redundancy of the data is 
essential whereas radiation damage due to overexposure of the crystals should be 
avoided. This can be accomplished by a reduction of the beam intensity to minimize 
radiation damage and the collection of several complete datasets of one crystal. As most 
commonly used method to introduce anomalous scatterers into the crystal, the heavy 
atom selenium is incorporated into the protein during expression, by replacing the 
amino-acid methionine with Se-methionine. 
In 1990 the first time Se-methionine (Se-Met) labeled protein was used for 
phasing by Hendrickson, Horton and LeMaster (Hendrickson et al., 1990). Since then 
several modified versions of the protocol to generate Se-Met derivatives have been 
applied (Doublié, 2007). An important concept of this strategy is that prokaryotic and 
eukaryotic cells can incorporate seleno-methionine instead of the naturally occurring 
methionine during protein synthesis. Two main approaches have been used to increase 
the incorporation efficiency of seleno-methionine. BL21(DE3) derived methionine 
auxotroph E. coli strains have been used successfully for the T7/ IPTG based expression 
system (Doherty et al., 1995). These strains can metabolize arabinose and are therefore 
not suitable for arabinose-inducible expression systems. In an alternative approach 
compatible with expression controlled by the arabinose promoter the methionine 
synthesis can be inhibited by the addition of L-Lysine, L-Threonine, L-Phenylalanine, L-
Leucine, L-Isoleucine and L-Valine to the medium. These amino acids are known to 
inhibit the enzyme aspartokinase, which is necessary for methionine synthesis, in a 
synergistic way (Truffa-Bachi and Cohen, 1968). In both cases either minimal medium or 
a medium with a defined amino acid composition is used and sufficient amounts of Se-
Met have to be added to the medium. For MC1061, the E. coli strain used in this study, 
the medium has also to be supplemented with Thiamine (Vitamin B1). The protein yield 
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is generally lower for expression cultures growing in seleno-methionine containing 
medium and it can depend on the media composition. Therefore it is generally advisable 
to test different media suitable for seleno-methionine incorporation for their effect on 
the target protein expression. 
2.5.1. Expression screening of seleno-methionine labeled 
ScaDMTtru 
 
ScaDMTtru contains 9 endogenous methionines (i.e. 1 methionine per 50 amino acids), 
which is sufficient for Se-Met SAD (single anomalous dispersion) phasing (18 
methionine per asymmetric unit). In order to produce sufficient amounts of the labeled 
transporter, expression tests were performed in E. coli MC1061 cells. Three media 
containing all amino acids (with Se-Met replacing Met, MMAA) were compared with 
three minimal media (MM) containing, except Se-Met, only the amino acids needed to 
inhibit the methionine biosynthesis of the host strain (Table 10). Two different 
approaches were tested for each of the media conditions. In all cases the cultures were 
directly inoculated 1/100 from an o/n culture grown in Terrific Broth (without washing 
the cells). 
 
Strategy “Methionine first”: Methionine was available during initial growth by 
either the addition of methionine in the case of MMAA medium or by not repressing the 
methionine biosynthesis if MM was used. Prior to induction cells were harvested under 
sterile conditions and resuspended in the corresponding medium not containing 
methionine. The amino acid cocktail, which inhibits the methionine biosynthesis, was 
added to the cultures in MM. After a growth period to deplete cells from free methionine 
Seleno-methionine was added. Before expression was induced by the addition of 
arabinose, cells were allowed to adapt to Seleno-methionine for one hour.  
Strategy “Se-methionine”: All cultures were inoculated in the respective 
medium with Seleno-methionine added from the beginning. The media also included the 
Methionine biosynthesis inhibition cocktail for MM cultures. Prior to induction a second 
aliquot of the Met-inhibition cocktail was added to these cultures. Induction and o/n 
expression were carried out corresponding to the standard expression protocol.  
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 Nitrogen source/ buffer Amino acids and nucleotides Vitamins, Trace elements 
M
M
A
A
 1
 
M63 medium 
(NH4)2SO4, 
KPi 
0.2 g/l Cys, His; 0.3 g/l Ala, Arg, 
Asp, Asn, Gln, Glu, Gly, Ile, Leu, 
Lys, Pro, Ser, Trp, Tyr, Thr, Phe, 
Val; 0.5 g/l Adenine, Cytidine, 
Guanine, Thymine, Uracil 
MgSO4, CaCl2, ZnSO4, MnCl2, 
(NH4)6Mo7O24, CuSO4, FeSO4, 
CoCl2, H3BO4, Kao-Michayluk 
Vitamin solution and additionally 
Biotin and Thiamine 
M
M
A
A
 2
 M63 medium 
(NH4)2SO4, 
KPi 
2 mg/l Ala, Arg, Asn, Asp, Cys, 
Gln, Glu, Gly, His, Ile, Leu, Lys, 
Phe, Pro, Ser, Thr, Tyr, Val, 
1mg/L Trp; 2mg/l uracil 
MgSO4, CaCl2, FeSO4, Biotin, 
Nicotinamide, Riboflavin, 
Thiamine 
M
M
A
A
 3
 M63 medium 
(NH4)2SO4,  
KPi 
20 mg /l Ala, Arg, Asn, Asp, Cys, 
Gln, Glu, Gly, His, Ile, Leu, Lys, 
Phe, Pro, Ser, Thr, Tyr, Val, 
1mg/L Trp 
MgSO4, CaCl2, FeSO4, Thiamine 
M
M
 1
 M63 medium 
(NH4)2SO4,  
KPi 
- MgSO4, CaCl2, FeSO4, Thiamine 
M
M
 2
 M9 medium 
NH4Cl 
Na/KPi 
- MgSO4, CaCl2, FeSO4, Thiamine 
M
M
 3
 M9 medium 
NH4Cl 
Na/KPi 
 MgSO4, CaCl2, ZnSO4, MnCl2, 
CuSO4, FeSO4, CoCl2, H3BO4, 
Kao-Michayluk Vitamin solution  
 
Table 10 Overview of the different growth media used for the small-scale expression test. 
Medium MMAA 1 is based on a protocol by A. Evdokimov which is itself a modification of the 
original protocol published by S. Doublié (Doublié, 2007; Evdokimov). The carbon source was 
in all cases 0.75% glycerol. 
 
Cells were lysed by bead-beating and membrane proteins were extracted by addition of 
DM. After removal of aggregates by ultra centrifugation the supernatant was used for 
western blot analysis. ScaDMTtru was detected with an anti-His HRP conjugated antibody 
(Figure 40). The difference between the MMAA and MM strategy with respect to 
ScaDMTtru expression was striking. Independent of the time point for the addition of 
Seleno-methionine all three MM cultures expressed significantly more protein than the 
MMAA cultures. As shown in Figure 40, only for one MMAA culture a protein band at 
the right molecular weight was detectable when seleno-methionine was added one hour 
before induction.  
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Figure 40 ScaDMT expression analysis for seleno-methionine labelled protein. 
The extracted membrane protein fraction was separated by SDS-PAGE and then transferred 
onto a PVDF membrane. The western blot analysis was performed with an anti-his HRP 
conjugated antibody. Lane (+) ScaDMTtru expressed in standard TB was loaded as a reference. 
Lanes 1-3 correspond to MMAA media where the cells were exposed to seleno-methionine only 
one hour prior to induction Lane 1-2 no protein is detectable. Lane 2 a faint band of ScaDMTtru 
is visible. Lane 4-5 Significantly more expression of ScaDMTtru is detected in all three cases 
where medium without addition of all amino acids is used. Lane 7-8 No protein is detected for all 
three media containing amino acids when Seleno-Methionine is added from the beginning. Lane 
10-12 Comparable amounts of ScaDMTtru where detected for the cultures grown in minimal 
medium with addition of Seleno-Methionine. 
 
From these results it can be concluded that a sufficient amount of protein was produced 
with the MM but not the MMAA expression strategy. Cultures that were treated with the 
methionine-biosynthesis inhibition cocktail for one hour, followed by a one-hour 
adaptation to seleno-methionine prior induction, gave double the amount of biomass at 
harvest. As also this strategy, which includes additionally trace elements and the Kao-
Michayluk Vitamin solution (MM3), has yielded the higher expression levels (see Figure 
40, lane 5), it was used for scale-up. In total 50 flasks, with a volume of 0.6 l each, were 
grown according to the protocol and induced with arabinose at an OD600 of 0.6. Three 
hours post induction the culture was supplemented with an additional aliquot of the 
methionine-biosynthesis inhibition cocktail. Cells were harvested fourteen hours after 
induction at an OD600 of ~3.0. The resuspended cells were lysed by sonication, and 
membrane protein extraction was started directly after a low-spin centrifugation step, to 
remove unbroken cells and debris. The protein was purified by IMAC, only half of the 
Ni-NTA resin was used compared to the standard protocol for the unlabeled transporter, 
to compensate for the lower expression levels. Efficient incorporation of seleno-
methionine into ScaDMTtru was confirmed by MALDI-MS (Data not shown), which 
revealed an incorporation of 7-8 seleno-methionines per transporter corresponding to an 
 
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	
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incorporation efficiency of 83%. After SEC in the detergent DM the seleno-methionine 
labeled transporter ScaDMTtru was combined with the purified, unlabeled nanobody and 
subjected to an additional SEC run on a S200 column, equilibrated in a buffer containing 
the detergent NM. The protein complex was concentrated to 11 mg/ml and set-up in 
sitting-drop vapor diffusion experiments, screening in a constricted range around the 
ideal condition used for the native crystals. Overall the protein behaved comparable to 
unlabeled ScaDMTtru during purification, despite the low yield of 37 μg/l culture. The 
protein did crystallize, although the crystals were thinner and nucleation was less 
frequently observed, which can be partly explained by the slightly lower protein 
concentration (11 instead of 12 mg/ml) used to set up the crystallization experiments. 
2.5.2. Structure determination of the ScaDMTtru-nb16 complex 
 
Diffraction data of the seleno-methionine derivatized crystals was collected close to the 
absorption edge for selenium, at λ = 0.9795 Å at low beam intensity with an oscillation 
range 0.5° per image. In order to obtain high redundancy 1500 frames were collected, 
which results in a total oscillation range of 750°. The data was indexed, integrated and 
scaled with XDS (Kabsch, 1993). A summary of the data statistics is shown in Table 11. 
The data is 22.0-fold redundant and 99.2% complete (with a 22.5-fold redundancy and a 
completeness of 95.4 % in the highest resolution shell (3.8-3.6 Å). An I/σI of 2.94 in the 
highest resolution shell indicates a diffraction limit close to 3.6 Å. The anomalous signal 
of selenium is detectable up to ~4.6 Å (F’’/σI of 1.127 at 4.8 Å and 0.933 at 4.4 Å). 
 
Table 11 Data collection statistics of the ScaDMTtru-nb16 data set used for SAD phasing. 
The number of reflection, the completeness of the data set, its calculated R-factor, I/σI and the 
anomalous signal are displayed for different resolution shells. 
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SHELX C and D (Schneider and Sheldrick, 2002) were used to identify the 18 selenium 
sites present in each asymmetric unit. In Figure 41 the signal-to-noise ratio (I/σI) is 
plotted in dependence of the resolution, which defines the high-resolution limit of the 
dataset as 3.5 Å. In the same figure on the right, the ratio of anomalous differences over 
background is shown against resolution, indicating an anomalous signal over-noise of up 
to 4.4 Å. The selenium sites were determined from the anomalous difference Patterson 
map by Patterson superposition methods. Whereas incorrect solutions have a correlation 
coefficient (CC) below 20%, a value above 35% is indicative for a correct substructure 
solution. The histogram depicted in Figure 42 illustrates the distribution of all calculated 
solutions. In combination with the CC the Patterson figure of merit (PATFOM) for each 
trial is useful to distinguish correct from wrong solutions (Figure 42 right panel). The 
highest CC and PATFOM values indicate the correct solution of the substructure search.  
 
 
Figure 41 SHELXC: I/σI vs. resolution and f”/ σI vs. resolution. 
(left) I/σI is plotted against the resolution (Å). With higher resolution the signal-to-noise ratio 
drops to a value where the signal is no longer distinguishable form the background (I/σI < 2.0). 
(right) The ratio of anomalous differences over background is shown against resolution. 
 
SHELXD ranks the selenium sites based on their relative occupancies (with a maximum 
occupancy of 1.0). This graph allows estimating the number of sites reliably identified. A 
steep decrease of the occupancy usually indicates the boundary between heavy atoms of 
the substructure and noise. Sites with an occupancy of less than ~20-25% are usually 
considered insignificant. The corresponding graph for the ScaDMTtru-nb16 data is 
presented in Figure 43. The site occupancies gradually decrease with increasing site 
number but there is no distinct drop observed. Since the occupancy of the first 18 sites is 
above 25%, all sites present in the asymmetric unit have been correctly identified. 
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Figure 42 Graphical output of SHELXD. 
(left) Histogram of the calculated solutions (quantity) plotted against the weighted correlation 
coefficient between Eobs and Ecalc weighted by 1/σE (CCall in %). (right) For each trial CCall is 
plotted against the PATFOM value. 
 
 
Figure 43 SHELXD statistics: Selenium site occupancies vs. peak number. 
Site occupancies are normalized to the highest value. The number of significant peaks in the 
substructure can be estimated by plotting the peak height (site occupancy) in descending order. 
 
During the Patterson calculations the direction of the anomalous signal that allows 
distinguishing the two enantiomers is lost. Both hands of the atomic substructure thus 
give rise to the same anomalous differences. To resolve this ambiguity SHELXE applies 
density modification to both enantiomorph solutions (original and inverted), which 
permits identification of the correct hand by a stronger increase in contrast (non-
solvent/solvent) in the right solution over the wrong hand. The graphical output of the 
SHELXE statistics is displayed in Figure 44. Over the course of 150 cycles the contrast 
of the original solution increases stronger than the one of the inverted solution. The 
CCmap of the correct solution is higher compared to the inverted solution over the entire 
resolution range. 
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Figure 44 Solving the enantiomorphism problem with SHELXE. 
(left) The contrast for each cycle is shown. The correct solution, (red) shows a stronger increase 
in contrast compared to the inverted solution (blue). (right) The CC of both maps is plotted 
against the resolution (Å).  
 
The heavy atom coordinates identified in SHELXD were refined, and a first set of single 
anomalous dispersion phases was calculated in SHARP (De La Fortelle and Bricogne, 
1997). During refinement the xyz coordinates, occupancies and B-factors of the selenium 
sites were optimized. The phasing power of the anomalous component gives an 
indication of the quality of the phases in dependence of the resolution (Figure 45). The 
phasing power decreases towards higher resolution and drops below 1 at around 5 Å 
(Figure 45 top graph). The FOMcen is a quality measure of the phases of the centric 
reflections. As shown in Figure 45 (lower graph) the phase probabilities are decent up to 
5 Å resolution. The initial SAD phases were subsequently improved and extended in DM 
(Cowtan, 1994), by solvent flattening, histogram matching and non-crystallographic 
symmetry (NCS) averaging between the two copies of the ScaDMTtru–nb16 complex, 
present in the asymmetric unit of the crystals. Initial NCS symmetry operators were 
determined from the heavy atom positions and a monomer mask was generated based on 
the low-resolution boundaries of the electron density. In that way the phases were 
extended to 3.1 Å, the resolution limit of the best native data set.  
The improved phases were of sufficient quality for interpretation by an atomic 
model. The structure was built in COOT (Emsley and Cowtan, 2004) and refined in 
PHENIX (Adams et al., 2002). Figure 46 displays electron density calculated with 
experimental phases that were improved by NCS averaging, next to the 2Fo-Fc density 
calculated with phases of the refined model at 3.1 Å. The R/Rfree values of the final 
model are 25.0% and 28.5%. Rfree values were calculated from 5 % of the reflections that 
were excluded from refinement. 
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Figure 45 SHARP statistics: Phasing power and FOMcen vs. resolution. 
(top) The Phasing power of the anomalous data set is plotted against the resolution (Å). (bottom) 
The figure of merit of the centric reflections (FOMcen) is shown in dependence of the resolution 
(Å).  
 
 
Figure 46 Electron density after SAD-phasing and after structure refinement. 
(left) Elecron density at 3.5 Å that was calculated from experimental phases that were improved 
by NCS averaging. The density, contoured at 1 σ and superimposed on the final model, is shown 
in blue. (right) 2Fo-Fc density at 3.1 Å calculated with the phases of the refined model and 
contoured at 1 σ,  is shown in cyan. 
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2.5.3. Summary 
 
For SAD phasing crystals of seleno-methionine labelled protein were prepared. In order 
to produce Se-Met labelled protein, cells were grown under defined conditions with the 
endogenous methionine synthesis inhibited by the addition of the amino acids L-Lysine, 
L-Threonine, L-Phenylalanine, L-Leucine, L-Isoleucine and L-Valine. During initial 
expression screening, a large difference in protein yield was detected depending on the 
media and growth conditions. The results of this initial screen allowed to identify 
conditions with high expression levels. These improved expression conditions permitted 
scale-up and purification with a protein yield of 1.1 mg from a 30 l culture and an 
incorporation efficiency of seleno-methionine of >80 %. The crystals of Se-Met-
derivatized protein grew in space group P3121 with two proteins per asymmetric unit, 
and were isomorphous to the native protein complex. 
Anomalous data collection of Se-Met crystals has provided an initial set of phases 
by the SAD method, which has subsequently led to the structure determination of the 
ScaDMTtru-nb16 complex at 3.1 Å resolution. The workflow during phasing is 
summarized in Figure 47. After data reduction in XDS, the SHELX suite (C/D/E) was 
used to solve the selenium substructure. SHARP was used to refine the selenium sites 
and calculate phases to 4.5 Å (SAD data set). Solvent flattening, histogram matching and 
2-fold NCS symmetry averaging in DM improved the phases and allowed phase 
extension to 3.5 Å. This map was used to build an initial atomic model in COOT. The 
model was improved by refinement with PHENIX using a native dataset at 3.1 Å.  
 
 
 
 
 
 
 
Figure 47 Workflow of the SAD phasing 
process for the ScaDMTtru-nb16 complex 
Schematic representation of the workflow 
applied for the ScaDMTtru-nb16 complex 
solved by the SAD method.  
 
XDS
indexing, integration, scaling
output: structure factor amplitudes
SHELXC/D
heavy atom substructure search 
based on Patterson superposition
SHELXE
discrimination between enantiomorph solutions
solvent ﬂattening 
output: se-sites.pdb
 SHARP
phasing and reﬁnement of selenium sites
DM
phase improvement: solvent ﬂattening, 2-fold NCS averaging  
phase extension (native data set)
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2.6. Functional characterization of ScaDMT 
2.6.1. Isothermal titration calorimetry of ScaDMT wild type, 
binding site mutants and ScaDMTtru 
 
Isothermal titration calorimetry (ITC) is a powerful biophysical tool to determine the 
thermodynamic parameters of interactions between biological molecules and their 
ligands. In ITC measurements the small enthalpy differences that occur upon binding of 
a ligand to a receptor molecule (e.g. binding of an ion to a protein in solution) are 
detected. For this purpose, ITC devices have two compartments, one cell containing the 
sample in solution (e.g. protein) and one reference cell filled with buffer (or water). 
These cells are set to a fixed reference power and the instrument tries to maintain equal 
power between them. Upon injection of the ligand to the sample cell, heat is released or 
taken up by the system, depending on the enthalpy of the chemical reaction. In response, 
the sample cell is either heated or cooled to compensate for the temperature difference 
between sample and reference cell. These power changes are recorded over time. In an 
exothermic reaction heat will be released upon ligand binding, and the power will be 
down regulated (by cooling) to keep the sample cell at the reference power. An 
endothermic reaction will take up heat upon ligand binding, and therefore the system 
needs to be heated. For every injection the total energy is integrated and plotted against 
the ligand concentration. For analysis the integrated heat exchange values are fitted to a 
suitable binding isotherm, which allows the calculation of the binding affinity (Ka) and 
other thermodynamic parameters (enthalpy changes ΔH, Gibbs free energy changes ΔG, 
entropy changes ΔS and binding stoichiometry n). In that way, affinities in the 
nanomolar to sub-millimolar range can be detected reliably. As ITC experiments measure 
the energy changes of the system, they are independent of the ligand size, which is an 
advantage over similar label-free techniques (e.g. surface plasmon resonance or 
microscale thermophoresis), where most ions are not detectable. Large quantities of pure 
and stable protein, as well as ligand, supplied in the same buffer composition are needed 
for ITC measurements. The temperature used during the experiments, is chosen to 
ensure measureable enthalpy differences. A high protein concentration is advantageous, 
not only to improve the signal-to-noise ratio, but more importantly to measure the entire 
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range from sub-stoichiometric binding to ligand saturation. Because the stability of the 
protein during the measurement is of high importance, lower protein concentrations may 
have to be used, which may not permit the reliable measurement of all thermodynamic 
quantities. Despite this limitation, Ka values can be determined with satisfying precision 
to answer biochemical questions.  
In the case of ScaDMT, we were interested in the binding affinity of a 
transported ion to the protein, and thereby compare the binding affinities of binding site 
mutants to the wild type protein. ITC measurements also allowed us to show that the 
truncated version of ScaDMT, ScaDMTtru, binds cadmium with similar affinity as the 
wild type transporter. For these measurements, cadmium (as CdCl2) was preferred over 
manganese or other divalent transition-metal substrates, because it is stable in aqueous 
solution (under the conditions used) and therefore would allow us to measure affinities 
with higher reliability/precision than with less stable divalent metal ions. Manganese was 
tested as well, but noise levels were higher, and Kd values were thus determined less 
accurately (data not shown). Cadmium was advantageous for a second reason: In our 
competition transport assays (see next chapter) cadmium is preferably transported over 
manganese, indicating a higher affinity for cadmium in ScaDMT, which has also been 
shown for hDMT1 (Mackenzie et al., 2007). 
For ITC analysis, ScaDMT was purified with the same protocol used for 
crystallization, in the detergent DM. After SEC the protein fractions were pooled 
(concentration ~1 mg/ml) and dialyzed 1/100 against the ITC buffer containing 2.8x 
CMC DM. This is necessary because slight differences of the sample buffer and the 
titration buffer can cause large background signals (heat absorbed or released upon 
solvation), thereby perturbing accurate measurements of the ligand binding reaction. The 
next day, ScaDMT was concentrated with a centrifugal filter device with a MWCO large 
enough to allow the passage of empty DM micelles. Just before the ITC experiment, the 
protein was filtered trough a 0.1 μm centrifugal filtration device, and the concentration 
was determined by spectrophotometry. The ITC measurements were carried out with 
protein concentrations between 5.5-6 mg/ml (110-180 μM). An ITC200 (GE, Microcal) 
instrument was used, which has a small sample cell of ~230 μl (a bit more sample is 
needed to ensure there are no air bubbles left that would cause the detergent to foam 
when stirring starts). One run, thus consumed around 1.5 mg of purified protein. As 
ScaDMT is more stable at low temperatures, 6 °C was found to be the temperature 
where ScaDMT is stable, and the heat differences are well enough detectable. The 
 88 
cadmium chloride solution was prepared in the buffer the protein was dialyzed into. For 
ScaDMT and ScaDMTtru ITC measurements, the cadmium concentration in the syringe 
was 4 mM and titrated in aliquots of 2 μl. The raw data of the absorbed heat upon 
cadmium injection is shown in Figure 48 (top). All measurements were background-
corrected. For every run, cadmium was titrated into the respective buffer (no protein) 
and the signal was subtracted from the sample run (with protein). ScaDMT binds 
cadmium, with an affinity of 29 ±10 μM and ScaDMTtru was found to bind cadmium 
with comparable affinity of 37 ±8 μM. After the ITC run, the integrity of the protein-
Cd2+ samples was analyzed by SEC. All constructs were eluting as one single peak at the 
expected molecular weight, with no detected aggregation peak (data not shown).  
 
 
 
Figure 48 ITC measurements of 
Cd2+ binding to ScaDMT and 
ScaDMTtru 
(Top graphs) Heat absorbed upon 
injection of Cd2+ into the cell, 
containing the respective protein. 
(Bottom graphs) Fit of the integrated 
and buffer corrected heat to a single-
site binding isotherm (red line). The 
exponent n was constrained between 
0.9 and 1.1. 
Alanine mutants of binding site residues of ScaDMT were constructed by mutagenesis, 
expressed and purified in DM with the same protocols as used for the wild type protein. 
Expression levels of D49A and N52A mutants were lower, yielding 12 % and 35 % less 
protein than for wild type ScaDMT (1.56 mg/l culture and 1.13 mg/l culture 
respectively). The mutant M226A yielded about 90 % more protein compared to wild 
type (M226A 3.4 mg/l culture compared to 1.77 mg/l for ScaDMT). For ITC 
measurements of two binding site mutants (D49A and N52A) a higher cadmium 
concentration (up to 25 mM) and the concatenation of two runs (of twice 20 times 2μl 
injections) was needed to measure saturated binding. Background was measured and 
subtracted as described before. The heat release and the integrated and fitted data are 
depicted in Figure 49. In all three mutants the binding of cadmium to the protein is 
exothermic (at 6°C with the specified buffer and detergent), whereas it is endothermic 
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for wild type and truncated ScaDMT. Similar changes were reported in the literature for 
another protein (Grenha et al., 2013). The exact cause of such a change from an endo- to 
exothermic process is unknown. One could speculate that the preferred conformation of 
the mutant is not the same as for the wild type protein, which might have an impact on 
the energy status of the system. The mutation of single residues of the binding site was 
found to have a strong effect on cadmium binding. The affinity for cadmium shifted by 
more than an order of magnitude, towards higher cadmium concentration. Kd values are: 
475 ±38 μM for D49A, 929 ±151 μM for N52A and 769 ±27 μM for M226A. All three 
mutants were subjected to SEC after the ITC experiments to confirm their stability. No 
void peaks were detected and the proteins eluted as single peaks at their expected elution 
volume (data not shown). 
 
 
Figure 49 Binding of Cd2+ to ScaDMT binding site mutants 
From left to right: D49A, N52A and M226A. (Top graphs) Heat absorbed upon injection of 
Cd2+ into the cell containing the respective protein. (Bottom graphs) Fit of the integrated and 
buffer corrected heat to a one-site binding isotherm (red line). The exponent n was constrained 
between 0.9 and 1.1. 
 
In summary, the ITC experiments have allowed me to determine the affinity of cadmium 
to a single binding site in ScaDMT (Kd 29 μM). I could show that the truncation of N-
terminal residues in the construct ScaDMTtru does not have strong effects on the binding 
affinity of cadmium (Kd 37 μM), thus confirming that its binding site remained intact. 
Furthermore, ITC measurements of the binding site mutants revealed drastic shifts in the 
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ion binding affinities compared to the wild type protein (D49A Kd 475 μM, N52A Kd 
929 μM and M226A Kd 769 μM). ITC can precisely measure affinities and reveal 
thermodynamic parameters, but it does not assess transport properties. To measure the 
transport of various divalent metal ions, I have established a fluorescence-based 
proteoliposomal assay, described in the following chapter. 
2.6.2. Transport assays of ScaDMT and ScaDMTtru 
 
Methods to reconstitute membrane proteins into liposomes have been used since more 
than 35 years, for the development of cell-free transport assay (Darszon, 1979). Yet 
successful incorporation of detergent solubilized (active) protein into lipid vesicles can be 
highly dependent on the lipid composition, the protein and the detergents used. 
Therefore, different reconstitution methods are described in the literature. They mostly 
differ in two steps, the preparation of lipids (e.g. by the use of pre-formed liposomes or 
detergent solubilized lipids) and the strategy of lipid-removal (e.g. by dialysis, rapid 
dilution, bio-bead addition or sucrose density centrifugation).  
For the reconstitution of ScaDMT, a protocol based on the preparation of 
preformed liposomes, destabilized with Triton-X-100 was applied (Geertsma et al., 
2008b). E. coli polar lipid extract and phosphytidylcholine from egg-yolk were mixed in a 
3:1 ratio and washed with chloroform and diethylether. Diethylether was removed under 
vacuum or a nitrogen gas stream. The lipids were resuspended in the reconstitution 
buffer and homogeneous unilamellar liposomes were prepared by extrusion trough a 
polycarbonate filter. The vesicles were destabilized with Triton-X-100 beyond saturating 
concentrations, and then combined with the freshly purified transporter (in the detergent 
DM). Polystyrene beads (Bio-Beads) were used to remove the detergent, and to allow 
proteoliposome formation. Bio-Beads were removed by filtration. Proteoliposomes were 
harvested by centrifugation, flash frozen and stored in liquid nitrogen until use. Efficient 
incorporation of ScaDMT was assessed by freeze-fracture electron microscopy shown in 
Figure 50. The protein was reconstituted at a protein-to-lipid ratio of 1:40 (w/w) (= LPR 
40). 
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Figure 50 Freeze-fracture electron micrograph of 
proteoliposomes with incorporated ScaDMT. 
The protein was reconstituted into liposomes at an LPR of 40. 
Proteoliposomes were frozen under high-pressure in liquid 
nitrogen, fractured under vacuum, subsequently shaded with a 
carbon-platinum layer at 45° and coated with carbon at an 
angle of 90°. The image was taken with a Philips CM100 
transmission electron microscope. 
 
Transport of the reconstituted protein can be measured with fluorescence dyes. These 
dyes need to be metal sensitive; their fluorescence is either quenched or increased when 
the divalent metal ion is present. Additionally the dye needs to be efficiently trapped in 
the liposome, which can be achieved by extrusion of the proteoliposomes together with 
the dye and subsequent removal of the untrapped dye. It is critical that the dye is 
sufficiently hydrophilic to be membrane impermeable. To my knowledge, there are no 
commercially available fluorescence dyes that are equally sensitive to all the divalent 
metal ions. Often these dyes are engineered for maximum calcium sensitivity (an earth 
alkaline metal ion) or zinc sensitivity (a transition metal ion). The two fluorophores used 
in this study are calcein and fura-2. Their signal in response to different metal ions was 
assessed in aqueous solution to have an estimate of their sensitivity under conditions 
close to the experimental set-up. Table 12 summarizes the fluorescence response of 
calcein to different metal ions and the fluorescence change of fura-2 observed in the 
presence of cadmium and calcium. Signals were measured with a plate reader at the 
optimal excitation and emission wavelength for the respective fluorophore. Calcein is 
efficiently quenched by Mn2+, Co2+ and Ni2+ but not by Cd2+, Zn2+, Ca2+, Sr2+ and Ba2+.  
Although calcein was designed as an indicator for calcium it is only sensitive to 
calcium at strongly alkaline pH (Lewin et al., 1969). The sensitivity of calcein for Mn2+ is 
lower than for Co2+ and Ni2+. The fluorescence of fura-2 is strongly increased upon 
addition of cadmium. Fura-2 is a highly sensitive fluorophore designed to detect small 
changes (nM range) in calcium concentration but at calcium concentration above 1 μM 
its fluorescence is basically calcium independent (Kong and Lee, 1995). Besides calcein 
and fura-2, phengreen and fluozin-3 were tested as well, but they were both leaking out 
of the liposomes (since they are probably too lipophilic), and were as a consequence not 
suitable for the transport measurements. Additionally no fluorescence changes of 
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phengreen in response to cadmium and manganese were observed under the investigated 
conditions (aqueous buffer, ion concentrations between 5 nM and 1mM). 
 
Table 12 Ion selectivity of calcein and fura-2. 
The fluorescence signal of calcein (0.5 μM) and fura-2 (0.5 μM) in response to different divalent 
metal ions (molar ratio of fluorophore to ion is 1:1) is presented as percentage of the maximum 
fluorescence measured in buffer without the addition of divalent metal ions (100%). Calcein was 
excited at 492 nm and emission was detected at 518 nm. Fluorescence changes of calcein in 
response to Cd2+, Zn2+, Sr2+ and Ba2+ were less than 10% at all tested concentrations. Fura-2 was 
exited at 335 nm and emission was detected at 505 nm. Both fluorophores are insensitive to 
calcium (under the investigated conditions). 
 
Calcein is very light sensitive (upon light exposure the fluorescence will increase by 
~10% and then decrease back to starting levels within 2-3 min). To exclude this effect 
during time-dependent measurements, the measurement and the pipetting steps were 
carried out in the dark. Fura-2 does not show this effect but generally the baseline 
fluorescence showed a higher fluctuation. Calcein-trapped proteoliposomes were used to 
detect ScaDMT and ScaDMTtru mediated import of manganese (Figure 51). For that 
purpose, Mn2+ was added to the outside medium and the fluorescence change of the 
trapped calcein was measured every 20 seconds over a time course of 30 minutes. 
Towards the end of the experiment, the divalent metal ion selective ionophor calcimycin 
was added to measure maximal quenching in both, the proteoliposomes and the control 
liposomes devoid of protein. The assay as such is not strictly quantitative, but it allows a 
qualitative comparison between the different traces of the same metal ion. Interestingly 
ScaDMTtru does still transport manganese into the vesicles, although clearly at a lower 
rate than ScaDMT.  
 
Fluorophor molar ratio 1:1
Calcein     λex 492 nm Mn2+ 70%
λem 518 nm Co2+ 18%
Ni2+ 20%
Ca2+ 105%
insensitive       Cd2+, Zn2+, Sr2+, Ba2+ 
Fura-2       λex 335 nm Cd2+  173% 
λem 505 nm Ca2+ 100%
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Figure 51 Transport of manganese. 
ScaDMT and ScaDMTtru mediated uptake of manganese. Calcein is quenched inside the vesicles 
when manganese (300 μM) is added to the external medium (red). A control trace of liposomes 
devoid of protein is shown in black. 
 
To measure cadmium transport, fura-2 was trapped inside the vesicles and the 
fluorescence increase of the fluorophore in response to cadmium supplied to the external 
medium, was assayed. In Figure 52 the traces for ScaDMT and ScaDMTtru are displayed. 
For ScaDMTtru the picture is similar to the uptake of manganese: ScaDMTtru does still 
transport cadmium but the curve is not as steep as the one for ScaDMT, indicating lower 
transport levels for cadmium in case of the truncated protein. 
 
 
Figure 52 ScaDMT and ScaDMTtru mediated uptake of cadmium. 
The fluorescence of fura-2, trapped inside the vesicle, increases upon addition of cadmium (200 
μM) to the external medium (yellow). A control trace of liposomes devoid of protein is shown in 
black. 
 
In all transport assays the transport was triggered by the addition of the divalent metal 
ion to the external medium. The pH of the inside and the outside solution was kept at 
7.5. The transport of the divalent metal ion was driven by its concentration gradient and 
independent of sodium or potassium gradients applied (data not shown). The fact that 
the presumably electrogenic transport proceeds without dissipation of the membrane 
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potential is probably due to the leakiness of the liposomes for protons. Tests with the 
pH-sensitive fluorophore pyranine revealed that the liposomes were leaky to protons 
over the timescale used in the assays. Optimization of the liposome preparation and 
reconstitution procedure is required to improve the tightness of the liposomes. Future 
experiments with proton-tight liposomes might allow us to reveal if the transport of 
divalent metal ions by ScaDMT is coupled to protons. 
2.6.1. Summary of the functional characterization of ScaDMT  
 
The binding and transport properties of ScaDMT wer characterized by the application of 
biophysical and functional methods. With ITC the binding affinity of detergent 
solubilized ScaDMT for cadmium could be determined (Kd 29 μM). The affinity of the 
truncated protein ScaDMTtru (Kd 37 μM) was only slightly shifted compared to the full-
length protein indicating that the truncation did not alter the conformation of the ion-
binding site. Kd values of the three individual binding site mutants were strongly shifted 
towards higher concentrations, thus underlining the importance of the three residues 
(D49, N52 and M226) for ion binding. 
An initial transport assay was successfully established, which allowed me to 
investigate divalent metal ion transport into proteoliposomes containing purified and 
reconstituted ScaDMT. ScaDMT dependent manganese and cadmium import was 
measured by metal sensitive fluorophores. Interestingly the truncated transporter 
ScaDMTtru that we used for structure determination is still capable of transporting 
manganese and cadmium, although with slower kinetics. In ion-competition experiments, 
(see chapter 2.7) we saw that the earth alkaline metal ions calcium, barium and strontium 
are not transported by ScaDMT, even at concentrations up to 1 mM. A potential 
coupling of metal ion transport in ScaDMT to protons, which was found for eukaryotic 
SLC11 members, remains to be investigated. Future experiments with an improved 
experimental set-up might allow us to address this important question. 
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2.7. Crystal structure of a SLC11 (NRAMP) transporter reveals 
the basis for transition-metal ion transport 
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3. DISCUSSION 
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Discussion  
 
With the structure determination of the prokaryotic transporter ScaDMT, the results of this 
thesis have allowed first detailed insight into the architecture of the SLC11 family and they have 
provided the structural basis of transition metal ion selectivity. ScaDMT adopts an inward-facing 
conformation that exposes a metal binding site to the cytoplasm. Three conserved residues that 
are located in the center of the transporter coordinate the divalent transition-metal ions Mn2+, 
Fe2+ and Cd2+. Fluorescence based assays have allowed me to measure transport of several 
transition-metal ions and they showed that the presence of the alkaline earth-metal ions Ca2+, Sr2+ 
and Ba2+ does not affect the transport of manganese, thus indicating that they are neither 
substrates nor inhibitors of ScaDMT. Cadmium affinities of ScaDMT and mutants of ion-
coordinating residues by ITC underline the important role of this binding site for ion 
coordination. The conservation of ion-protein interactions was confirmed by electrophysiology. 
Towards this end I have applied two-electrode voltage-clamp measurements to investigate the 
effect of binding site mutants in human DMT1. One mutant evokes cadmium induced currents 
only at higher concentrations compared to wild type hDMT1 and no cadmium-induced currents 
were observed for two other mutants despite their strong expression in X. laevis oocytes, thus 
suggesting that the same residues coordinate transition metal ions in SLC11 transporters from 
bacteria to human. 
 
ScaDMT shares its fold with LeuT 
 
The crystal structure of ScaDMT reveals that SLC11 transporter share a common architecture 
with otherwise unrelated transport proteins, which was first identified in the amino acid 
transporter LeuT from the bacterium Aquifex aeolicus (Yamashita et al., 2005). Our work thus 
confirms a previous bioinformatics analysis that has predicted a structural relationship to 
transporters sharing a LeuT-fold (Cellier, 2012a, 2012b). In these proteins two sub-domains of 
five transmembrane segments are organized as inverted structural repeats (Yamashita et al., 
2005). In LeuT the transmembrane segments TM1-5 are related via a pseudo-symmetry axis, 
parallel to the membrane to the segments TM6-10. The first transmembrane helix of each repeat 
is unwound in its center with residues (in this unwound region) contributing to substrate binding 
(for a schematic drawing see Chapter 2.7, Figure 2b). Over the last years several secondary active 
transporters of unrelated sequence have been found to share the same fold (Forrest et al., 2011; 
Perez et al., 2012; Shi, 2013). All of them contain a core of two five-helix repeats, often followed 
by 1-2 additional helices.  
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The sodium/galactose symporter SGLT from the bacterium Vibrio parahaemolyticus (Faham et al., 
2008) and the sodium/glycine-betaine symporter BetP (Ressl et al., 2009) from Corynebacterium 
glutamicum are examples where the core is preceded by either one or two N-terminal helices 
respectively. Besides their similar architecture these proteins have no apparent sequence 
homology and transport unrelated substrates such as amino acids, sugars, or ions (Forrest and 
Rudnick, 2009; Theobald and Miller, 2010). Several of them use the symport of sodium as the 
electrochemical driving force to transport a solute against its concentration gradient. Three 
bacterial transporters have been identified as antiporters: AdiC form Salmonella typhimurium and E. 
coli (Fang et al., 2009; Gao et al., 2010; Tsai and Miller, 2013) exchanges arginine with agmatine, 
and CaiT (Proteus mirabilis PmCaiT and E. coli EcCaiT) L-carnitine with γ-butyrobetaine (Schulze 
et al., 2010; Tang et al., 2010) and GadC from E. coli exchanges glutamate with GABA(Ma et al., 
2012). The prokaryotic transporter ApcT from Methanocaldococcus jannaschii is a proton-coupled 
symporter for amino acids (Shaffer et al., 2009). Based on the alternate access model introduced 
~50 years ago in the absence of structural information, transport of a solute requires at least three 
conformations. In two conformations the binding site of the transporter is exposed to either one 
or the other side of the membrane. Both states are connected by a transient conformation in 
which the binding site is closed to both sides (Jardetzky, 1966; Mitchell, 1957). Several structures 
of the amino acid transporter LeuT in different conformations have confirmed the alternating 
access model (Krishnamurthy and Gouaux, 2012; Singh et al., 2007, 2008; Yamashita et al., 2005). 
In Figure 53 the structures of LeuT in three distinct conformations are shown. In an outward-
facing conformation (A, D) the residues coordinating the substrate are accessible from the 
outside. Upon substrate binding, conformational changes are induced that cause the closure of 
the extracellular binding cavity while the intracellular site remains closed. In this state the binding 
site is occluded to both sides of the membrane, completely surrounding the substrate. (B, E) The 
transient occlusion is followed by conformational rearrangements that cause the intracellular site 
to open up, hence allowing the release of the substrate to the cytoplasm (C, F). Structures of 
different conformations of other secondary active transporters sharing the LeuT fold, are in 
agreement with the alternate substrate access observed in LeuT, and have allowed the 
identification of additional conformations transiently present during the transport cycle (Faham 
et al., 2008; Fang et al., 2009; Gao et al., 2009; Ma et al., 2012; Malinauskaite et al., 2014; 
Penmatsa et al., 2013; Ressl et al., 2009; Schulze et al., 2010; Shaffer et al., 2009; Shimamura et al., 
2010; Weyand et al., 2008). In agreement with the model, the substrate binding sites are generally 
located in the center of the transporter, where the energy for a hydrophilic substrate traversing 
the membrane would be at its maximum.  
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In the case of ScaDMT, soaks of several transition-metal ions have allowed us to identify a single 
binding site composed of conserved residues located in the center of the membrane, which 
coordinate Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Cd2+ and Pb2+. This binding site is inaccessible from the 
extracellular side, since residues of α-helices TM1b TM6a, TM2 and TM10 seal the cavity.  
 
Figure 53 Structures of LeuT transporter in different conformations. 
(A) View from the extracellular side of an outward-facing conformation with bound substrate. (B) 
Extracellular and cytoplasmic view of a substrate-bound occluded conformation. (C) Bottom-view of the 
inward-facing conformation of LeuT. Figures A-C are shown as surface representation. (D-F) C-α 
representation of the corresponding conformations shown in A-C. The view is from within the 
membrane. The surface of the substrate-binding pocket is shown in grey. 
 
On the intracellular side, the binding site is partially shielded by residues of TM1a and the hinge 
between TM1a and TM1b, several residues of TM6b and two residues of TM8. Although the 
ScaDMT structure most likely shows an inward-facing conformation that is stable also in the 
absence of bound ions, the absence of part of helix 1 (in the construct used for structure 
determination) leaves some uncertainty on its exact correspondence to conformations of the 
transport cycle. Although the truncation was shown to have an unchanged binding affinity for 
ions, it cannot be excluded that in a full- length protein the N terminus could adopt a slightly 
different conformation. The fact that ions could be soaked into the crystals, without observed 
changes in the structure, is an indication that the binding site was easily accessible. 
 
inwardoutward occluded
intracellular
extracellular
A B C
D E F
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Based on the analysis of known structures, there were two models proposed of how substrate 
transport is conducted in transporters sharing a LeuT fold. These hypotheses are known as the 
“rocking-bundle” mechanism (Forrest and Rudnick, 2009; Rudnick, 2013) and the “hinge-
bending” model (Penmatsa and Gouaux, 2014; Yamashita et al., 2005). The rocking-bundle 
mechanism suggests that a so-called bundle comprised of TM 1-2 and TM6-7 moves as a single 
rigid entity, relative to the scaffold domain comprised of TM3-5 and TM8-10 (Figure 54A). The 
“hinge-bending” model suggests that the two halves of TM1 and 6 as well as TM2 and 7 move 
independently (the authors call TM1-2 and TM-7 core-domain), with respect to the scaffold 
domain that is comprised of the same helices as suggested in the rocking-bundle model (Figure 
54B). Remarkably, the rocking-bundle model does not explain the large outward movement of 
helix 1a, observed in the inward-facing conformation in LeuT (Forrest and Rudnick, 2009; 
Forrest et al., 2011).  
 
Figure 54 Rocking-bundle and Hinge-bending model. 
(A) Rocking bundle mechanism. The bundle (blue) moves with respect to the scaffold domain (grey) 
around the binding site. (B) Hinge-bending model. Helices 1, 2, 6 and 7 move individually, with respect to 
the scaffolding domain (grey). The substrate is depicted as red sphere. 
 
When comparing the inward-facing conformations of LeuT (pdb code 3TT3), Mhp1 (pdb code 
2X79) and BetP (pdb code 4C7R) a striking difference has been noted in the location of the first 
part of α-helix 1: Whereas TM1a moves by ~45° in LeuT, the movement is intermediate in 
vSGLT (Faham et al., 2008), and lowest (~18°) in Mhp1 and BetP (Penmatsa and Gouaux, 
2014). As all three structures were solved by crystallization of detergent-solubilized protein, it 
cannot be excluded that this local conformation is induced by the detergent, and would not occur 
if the protein would be embedded in a lipid bilayer (Forrest and Rudnick, 2009; Loland, 2014). 
The residual density we have observed in the low-resolution structure of full-length ScaDMT 
does not conclusively allow distinguishing if TM1a of ScaDMT is similar to the inward-facing 
conformation found in LeuT, or whether it closer resembles the inward-facing conformations of 
vSGLT, Mhp1 and BetP. Recent EPR and DEER studies of LeuT that tried to address this 
A B
1b
1b
1a 6b
2 7
1b
1b
1a
6b
2 7
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question would be compatible with the hinge-bending mechanism (Kazmier et al., 2014). Given 
the structural similarity of ScaDMT to LeuT, a similar structural transition into an outward-facing 
conformation appears plausible (see chapter 2.7, Figure 7). However, a detailed understanding of 
the molecular and thermodynamic determinants driving the conformational changes of the 
transport cycle in ScaDMT requires further structural and functional analysis. 
 
Proton-coupling in SLC11 transporters 
 
Transition-metal ion transport in eukaryotic SLC11 transporter is coupled to the cotransport of 
protons, which provide the electrochemical driving force for concentrative substrate uptake. This 
process was initially investigated in the rat DMT1, where uptake of Fe2+ was increased with 
decreasing pH, and where the import of protons was directly measured with pH sensitive 
microelectrodes (Gunshin et al., 1997). Compared to other secondary active transporters, this 
coupling appears less strict, as uncoupled fluxes of either substrate were observed in conditions 
lacking the other ion (Mackenzie et al., 2006). pH dependent transport of metal ions was also 
observed for the SLC11 transporter of E. coli, based on radioactive uptake into cells (Makui et al., 
2000). Unlike the determinants of metal ion selectivity, my study did not reveal the mechanisms 
underlying proton coupling. Due to limitation of the current transport assay, the question 
whether metal ion transport in ScaDMT would show a similar coupling, is still unresolved. The 
high sequence similarity to its mammalian counterparts and the strict conservation of residues in 
the proximity of the binding site makes a similar transport mechanism plausible.  
 
Figure 55 Conserved histidine residues in the vicinity of the metal binding site. 
Surface representation of ScaDMT viewed from within the membrane (left). Zoom into the binding site 
with His228 and His232 shown as sticks (right). 
 
H228
H233
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In that respect it is remarkable to find that two histidines located in TM6, whose mutations were 
previously identified to affect proton coupling in human DMT, are conserved in ScaDMT. These 
residues are located in the aqueous pathway leading to the metal binding site, with one residue 
found in the immediate proximity of the site (Figure 55). Unexpectedly the effect of mutations is 
stronger for the histidine that is found at a larger distance from the site towards the cytoplasm. It 
is thus currently not clear whether these residues would be the only proton acceptors within the 
protein or whether there may be a extended proton pathway throughout the protein that was 
proposed for other proton coupled transport proteins (Lim and Miller, 2009; Lim et al., 2012). A 
recent study of a proton coupled transporter sharing the LeuT-fold, showed a potential proton-
accepting residue at the equivalent position of the sodium binding site in LeuT, which suggests a 
way, how the ion-coupling could have been changed with minimal changes of the protein. 
Interestingly however, there is no suitable equivalent residue found in the ScaDMT structure, 
thus suggesting that the proton coupling in that protein may proceed by a different mechanism.  
 
Outlook 
 
Although the work of this thesis has provided a breakthrough in the structural understanding of 
the SLC11 family, it should be considered as one out of many steps to be taken towards a 
complete comprehension of the mechanisms of transition-metal ion transport by these secondary 
active transporters. Future investigations will have to employ different approaches to characterize 
SLC11 transporters in more depth. One challenge will be to obtain different conformations of 
the same or related homologs. Snap-shots of the binding site captured in different states of the 
transport cycle would allow to get insight into the residues involved in the formation of the, not 
yet identified, “thin gate” that might, similar as in sodium-coupled transporters sharing the LeuT-
fold, protect the substrate from dissociation in an outward-facing conformation (Forrest et al., 
2011; Loland, 2014; Perez and Ziegler, 2013). Towards this goal, specific mutations at strategic 
points within the protein might help to destabilize the inward-facing conformation that seems to 
be preferred by ScaDMT when solubilized in detergent. Additionally selection of nanobodies or 
other crystallization chaperones with ScaDMT (wt or mutants) embedded in a more native 
environment (e.g. in liposomes or nano-disks) might facilitate the selection of binders targeting 
different conformations (Inagaki et al., 2013; Pavlidou et al., 2013). Compounds that stabilize 
such conformations and thus inhibit transport might be useful for crystallization and functional 
analysis of ScaDMT (Cadieux et al., 2012; Zhang et al., 2012b). 
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Particular effort has to be put on improving the fluorescence-based assay described in this thesis. 
Although this assay was very useful for the initial functional characterization of ScaDMT, it has 
still several weaknesses that need to be resolved, in order to use the full potential of a 
reconstituted system. Due to the proton-leakage of the proteoliposomes observed during 
measurements, this assay cannot be used to investigate a potential proton coupling of metal ion 
transport in prokaryotic SLC11 homologs, which is an important question that has to be 
addressed. Future experiments to improve the transport assay, will have to explore other lipid 
sources, since a recent comparison of proteoliposomes in a study conducted, by Ming-Feng Tsai 
and Chris Miller revealed striking differences in proton-leakiness depending on the lipid 
composition (Tsai and Miller, 2013). The question whether zinc is a substrate or an inhibitor of 
ScaDMT should be elucidated by the use of zinc sensitive fluorescent dyes that are compatible 
with a liposomal assay. Alternatively, radioactive zinc could be used in uptake assays. Besides the 
direct investigation of coupled proton transport using pH-sensitive fluorescent dyes, an improved 
assay would also allow the determination of kinetic parameters such as Km values and Vmax for 
transport. Such quantitative assessment of transport would be very valuable, because it would 
allow us to characterize the substrate specificity of wild type ScaDMT and mutant constructs for 
different transition-metal ions. 
The establishment of the expression of a mammalian homolog for purification and 
reconstitution would be a remarkable achievement that would allow the characterization of the 
isolated transporters under controlled conditions. This would multiply the possibilities to address 
questions concerning the detailed mechanism of ion transport and coupling in mammalian 
transporters, such as the proposed uncoupled transport of either protons or metals. Besides its 
use for functional experiments such an overexpression system would also provide protein for 
crystallization experiments that aim for the structure determination of a mammalian SLC11 
transporter.  
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Isolation of genomic DNA. Genomic DNA was prepared according to Sambrook and Russell 
2001 (J. Sambrook, 2001) by phenol:chloroform extraction, with minor modifications: 
Additionally to Proteinase K and SDS which are components of the standard lysis-buffer, 
lysozyme was added to a final concentration of 5 mg/ml. In case incubation at the recommended 
37 °C was not sufficient to lyse the cells, temperature was increased up to 80 °C and incubation 
time was prolonged for a maximum of 5 hours. The DNA was concentrated by sodium- acetate- 
isopropanol precipitation and resuspended in TE buffer. 
 
PCR. Genes were amplified either with Phusion polymerase (Thermo Scientific Finnzymes or 
NEB) or Herculase II (Stratagene) or a PCR Mastermix containing Taq DNA polymerase 
(Thermo Scientific ABgene). Reactions were set up with 100-1000 ng genomic DNA, 0.5-1 μM 
of forward and reverse primer (Microsynth AG) and DMSO was added up to 3 % (v/v). The 
temperature settings for denaturation and elongation were chosen as suggested by the user 
manufacturer. The annealing temperature of 59 °C was decreased by 0.5 °C per cycle to reduce 
annealing at unspecific sequences in the first 15 cycles. The annealing temperature was set 
constant to 51 °C for additional 15 cycles. The PCR products were separated on a 1% agarose 
gel. DNA bands of the expected size were cut out and purified with High Pure PCR Product 
Purification Kit (Roche). 
 
Restriction digest and ligation. PCR products were cloned into the pINITIAL vector 
according to Geertsma and Dutzler, 2011 . In brief, 50 ng vector was mixed with purified PCR 
product at a molar ratio of 1:5 and digested with SapI for 1 h at 37 °C. The reaction was 
incubated for 20 min at 65 °C to heat-inactivate the restriction enzyme. For ligation ATP and T4 
ligase were added to the reaction and incubated for 1h at RT. Prior to transformation into 
chemo-competent E.coli MC1061 (Casadaban and Cohen, 1980) the ligase was heat inactivated by 
a 20 min incubation step at 65 °C.  
 
Small-scale protein expression. E.coli MC1061 was used for all subsequent expression cultures. 
All cultures were supplemented with the appropriate antibiotics. Pre-cultures were grown o/n at 
37 °C, 300rpm, in 96-deep-well plates (conical bottom) in TB medium supplemented with 0.75% 
(w/v) glycerol. Main cultures were grown in 4 ml (24-deep-well plates, conical bottom) TB 
supplemented with 0.75% (w/v) glycerol from a 1/100 inoculum. After 1.5 hours growth at 37 
°C, 300 rpm the temperature was reduced to 25 °C and cells were allowed to grow for an 
additional hour. The cultures were induced with the desired amount of arabinose (initial 
screening concentrations: 4*10-2%, 4*10-3%, 4*10-4% (w/v) arabinose, as 4*10-2% (w/v) arabinose 
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was not resulting in more well behaved protein of the homologs tested in the first round and 
4*10-4% (w/v) arabinose led to extremely low expression of the target protein only 4*10-3% (w/v) 
arabinose concentration was tested in the screening of subsequent homolog-rounds). Expression 
was carried out at 24 °C overnight, 300 rpm shaking. Cells were harvested by centrifugation at 
2000 g, 4 °C, 15 min and immediately used for subsequent experiments.  
 
Small-scale cell lysis and membrane protein extraction. The harvested cells were 
resuspended in 300 μl ice-cold PBS. Whole cell fluorescence was measured if the GFP-fusion 
construct was expressed: For this 150 μl of the cell suspension were transferred to a 96-black-
well flat bottom plates (Greiner) and fluorescence was recorded in a Tecan Infinite M1000 plate 
reader (excitation at 485 nm, emission at 535 nm, gain = 60). The OD600 of the cells was 
measured in 96-well transparent, flat bottom plates (Nunc) and used to correct the fluorescence 
signal for the cell densities (Fluorescence signal divided by OD600). For further analysis cells 
equalling ~3 mg total protein were resuspended in 400 μl pre-cooled lysis buffer (50 mM KPi pH 
7.5, 1 mM MgSO4, 10% (w/v) glycerol, 1x Roche Complete Protease Inhibitor Cocktail, 25 
μg/ml DNase), 300 mg glass beads (Sigma, 0.1 mm diameter) were added and cells were lysed 
using a bead-beating device (FastPrep-24, MP Biomedicals, two cycles, time 20 s, speed 6 m/s, 5 
min incubation on ice after each cycle). To extract the membrane proteins 200 μl of the 
supernatant were mixed with DDM to a final concentration of 1 % (w/v) and incubated on ice 
for 1h (mixing every 20 min). The extract was cleared by ultracentrifugation (Beckman Optima 
MAX XP, TLA 100, 10 min at 220 000 g, 4 °C). Samples were taken after lysis and after 
ultracentrifugation and separated by SDS-PAGE (corresponding to 75 μg total protein/lane). 
Directly after SDS-PAGE, in-gel fluorescence was detected for GFP-fusion proteins with a 
Fujifilm LAS-3000 imaging system (Fujifilm Super CCD camera, 460 nm EPI blue light, 
Y515AttoPhos Filter, Iris F2.8). The protocol is modified from Geertsma et al., 2008. 
 
Western blot analysis. Shortly after SDS-PAGE (gel was incubated 2 min in water) proteins 
were transferred onto a PVDF membrane (PVDF membranes were pre-soaked in methanol) by 
semi-dry electrophoretic transfer (BioRad Transblot SD, 50 min, 15 V). The filter paper was pre-
soaked for 10 minutes in pre-chilled transfer buffer (25 mM Tris, 192 mM glycine, pH 8.3, 20% 
methanol). PVDF membranes were blocked for 1h at RT with 5% (w/v) milk powder in PBS 
and then incubated with an anti-polyhistidine antibody (Roche 11965985001, 1:1000 (v/v)) in 
PBS supplemented with 1% milk powder. The blots were developed with Immobilon Western 
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chemiluminescent HRP substrate (Millipore) and imaged with a Fujifilm LAS-3000 imaging 
system (Fujifilm Super CCD camera). 
 
Large-scale expression of prokaryotic DMT homologs in fermenter culture. Cells were 
inoculated 1/100 in 9-18 l TB medium supplemented with 100 mg/l Ampicillin. Cells were 
allowed to grow for 1.5 hours at 37 °C with air supply (constant air flow airin = 1.2 bar, airout = 
0.9 bar, stirring speed = 250-350 rpm). Over the following 4 hours the temperature was reduced 
in steps of 4 °C until 25 °C were reached. Cells were allowed to grow at 25 °C for 60 min until an 
OD600 of 2.5-3.0 was reached. Cells were induced with 4*10
-3 % arabinose (w/v). Two hours after 
induction the temperature was reduced in two steps to 18 °C. 14-15 hours after induction cells 
were harvested by centrifugation at 5500 rpm for 15 min at 4 °C (rotor Sorvall F8S6x1000). The 
cell pellets were resuspended in pre-cooled 50 mM KPi pH 7.5, 150 mM NaCl (buffer A) 
supplemented with 1mg/ml lysozyme, 40 μg/ml DNase and 5 mM magnesium sulfate. Cells 
were either lysed with a custom-made cell disruptor (French press technology) or a Constant 
Systems cell disruptor, with 3-4 passages at 15-35 kPsi. The lysate was cleared by centrifugation at 
10,000 g for 30 min. Membranes were harvested by ultra-centrifugation at 43,000 rpm for 1 hour 
at 4 °C (rotor Beckman 45Ti or 70Ti). Membranes were diluted to 2 ml/1 g vesicle in pre-cooled 
buffer A supplemented with 10 % (w/v) glycerol in a Potter homogenizer, flash frozen in 10 ml 
aliquots (5g vesicles) in liquid nitrogen and stored at -80 °C. 
 
Purification of prokaryotic DMT homologs. For membrane protein extraction membrane 
vesicles were quickly thawed (in a water bath at RT) and suspended in pre-cooled buffer A 
containing 10 % (w/v) glycerol and either 1-1.2 % (w/v) n-dodecyl-β-D-maltopyranosid 
(Anatrace) or 1-2 % (w/v) n-decyl-β-D-maltopyranosid (Anatrace). All subsequent steps were 
carried out at 4 °C. The suspension incubated for 1 h, mild stirring. Unsolubilized material was 
removed by ultra-centrifugation at 43,000 rpm for 30 min (rotor Beckman 45Ti or 70Ti). For 
each 1 g of vesicles 0.4 ml metal affinity resin (Qiagen) was incubated with the supernatant for 1 
h, mild stirring. Unspecific binding of protein to the Ni-NTA resin was reduced by addition of 15 
mM imidazole. Gravity flow columns were used to remove the flow through and subsequently 
wash the resin with 20-25 column volumes buffer B, supplemented with 10 % (w/v) glycerol and 
50 mM imidazole (buffer B: 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.05 % DDM or 0.25 % 
DM respectively). The protein was eluted with buffer B supplemented with 6% glycerol and 300 
mM imidazole. For cleavage of the His10-tag (or GFP-His10-tag), the sample was digested for 2 h 
with 3C protease (~22 kDa) at a molar ratio of 5:1 while dialyzing into buffer C (20 mM HEPES, 
pH 7.5, 150 mM NaCl, 0.025 % DDM or 0.11 % DM respectively, 10 % glycerol) to lower the 
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imidazole concentration to 15 mM (Spectrapor Dialysismembranes MWCO 8 kDa). The His tag 
and the 3C protease were removed by incubation of the solution with (fresh) Ni-NTA resin for 
15 min (1ml resin per 8 mg total amount of protein) and collection of the flow through, which 
contains the cleaved protein. The cleaved protein was concentrated to 10-20 mg/ ml with an 
Amicon Ultra Centrifugation device (Millipore, MWCO = 50 kDa) and filtered through a 0.22μm 
centrifugal filter device. The filtered protein was subjected to size exclusion chromatography on a 
Superdex S200 column (GE Healthcare) equilibrated in 10 mM HEPES, pH 7.5, 150 mM NaCl,  
supplemented with the appropriate amount of detergent (either 0.05% DDM, 0.25% DM or 
0.84% NM, Anatrace). For crystallization experiments, peak fractions were pooled and 
concentrated to 5-12 mg/ml with an Amicon Ultra Centrifugation device (Millipore, MWCO=50 
kDa). 
 
Crystallization of ScaDMT. Purified ScaDMT concentrated to 7.5 mg/ml was used for 
crystallization. Crystallization trials were performed at the Protein Crystallization Facility at the 
University of Zurich. Crystallization trials were set up using sitting drop vapour diffusion, by 
mixing of the protein 1:1 (v/v) with mother liquor. ScaDMT crystals grew under conditions 
containing 25-35 % PEG 400 as precipitant, buffer at pH 4.5 to pH 7.5 and either CaCl2 or 
MgCl2. 
 
Biotinylation of ScaDMT and ScaDMTtru AVI tagged proteins. AVI-tagged transporters 
were purified following the standard purification protocol as described above. After the SEC run 
the peak fractions were pooled and concentrated to 8 mg/ml with an Amicon Ultra 
Centrifugation device (Millipore, MWCO=50 kDa). The biotinylation reaction was set-up with 2 
mg of protein in SEC buffer supplemented with 5 mM ATP pH 7.0, 10 mM MgSO4, 5 mM 
biotin (stock in bicine buffer, pH 9.0), 100 μg/ml BirA. The reaction was incubated o/n at 4 °C. 
Subsequently the solution was incubated with Ni-NTA resin to remove His-tagged BirA. The 
flow-through containing the biotinylated protein was subjected to another SEC run on a S200 
column. 
 
Shaker flask expression and purification of nanobodies. The nanobodies were cloned into an 
arabinose inducible expression vector containing an N-terminal pelB leader sequence, a His10 tag 
and the maltose-binding protein (MBP) located in front of the nanobody. For expression, 3 flasks 
with 600 ml TB medium supplemented with 100 μg/ml ampicillin were inoculated with an o/n 
culture of MC1061 cells containing the appropriate plasmid. Cells were grown at 37 °C to an 
OD600 of 0.6-0.8 and induced with 2*10
-2 % arabinose. For o/n expression the temperature was 
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reduced to 25 °C. Cells were harvested by centrifugation at 5500 rpm (rotor Sorvall F8S6x1000) 
and resuspended in buffer R: 50 mM KPi pH 7.5, 150 mM NaCl, 10 % glycerol supplemented 
with 1 mg/ml lysozyme, 40 μg/ml DNase and 5 mM magnesium sulfate. All following steps were 
carried out at 4 °C. Cells were lysed with a custom-made cell disruptor or with an Emulsiflex C3 
high-pressure homogenizer (Avestin) with 3-4 passages at 15-35 kPsi. The lysate was cleared by 
ultracentrifugation at 43,000 rpm for 30 min (rotor Beckman 45Ti or 70Ti). The cleared lysate 
was complemented with 15 mM imidazole pH 7.5 and incubated for 1 h with 3 ml Ni-NTA 
metal affinity resin (Qiagen). IMAC was performed as described for the transporter. The eluted 
nanobody was incubated with 3C protease (molar ratio 8:1) during o/n dialysis against 20 mM 
Hepes pH 7.5, 150 mM NaCl. The his-tagged protease and the cleaved MBP-His10-tag was 
removed by binding to fresh Ni-NTA (4 ml) resin. The nanobody was concentrated to 20 mg/ml 
with an Amicon Ultra Centrifugation device (Millipore, MWCO=3 kDa). The filtered (0.22μm 
centrifugal filter device) nanobody was subjected to SEC, and peak fractions were pooled and 
used for binding tests with ScaDMT. 
 
Qualitative size exclusion chromatography to test complex-formation of nanobodies with 
ScaDMT. ScaDMT and the nanobodies were purified separately as described above. 15 μg 
ScaDMT were mixed with 5 μg nanobody and injected on a Superdex PC 3.2/300 (GE 
Healthcare) column equilibrated in 20 mM Hepes pH 7.5, 150 mM NaCl, 0.25% DM. The runs 
were performed on an Agilent 1100 HPLC system (Agilent technologies) and absorbance at 280 
nm was recorded. 
 
Large-scale expression of nanobodies and co-crystallization were performed as described 
(Ehrnstorfer et al., 2014); with following addition: During initial screening the SEC run of the 
ScaDMT or ScaDMTtru -nanobody complex was performed on a S200 column equilibrated in 10 
mM Hepes, 150 mM NaCl, 0.25 % DM. 
 
Expression of seleno-methionine labeled ScaDMTtru . An o/n culture of ScaDMTtru grown 
in TB medium was diluted 1:100 into 50 flasks containing 0.6 l of M9 medium supplemented 
with trace elements, Kao and Michayluk-Vitamin solution (Sigma), 0.75 % glycerol and 100 mg/l 
ampicillin. Cells were grown at 37 °C, mild stirring and subsequently the temperature was 
decreased over 5 h to 24 °C until an OD600 of 0.6 was reached. The amino acid cocktail, 
containing L-Lys, L-Thr, L-Phe (each at a concentration of 125 mg/l), L-Leu, L-Ile and L-Val 
(each at a concentration of 62.5 mg/l) were added to the culture to inhibit the methionine 
synthesis pathway (Van Duyne et al., 1993). Cells were allowed to deplete from free L-Met for 1 
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h followed by addition of 50 mg/l L-seleno-methionine. One hour later, expression was induced 
by addition of 4*10-3 (w/v) arabinose. For o/n expression, the temperature was decreased to 
18°C. Cells were harvested by centrifugation at 5500 rpm for 15 min at 4 °C (rotor Sorvall 
F8S6x1000) and lysed by sonication. No membrane vesicles were prepared. Extraction was 
started from the cleared lysate (supernatant after centrifugation at 10,000 g for 30 min) by 
addition of 1.5 % DM (Anatrace). Purification and crystallization of the ScaDMTtru-nanobody 
complex were carried out as described in Ehrnstorfer et al., 2014. 
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